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Für alle Patienten und Patientinnen und die Menschen, die sie unterstützen. 
 
 
 
 
Man muss seinen Traum finden, dann wird der Weg leicht. 
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SUMMARY 
Haematopoietic stem cell transplantation (SCT) is an intensive treatment for life-threatening diseases of 
the blood building system. Worldwide, the number of transplantations has risen to more than 60.000 per 
year, with the number of treated patients now above one million 1. Although, for most of these patients, 
SCT is the only curative treatment, long-term survivors face a life-long increased risk of various adverse 
side effects, also termed ‘late effects’ 2-4. These can appear months or years after treatment has ended, 
can persist chronically, and are often experienced as distressing and burdensome 5. Also these 
complications can cause substantial morbidity and mortality and can impair quality of life 6. Recurrent 
disease is still the most common cause of late deaths among SCT patients. Other frequent causes of death 
include infections, organ failure, secondary cancers and chronic graft versus host disease (cGVHD), 
which involves attacks by donor T lymphocytes on the patient’s organs. Chronic GVHD can affect any 
organ and can be particular burdensome for patients 7. As many late effects manifest with symptoms, 
patient perspectives on symptom experience are extremely important.  
According to Leventhal’s self-regulatory theory 8, symptom experience involves two distinct 
dimensions, i.e., cognitive, measured using symptom occurrence (frequency, severity and duration) 
and emotional, i.e., symptom distress, reflecting a patient’s emotional response to a symptom 9. Symp-
tom experience can be measured efficiently via patient reported outcome (PRO) instruments, i.e., 
health status reports supplied directly by the patient 10. PRO instruments are essential for early 
detection, management and alleviation of symptoms 11, 12.  
Late effects and associated symptoms pose an immense long-term challenge for SCT  
patients 7, 13, commonly requiring life-long follow-up care. However, besides assessment, treatment and 
management of late effects and their symptoms, follow-up care also focuses on prevention and support 
of patients’ self-management capabilities 14, i.e., any actions performed by patients for themselves to 
manage their illness and treatment, thereby avoiding or delaying health deterioration 15. According to 
self-management theory, SCT patients have to work simultaneously on three fronts: (1) coping with the 
emotions they experience concerning their chronic illness, including the uncertainties and anxieties 
surrounding possible relapse; (2) managing their new life roles to maximize meaning and fulfilment, and 
(3) dealing with their medical regimens, in view of both general and disease-specific health behaviour 
tasks 15. While disease-specific tasks include responsibilities such as medication taking, organizing clinic 
visits or recommended vaccinations, general health behaviours embrace “any activities undertaken by an 
individual, regardless of actual or perceived health status, for the purpose of promoting, protecting or 
maintaining health, whether or not such behaviour is objectively effective towards that end.”16.  
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Although evidence is scarce on the prevalence of SCT recipients’ problems regarding self-
management and overall health behaviours, studies from the US have indicated widespread shortfalls. 
For example, only 29 to 36% of survivors exercise regularly 17, 18. Overweight was observed in 52%, 
with only 5% reporting a healthy diet, i.e., one low in fat and high in fruits and vegetables 18. And, 
disturbingly, 7 to 14% of survivors continued to smoke 17-19.  
So far, no study has specifically examined long-term sun-protective behaviours and medication 
intake following SCT. In other areas, findings increasingly demonstrate that supporting self-management 
particularly health behaviours-improves outcomes 20-22. Likewise, studies in mixed samples of cancer 
survivors encourage increased physical activity, smoking cessation and long-term dietary changes 23-25.  
Designing interventions aiming at supporting patient self-management and health behaviours 
demands a clear knowledge of current practice patterns. However, despite the weight of empirical 
evidence for various behavioural interventions, whether educational/cognitive, counselling/ behavioural, 
or psychological/affective 26, little is known about which are actually applied in clinical practice. 
Specifically regarding SCT patients, no studies have indicated how many healthcare providers offer 
health-behavioural interventions adequate to their needs. One promising strategy to assist healthcare 
professionals both to facilitate symptom self-management strategies and to implement health behaviour 
enhancing interventions is to provide a comprehensive evaluation of symptom experience and health 
behaviours. To date, no validated, comprehensive PRO instrument measuring symptom experience of 
SCT late effects exists, and little knowledge is available on health behaviours which might influence 
their occurrence or intensity. Therefore, to build a knowledge base for further intervention research, this 
multicentre research project had three overall aims: 1) to develop and validate a PRO instrument for 
assessing late effect symptom experiences in SCT long-term survivors; 2) to describe health behaviour 
patterns of this patient population; and 3) to evaluate healthcare providers’ patterns of practice 
supporting health behaviours, using the example of medication adherence, in SCT settings. This doctoral 
thesis involves a study sample of adult allogeneic SCT recipients from two Swiss centres ≥1 year post-
transplant. The research program involved several studies, summarized as follows. 
Following the US Food and Drug Administration’s state-of-the-art guidelines to develop a 
PRO instrument measuring patients’ SCT late effect symptom experiences 10, we began by conducting 
a sequential transformative mixed methods study 27. Therefore, the Patient-Reported Outcomes version 
of the Common Terminology Criteria for Adverse Events 3.0 (PRO-CTCAE) an item library 
consisting of 78 symptom terms was translated into German and linguistically validated using 
recommended translation protocols 28, 29. Next, patient cognitive debriefing (n=15) was used to select 
an item bundle significant for SCT associated late effects according to two predefined criteria: (1) 
PRO-CTCAE symptoms prevalent in ≥50% of SCT survivors and (2) recognized as important by SCT 
experts (n=9). Additional concepts concerning symptom experience were elicited from both patients 
and experts. A first draft of the PROVIVO (Patient-Reported Outcomes of long-term survivors after 
allogeneic SCT) instrument was then drafted. Additional cognitive debriefings of 15 further patients 
SUMMARY 
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were used to assess the instrument’s content validity. Finally, nine clinical experts were surveyed to 
provide item and scale content validity indices (CVIs). The final instrument comprises 49 items and 
captures both dimensions – occurrence and distress – of physical, emotional and cognitive symptoms. 
To improve the instrument’s utility for clinical decision-making, questions assessing limitations in 
activities of daily living, frequent infections, and overall wellbeing were also included. Cognitive 
debriefing was used to ensure that items were well- understood and relevant to the SCT survivor 
experience. As preliminary evidence of PROVIVO’s content validity, scale and item CVIs 
(respectively 0.94 and median = 1 (range 0.75-1)) were very high.  
Second, we refined the newly developed PROVIVO instrument and examined its validity and 
reliability. Therefore we used the data of a cross-sectional study in a sample of 376 patients ≥1 year after 
allogeneic SCT. Following the American Educational Research Association guidelines, we tested the 
questionnaire on three evidence levels: construct validity based on internal structure was tested by an 
exploratory factor analysis; and Cronbach’s alphas and inter-item correlations were calculated to 
examine internal consistency reliability. Relations to other variables were tested based on a set of 
evidence-based hypotheses. Based on performance testing, four original PROVIVO items were dropped. 
The exploratory factor analysis revealed an eight-factor model explaining 57.05% of variance. Internal 
consistency reliability was good for the entire scale (Cronbach's alphas .90), but only acceptable for the 
eight factor scores. Additional evidence supported relations between variables, e.g., between the number 
of symptoms and cGVHD occurrence, number of late and performance status. The initial evidence for 
the validity of the PROVIVO symptom experience scale was provided. The PROVIVO questionnaire 
may be useful to identify late effect symptoms warranting further testing. 
Next, we conducted a comparative cross-sectional multicentre study exploring the prevalence of 
SCT recipients’ health behaviours versus those of the general Swiss population. A convenience sample 
of 376 survivors from 2 Swiss SCT centres (54.8% males; mean age 50.4 years (SD=12.8); median 7 
years post allogeneic SCT (IQR=8.75), 40.6% cGVHD) was compared to case matched controls derived 
by propensity score matching from the data set of the 2007 Swiss Health Survey (SHS), a large-scale 
nationwide representative study (n=18760 participants) repeated at 5-year intervals. Propensity score 
matching was performed based on gender, age, educational status, living region and community type 
Health behaviours relevant to physical activity, dietary habits, alcohol consumption, smoking, influenza 
vaccination, and sun protection were compared. Statistical analysis was performed using McNemar or 
Wilcoxon signed-rank paired tests as appropriate. The results showed both favourable and unfavourable 
differences from national norms. Survivors were much more likely to be physically inactive (26.8% vs. 
12.5%; p=<.001), and typically consumed fewer portions of vegetables (≥3 pieces: 10% vs. 21.6%; 
p<.001), fruits (≥3 pieces: 6.5% vs. 10.6%; p<.001), and fish (31.2% vs. 60.9% weekly fish dish; 
p<.001). More desirably, survivors were more likely to consume dairy products daily (92.5% vs. 62.9%; 
p<.001), to use sun protection regularly (94.5% vs. 85.3%, p<.001) and to have received influenza 
vaccinations in the last year (58.4% vs. 21.5%; p<.001). Also, fewer smoked (13.4% vs. 35.4%; p<.001), 
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and their weekly alcohol consumption was lower than their controls’ (medians: 1.5 servings (IQR 4) vs. 
4.5 (IQR 10.3); p<.001).  
Among allogeneic SCT recipients, correct immunosuppressant (IS) intake is essential to 
prevent and treat cGVHD. So far, no previous study had investigated the prevalence and consequences 
of post-SCT medication nonadherence (MNA), although research in solid organ transplantation 
indicates a clear connection with increased mortality 30, 31. Therefore, our fourth study aimed to 
examine MNA prevalence and its relationship first with a defined set of clinical and demographic 
characteristics, then with cGVHD. We performed a secondary data analysis of a subsample of patients 
taking IS medications (n=99) in the above mentioned cross-sectional study phase. Patient-reported 
MNA over the previous 30 days was measured using the 6-item BAASIS® questionnaire, which 
assesses following dimensions of medication taking behaviour: implementation (taking & timing), 
drug holidays; dose reductions; discontinuation and overall nonadherence). Also, physicians estimated 
patients MNA (adherent/non-adherent) for the last 30 days. Patients were classified as non-adherent 
based either on their self-reports (i.e., if they reported nonadherence to at least one of the BAASIS® 
criteria or on their physicians’ collateral reports. Results from the BAASIS® indicated that 33.3% of 
patients had not taken their IS medication at least once, while 61.2% had not adhered to the 
recommended intake time; and 3.1% terminated their medication regimens too early. Together, 65.7% 
of patients were non-adherent to at least one criterion of the BAASIS®. Physicians estimated MNA in 
18.9% of patients, which resulted together with the patient-reported MNA in a composite MNA rate of 
68.7%. MNA correlated with higher numbers of IS [odds ratio (OR):1.42; p=0.011] and fewer co-
medications (OR:0.85; p=0.02). MNA was significantly associated with higher grades of cGVHD 
(OR: 3.01; p = 0.012). Patients with higher cGVHD were more likely to have problems in the 
implementation of the medication regimen (OR:2.60; CI:1.14-5.91; p=0.023); in particular regarding 
taking (OR:2.46; p=0.028) and self-initiated dose reduction (OR:15.57; p=0.022). This study indicates 
high levels of MNA in SCT patients, calling for adherence-enhancing interventions. 
Such a high MNA prevalence indicates a need to understand healthcare professionals’ practice 
patterns regarding medication self-management support. We therefore aimed to identify nurses’ 
practice patterns in view of assessing medication adherence, screening for risk factors, and offering 
adherence-enhancing interventions. We also assessed nurses’ perceptions of the applied methods’ 
effectiveness. A convenience sample of 143 European nurses attending the Meeting of the European 
Group for Blood and Marrow Transplantation completed a self-developed 29-item questionnaire 
measuring the frequency and perceived effectiveness of adherence assessment/screening methods and 
each of three adherence enhancing intervention types (educational/cognitive, counselling/behavioural, 
and psychological/affective).  
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The results showed that the most regularly used assessment method was questioning patients 
about adherence (51.5%). Nurses used a median of 7 interventions (IQR: 6) ‘frequently’, the most 
frequent being educational, i.e., providing reading materials (79%), followed by training during 
inpatient recovery (66.4%). Those perceived as most effective were individual patient/family teaching 
and providing reading materials. The high preference for educational interventions contrasts with data 
suggesting limited efficacy of educational interventions alone32 – a more optimal solution being a 
combination of educational, behavioural and psychological interventions. 
The research reported in this doctoral thesis contribute in four main ways to the evidence base 
regarding SCT patients’ symptom experience, self-management, and, more specifically, adoption of 
healthy behaviours, including medication adherence. First, following FDA guidelines, we both 
developed and presented preliminary data on the validity and reliability of a PRO instrument to assess 
late effect symptom experiences. Second, we used propensity score matching to compare, for the first 
time, a comprehensive set of health behaviours between SCT survivors and a representative sample of 
the general Swiss population. Third, we provided detailed information on the prevalence of medication 
nonadherence in SCT patients taking IS, including a relationship between MNA and higher grades of 
cGVHD. Fourth, we increased the very limited pool of available knowledge regarding current patterns 
of medication adherence support practices among nurses working in SCT settings. Our findings 
indicate a clear need for deeper exploration of the efficacy of interventions to increase survivors’ 
positive health behaviours, including medication adherence.  
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1.1 Haematopoietic stem cell transplantation 
Haematopoietic stem cell transplantation (SCT) is a curative treatment for life-threatening diseases of 
the blood building system. Since the first SCT in 1968, the number of transplantations performed 
worldwide has risen to more than 60.000 per year; the number of treated patients now exceeds 
1.000.000 1. It is mainly indicated against leukemia, lymphoma, myelodysplasia, myeloma, bone 
marrow failure conditions, severe red blood cell disorders (e.g., sickle cell disease or thalassemia), and 
certain solid tumors 2.  
In Switzerland, an annual average of 35 men and 26 women per 100.000 inhabitants are newly 
diagnosed with haematological malignancies 3. To treat these, haematopoietic stem cells can be obtained 
from the bone marrow, peripheral blood, or umbilical cord blood either of related or unrelated donors 
(i.e., allogeneic SCT), or from the patients themselves (i.e., autologous SCT). Roughly 200 allogeneic 
and 350 autologous SCTs are performed each year in Switzerland 4. The choices of whether to use 
allogeneic or autologous SCT and of graft source (bone marrow, peripheral blood, or cord blood) depend 
mainly on the patient’s underlying disease and disease status prior to transplantation. Treatment is 
stringent. Before SCT, to eradicate cancerous cells and to suppress the patient’s immune system, 
preventing it from attacking the donor hematopoietic cells, the patient is treated with highdose 
chemotherapy, which may include total body irradiation (TBI). Significant post-transplant problems can 
result from toxic effects related to the preparatory treatments, infections, relapse of the underlying 
disease and chronic graft versus Host disease (GVHD) which involves attacks by donor T 
lymphocytes on the patient’s organs. Chronic GVHD can affect any organ and can be particular 
burdensome for patients 5, 6. 
 
 
 
 
 
 
 
 
 
Figure 1: Causes of late effects Adapted from: Deeg H.J., 1999. Delayed complications after haematopoietic cell 
transplantation, in: Boston Forman S, Blume KG, Thomas ED, Hematopoietic Cell Transplantation, 3 ed. Blackwell 
Scientific Publications, Inc., pp. 776-806 
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1.2 Late effects 
Side effects occurring more than 3 months post-SCT are classed as late effects. These can be further 
classified according both to the time of their onset, i.e., as delayed (3 months to 2 years), late (2 to 10 
years), and very late events (≥10 years) 7, and to whether they are malignant 8, 9.  
Malignant late effects are known complications of high-dose chemotherapy and TBI, and 
include solid cancers and three types of late haematological malignancy: late relapse of the primary 
malignant disease, therapy-related secondary haematological malignancies, and donor type leukemia 
(following allogeneic SCT). Among allogeneic SCT recipients, the estimated risk of malignant late 
effects is 2% to 6% at 10 years, increasing to 15% at 15 years 10, 11. Particularly during the first 5 years 
post-treatment, the most common cause of late deaths (41% of all deaths) remains relapse 12. 
Nonmalignant late effects, which can affect any organ, are widely heterogeneous in nature and 
intensity11. Their type and severity depend on the type, duration and intensity of the treatment applied; 
multiple causes are frequently involved. Common late effects include ocular, endocrine, skeletal, 
cardiac, gastrointestinal and hepatic dysfunction, the cumulative effects of which have a critical 
impact on patient morbidity and mortality. Worse still, the number of late effects increases with time. 
In the first 5 years after SCT, two-thirds of recipients develop at least one chronic health condition; a 
fifth develops severe or life-threatening conditions 13. This is particularly problematic for children. 
Within a median of seven years following childhood SCT, 90% of survivors experience at least one 
late effect; for 25%, these are severe and even disabling 14, 15.  
The effect on health-related quality of life (QoL) can be harsh. Although, for the majority of 
SCT recipients, longitudinal studies indicate a good to excellent QoL 16, patients with late effects, and 
especially those suffering from cGVHD, find this quality compromised5. Furthermore, for at least 30 
years following SCT, across all age groups, recipients’ mortality risk is fourfold to nine-fold that of 
the normal population, reducing estimated life expectancy by 30% 13, 17. Several excellent reviews 
systematically describe all known late effects. 7, 9, 13 
1.3 Symptom experience related to late effects after stem cell transplantation 
Many late effects manifest as symptoms, a variety of which continue to affect approximately 25% of 
patients two years after SCT 18. Not surprisingly, symptoms accompanying cGVHD entail greater 
distress 5, 19, 20. However, clinicians might underestimate both the incidence and severity of cancer pa-
tients’ symptoms, as well as the distress they cause 21. To correct these false estimates, using patient self-
reporting is increasingly recognized as an important source of subjective information22. Using a non-
validated clinical follow-up questionnaire, a cross-sectional study at the Basel SCT follow-up clinic 
showed that, on average, at the time of their annual examinations, long-term survivors reported five 
physical symptoms (IQR 4-10). Most commonly reported were dry skin (47.8%), tiredness (42%), and 
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dry eyes (42%). Nearly a quarter (23.9%) reported difficulty managing stressful emotional situations, 
anxiety regarding relapse (22.1%), and memory disturbances (21.2%)23. Further research showed that, 
compared to the general population, SCT survivors suffer significantly more problems with cognitive 
impairment (20% vs. 7%); muscle weakness (16% vs. 7%), joint stiffness (9% vs. 1%) and leg cramps 
(16% vs. 4%) 24. Compared to their matched donor siblings, they also have elevated prevalences of oral 
symptoms, e.g., dry mouth (10.7% vs 0.9%) and problems chewing or swallowing (7.7% vs. 1.3%). 
Similarly, more survivors experience neurological concerns, e.g., abnormal sense of taste and smell 
(10% vs 0.6%), or touch (15.5% vs 9.7%) as well as problems concerning balance, tremor or weakness 
(13.5% vs 5.3%) 25.  
According to the self-regulatory theory 26, symptom experience involves two main dimensions: 
cognitive (measured according to occurrence, including frequency, severity and duration) and emotional 
(represented by distress, which may put survivors at risk of uncertainty and fear (e.g., of relapse)) 27 28. 
For instance, a patient may experience a mild numbness in his feet (≈symptom occurrence) but may 
report that this is very distressing (≈symptom distress). Measuring symptom experience on these two 
dimensions is crucial, as research in other patient populations has linked symptom distress to lower 
perceived QoL, which may trigger medication nonadherence 29. 
 
 
 
 
 
 
 
 
Figure 2: Symptom experience according to the self-regulatory theory 
Research suggests that SCT recipients experience a broad range of symptoms, several of which 
impede daily functions 30; however, knowledge is limited regarding SCT symptom experience. While 
several studies have chronicled symptom distress during the first 6 months post-treatment 31-36, few 
have measured symptom occurrence alongside symptom distress in the first years following SCT 37-39. 
One of the few to do so is Larssen et al.’s (2007) examination of the association between perceived 
health status and symptom experience from discharge to one year post-transplant. The results indicated 
a strong correlation between perceived health status and the number of symptoms both at discharge 
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(OR 1.33, p =.009) and at one year post-SCT (OR 2.0, p =.010), i.e., patients reporting “poor health 
status” had a stable median of 7 to 10 symptoms. However, symptom distress levels did not change 
significantly over time37. Edman et al. (2001) reported that, two to four years after SCT, 88% of 25 
survivors had persistent symptoms. Affecting 50% of patients, the most distressing of these were eye 
problems, sexual dysfunction, tiredness, anxiety, and changes of taste38. Another study followed 31 
SCT recipients prospectively for two years following treatment, finding that lower symptom distress 
was a positive predictor of survival 39.  
One prospective US study used the generic 23-item Rotterdam Symptom Checklist to examine 
the evolution of symptom distress from 3 to 6 years post-SCT. The results showed substantial health 
status and QoL variability based on time since SCT, for which physical symptom distress was a 
significant predictor. In that case, patients with higher symptom distress reported physical and mental 
health status significantly lower than healthy population norms. Moreover, in survivors with high 
symptom distress, the trajectory of physical health reflected impairment throughout and beyond the 
first decade post-transplantation. Bevans et al. (2013) concluded that post-transplantation comorbid 
conditions, late treatment effects, cGVHD, and side effects of immunosuppression are particularly 
related to symptom distress in allogeneic SCT recipients30. 
However, the above-cited studies used various self-report instruments, including the MDASI-
BMT 40, FACT-BMT 36, and EORTC-HDC29 41, all of which were specifically designed for acute 
treatment and might only address subsets of the long-term post-SCT symptom array. For instance, none 
capture muscle cramping, blurred vision or skin rash, all of which are common late effects. Furthermore, 
these instruments have received limited testing in long-term SCT survivors. To our knowledge, only 
Velikova and colleagues, while developing the EORTC-HDC-29, enlisted survivors more than 1 year 
post-SCT41, as is recommended 42, 43. Also, while the Lee Chronic GVHD Symptom Scale has 
demonstrated validity for the assessment of cGVHD symptoms in long-term survivors 44, it ignores 
symptoms caused by late effects other than cGVHD (e.g., palpitations and sensory neuropathy). 
1.4 Patient-reported outcome (PRO) instrument in cancer follow-up  
Since many symptoms only manifest subjectively and are rarely captured during clinician-based 
evaluations, self-reporting is crucial for early symptom detection. However, reliably capturing the 
patient’s illness experience requires well-developed and validated instruments. Optimally, SCT patient 
follow-up should be based on a combination of objective diagnostics and patient reported outcomes 
(PROs), i.e., reports of the patient’s health condition status supplied directly by the patient, without 
interpretation by a clinician or anyone else 45. 
By channelling clear communication between healthcare professionals and patients, PRO 
instruments facilitate informed decisions regarding symptom management and treatment, and may 
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even allow prevention of some late effects. Therefore, it is recommended that self-reporting be treated 
as a guiding element in follow-up care 46. However, no PRO instrument is yet available to assess late 
effect symptom experience.  
In response to this and similar needs, the US Food and Drug Administration has provided a 
guidance report, including a five-step breakdown of the PRO development process: (1) Hypothesize a 
conceptual framework; (2) adjust the conceptual framework and draft the instrument; (3) confirm the 
conceptual framework and assess other measurement properties; (4) collect, analyse, and interpret the 
data; and 5) modify the instrument 45.  
In Chapter 3, the article “Understanding the Importance of Using Patient Reported Outcome 
(PRO) Measures in patients with Immune Thrombocytopenia” illustrates the value of PROs to 
gather information on a rare haematological disease. The same article also summarizes the 
methodological steps necessary to develop PRO instruments, and discusses challenges to their 
integration into research and clinical practice. 
Traditionally, cancer follow-up assessed symptoms indirectly, using adverse event forms or 
checklists based on the Common Toxicity Criteria for Adverse Events (CTCAE), a long-standing, 
empirically developed dictionary designed to help clinicians detect and document adverse events in 
clinical trials 47. However, in clinical practice and other research settings, the CTCAE might not 
accurately reflect either patients’ illness experiences or the burden of late effects 48, 49.  
To improve the CTCAE’s precision and reliability regarding cancer treatments’ symptomatic 
toxicities 50, 51, the US National Cancer Institute (NCI) has augmented the CTCAE with a patient -
reported outcome item library: the PRO-CTCAE 52. This is comprised of 124 PRO items, reflecting 78 
symptom terms, each of which is assessed according to attributes including presence/absence, 
frequency, severity, and/or interference with usual or daily activities.  
While the PRO-CTCAE is designed to capture the full range of symptomatic treatment effects 
across a variety of disease sites and treatment modalities, it has received only limited testing in SCT 
settings. Wood et al. (2013) recently used PRO-CTCAE items to evaluate symptomatic toxicities in 
the first 100 days post-SCT, but it is currently unknown which items are most suitable to measure late 
SCT effects. Moreover, while collaborators are developing translations in Chinese and Japanese, the 
full item bank currently exists only in English and Spanish; no German version is yet available.  
Cancer researchers are encouraged to use the PRO-CTCAE item bank to select relevant items 
for their study populations and to create self-report questionnaires. Yet, as the item bank is designed 
for cancer populations in general, additional studies are necessary to determine which items fit specific 
disease populations and to verify each PRO’s validity and reliability 53. Representing a clear gap for 
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research and clinical care, so far no instrument has been derived and validated specifically for use in 
patients with SCT. For this reason, we collaborated with the NCI to translate the PRO-CTCAE in 
German and to select symptom items specific for long-term SCT survivors. Based on the PRO-
CTCAE item bank, as patients’ and experts’ input, we created and preliminary validated a PRO 
instrument measuring late effect symptom experiences.  
Chapters 4 and 5 describe the development and preliminary psychometric testing of the 
PROVIVO instrument – a PRO measure of post-allogeneic SCT late effect symptom experience.  
1.5 Patient self-management and health behaviours in stem cell transplantation  
In addition to assessment, treatment and management of late effects and the associated symptom 
experiences, follow-up care focuses also on support of patients’ self-management capabilities and, 
where possible prevention of adverse developments. 54. Self-management involves three main tasks: 
‘managing emotions’, ‘managing (new) roles’ and ‘managing the medical regimen’. Emotional 
management requires a survivor to deal with the emotional sequels of cancer experience. Its success 
relies on the balance between the distress a survivor feels and the individual response resources 
available 27. Within the scope of `managing life roles’, survivors face challenges not only to their 
social roles, e.g., as partners, parents or friends, but also to their professional roles, which can be 
particularly troubling. While 60 to 70% of survivors have returned to the workforce two years after 
SCT 18, 55, 56, only 29% to 31% have returned to full-time employment 18, 56.  
While disease specific tasks include responsibilities such as taking medications, organizing 
clinical visits or receiving recommended vaccinations, health behaviours embrace “any activities 
undertaken by an individual, regardless of actual or perceived health status, for the purpose of 
promoting, protecting or maintaining health, whether or not such behaviour is objectively effective 
towards that end.”57 However, data on the prevalence of problems related to self-management and in 
particular health behaviours in SCT are scarce. 
One notable example is adherence to recommended vaccinations. Thus far, only Bishop et al. 
(2009) have studied this topic, reporting that SCT survivors (59.7%) were more likely to have had 
influenza vaccine in the past year than healthy controls (32.7%) but less likely than those over the age 
of 65 (73%) - for whom the vaccine is also recommended 58. Also, to our knowledge no studies have 
measured adherence to sun protection and medication. Since SCT patients are at a high risk for 
developing skin cancer 59, 60, they should be encouraged to perform frequent skin examinations and to 
avoid unprotected skin UV exposure. Although most centres recommend wearing protecting clothes 
and applying sunscreen (SPF 30 or higher) when exposed to sun, it is not known how fully patients 
adhere to this recommendation.  
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More data is available on diet. Monitoring for abnormal body mass index (BMI) is crucial, as 
both under- and overweight are common among SCT survivors 61, and both represent health risks. 
Overweight is associated with cancer recurrence and increased mortality 62, underweight with fatigue 
and lack of stamina 63. As a questionnaire survey indicated that only 5% of 137 allogeneic stem cell 
recipients regularly ate a healthy diet, i.e., one low in fat and high in fruit and vegetable ingredients, 
cancer survivors clearly need improved dietary education and support 24.  
Another important post-treatment recovery factor is physical activity.64-66 In the general cancer 
population, regular exercise has been linked to a range of positive outcomes, including improved 
physical function 67, less side-effects 68, increased survival 64, enhanced immune function 69, improved 
quality of life and enhanced psychological well-being 70. However, symptoms such as fatigue and 
muscle impairment might deter survivors from exercising 71, 72. In a questionnaire survey of 2,684 
adult acute leukaemia survivors, 53% of respondents fell short of the Centres for Disease Control and 
Prevention’s physical activity recommendations, i.e., 30 minutes of moderate-intensity physical 
activity ≥5 days per week or 20 min of vigorous-intensity activity ≥3 days per week. Further US 
studies indicate that 29-36% of SCT survivors exercise for at least 20 - 30 minutes three times per 
week, compared to 30-45% of matched controls 24, 58.  
On the other hand, one well-documented health-endangering behaviour is smoking. Still, data 
indicate that 7% to 14% of survivors continue to smoke post-transplantation 24, 58, 73. Among CML 
patients who received SCT, the 5-year survival rate was highest among non-smokers (68%), compared 
to low-dose smokers (1-9 pack-years: 62%) and high-dose smokers (>10 pack years, 50% survival) 74. 
Monitoring 148 patients undergoing SCT against acute leukaemia for a median of 3.5 years, another 
study showed that, compared to life-long non-smokers, current smokers required significantly more days 
of hospitalization (46.2 days versus 25.7 days, p=0.025), and had poorer overall survival rates (hazard 
ratio =1.88; 95% CI 1.09–3.25) 75.  
Another health risk is alcohol consumption. The American Cancer Society recommends 
limiting alcohol intake to not more than two drinks per day for men and one drink/day for women 76. It 
is known that adult SCT patients radically reduce alcohol consumption within the treatment period, 
and commence drinking after an average of 6 months post-SCT; however they rarely reach pre-
transplant consumption levels 77. Of 2,849 childhood leukaemia survivors with a mean age of 30.1 
years (range 16-74.2), 75.5% were alcohol drinkers, 22.3% consumed above weekly 
recommendations, and 3.5% consumed potentially harmful amounts 78. Bishopt et al. reported that 
20.1% of males and 12.1% of women occasionally drank more than 2 glasses of alcoholic beverages in 
a day - notably less than in healthy matched controls 58 ; and another cross-sectional study reported that 
highrisk drinking was less prevalent in SCT survivors (9.5%) than in controls (13.3%):73  
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To date, no study has examined a comprehensive set of health behaviours. Further, knowledge 
is lacking as to whether health behaviours among European SCT survivors differ from those of the 
general population. 
Chapter 6 discusses the results of a comparative cross-sectional multi-centre study. Using 
propensity score matching to pair survivors with controls from the general Swiss population, 
“Differences in health behaviours between survivors after allogeneic haematopoietic stem cell 
transplantation and the general population” explored prevalences of SCT recipients’ health 
behaviours. The findings reveal that survivors are most likely to adopt beneficial health 
behaviours, namely not smoking and reduced alcohol consumption. Yet, relative to the general 
population, a considerable group still engages in unfavourable behaviors, particularly regar-
ding physical activity and dieting. 
1.6 Medication adherence within patient self-management  
As a core characteristic of self-management, medication adherence, i.e., the process by which patients 
take their medications as prescribed 79, has been studied extensively in various chronically ill 
populations. Conversely, medication nonadherence (MNA) is defined as “a deviation from the 
prescribed medication regimen sufficient to influence adversely the regimen’s intended effect” 80, 
Evidence on the overall population is disturbing: up to 50% of patients take their medications other than 
as prescribed 81, 82 .  
Medication adherence starts with the initiation of treatment, when the patient takes the first 
dose of a prescribed medication. It continues with implementation of the dosing regimen, i.e., the 
extent to which a patient’s actual taking behaviour corresponds to the prescribed dosing regimen. 
Discontinuation refers to a patient terminating a treatment earlier than recommended and not 
restarting. Nonadherence can involve any or all of these: late or non-initiation of the prescribed 
treatment, sub-optimal implementation of the dosing regimen, or early discontinuation.79  
Nonadherence to immunosuppressant medication is particularly problematic. As observed in 
solid organ transplant recipients 83-86, incorrect intake can seriously affect outcomes, resulting in higher 
rates of hospitalization, avoidable use of multiple other services, and higher healthcare costs.87, 88 
Unfortunately, while more than a third of SCT patients are prescribed a wide array of medications, 
including immunosuppressants 89, no study has yet evaluated the prevalence, determinants and 
consequences of medication nonadherence in this population.  
Chapter 7 contains the manuscript “Medication nonadherence in long-term survivors taking 
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immunosuppressants after allogeneic stem cell transplantation (PROVIVOmed): a multicentre 
cross-sectional study”. This paper reports the target group’s prevalence of MNA to 
immunesuppressants, examining its correlates and exploring its association with cGVHD. 
1.7 Healthcare professionals’ practice patterns for supporting medication 
adherence 
Healthcare professionals have a duty to assess, monitor and support patients’ medication management. 
Regarding adherence enhancing interventions, however, the extent and content of adherence support 
varies tremendously between clinical settings, often falling short of the state-of-the-art 90, 91. Important 
first steps include routinely assessing patients’ adherence and screening them for nonadherence risk 
factors. For those identified as non-adherent or at risk of nonadherence, three types of adherence 
enhancing interventions are available, all of which can quickly be integrated into normal healthcare 
practice:  Educational/cognitive interventions present information or knowledge individually or in a 
group setting verbally, in a written format, or audio-visually; counselling/behavioural interventions 
reduce, shape or reinforce specific behaviours, empowering patients to participate in their own care, 
while improving their skill levels or normal routines; and psychological/affective interventions focus 
on patients' feelings and emotions or relationships and social support92. 
However, even for apparently direct needs such as patient education, no individual 
intervention type offers a definitive solution. A 2009 meta-analysis showed that educational interven-
tions, which are most frequently used, actually have limited efficacy, as substantial learning requires 
the development of knowledge-building behaviours 93. As an alternative, mixed interventions combine 
the benefits of any or all of the basic types to overcome their individual weaknesses 94. For medication 
taking, a compelling range of evidence indicates that mixed multi-level interventional approaches, 
typically including multiple potentially interacting techniques, improve patient behaviour more 
efficiently than individual methods 93-97.  
With the increasing use of such mixtures comes the need for understandable methods of 
analysing them. To allow clear and accurate reporting of the behavioural content of interventions 
described in protocols and study reports on healthy eating, physical activity, alcohol use, and smoking 
cessation, Michie and colleagues developed a taxonomy of 93 behaviours change techniques (BCT), 
clustered in 16 groups. Along with criteria for the operationalization of each BCT, clear labels are 
supplied to categorize and report each intervention component 98. Elsewhere, a recent meta-analysis by 
Dusseldorp et al. provided evidence for effective combinations of BCTs, finding that providing 
information about healthy and unhealthy behaviours and their likely outcomes, encouraging prompt 
formation of intentions, and using follow-up prompts were particularly effective 99.  
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Still, a considerable gap always exists between current knowledge and clinical practice. With 
no information available on which patterns of practice are congruent with state-of-science adherence 
enhancing interventions in the field of SCT, then, it must be assumed that their actual use is lacking; 
and where such interventions are used, their relative efficiencies remain to be seen.  
Chapter 8 presents “Nurses’ practice patterns in relation to adherence enhancing interventions 
in stem cell transplant care: a survey from the Nurses’ Group of the European Group for Blood 
and Marrow Transplantation”.  
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Given the gaps in the evidence regarding symptom experience of late effects, self-management, health 
behaviours and in particularly medication adherence in survivors after allogeneic SCT, the aims of this 
dissertation were following: 
1. To develop a patient-reported outcome (PRO) instrument measuring symptom experience of 
late effects after SCT and to test the initial content validity  
2. To validate the newly developed PRO instrument and assess its psychometric properties 
3. To determine the prevalence of eight health behaviours in SCT survivors (i.e., physical activity, 
dietary habits and weight control, alcohol intake, smoking, influenza vaccination, sun 
protection, and medication adherence) and to compare survivors’ health behaviours with those 
of matched controls from the general population 
4. To determine prevalence and correlates of medication nonadherence to immunosuppressants in 
allogeneic SCT patients and to explore the association between patient-reported medication 
nonadherence to immunosuppressants and cGVHD 
5. To assess practice patterns of assessment/screening methods and interventions used to enhance 
medication adherence and to determine nurses’ perceived efficacy of used assessment/screening 
methods and adherence-enhancing interventions 
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3.1 Abstract 
Incorporating patient-reported outcomes (PRO) when studying patients with immune thrombo-
cytopenia (ITP) is essential since treatment decisions are complex and using platelet count only partly 
explains disease burden. Since most symptoms are only experienced subjectively and are seldom 
captured during clinician-based evaluations, using self-report is crucial for early symptom detection. 
Capturing the patient’s illness experience, however, necessitates using well-developed and validated 
instruments. This article provides insight on the importance of using PROs in ITP, summarizes the 
methodological steps to develop PRO instruments and discusses challenges related to integrating 
PROs into research and clinical practice. 
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3.2 Background 
Immune thrombocytopenia (ITP) affects between 26 people per 100.000 per year1. While the disease 
in children generally has a sudden onset but a good prognosis, ITP in adults often presents gradually, 
but tends to be chronic in nature. Choosing the right therapy at the right time is the most challenging 
task for clinicians. Treatment side effects can be substantial, and are often perceived by patients as 
worse than the symptoms of the disease 2. Traditionally, the assessment of a patient’s response to the 
chosen treatment has been exclusively made by clinicians based on platelet count and clinical bleeding 
3. Given, however, that many patients with very low platelet counts do not bleed, it is emphasized that 
treatment choice should rely more on symptoms4, underscoring the importance of incorporating the 
patient’s perspective by using patient reported outcomes (PROs). A PRO is any report of the status of 
a patient’s health condition that comes directly from the patient, without interpretation of the patient’s 
response by a clinician or anyone else. Examples include quality of life (QoL), symptom experience, 
treatment satisfaction, and adherence 5.  
The importance of PROs in drug development is currently acknowledged worldwide, with the 
requirement that the PRO instruments are created and validated according to well-described standards 
outlined in the US Food and Drug Administration (FDA) guidance and the reflection paper on the 
measures of health-related QoL of the European Medicines Agency 5, 6. This article summarizes the 
advantages of using PROs in ITP, provides insight into the different methodological steps involved in 
developing or modifying instruments, and provides examples of how they can be incorporated into 
research and clinical practice. 
 
3.2.1 Advantages of the use of PROs in ITP 
First of all, PROs facilitate better understanding of the impact of the disease and treatment on the 
patients’ life. Assessing the patient's perspective may reveal valuable information that would be 
missed when relying exclusively on clinician report7. For example, current ASH treatment guidelines 
focus on corticosteroids’ medical side effects including hyperglycemia and osteoporosis, whereas 
weight gain, mood swings and puffy face are most bothersome to patients8. Secondly, the patients’ 
perspective might provide unique insights on treatment effectiveness. Directly asking the patient about 
adherence in the situation of nonresponse to steroids, for instance, might facilitate a deeper 
understanding why the drugs are not working. Thirdly, PROs can be relevant in decision making 
processes. Two drugs can have similar effectiveness, but different side effect profiles. In particular, 
patients report higher treatmentbother with corticosteroids than with other ITP therapies9. Patients’ 
preferences might therefore guide treatment choice. 
Because of these recognized values, the European Hematology Association Scientific Working 
Group “Quality of Life and Symptoms” developed the “Patient-Reported Outcomes in Hematology” 
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guidelines which cover conceptual, methodological and practical issues surrounding PRO measurement. 
They provide an overview of existing instruments, and describe state-of-the-art studies incorporating 
PROs of which some key insights are discussed below10. 
3.2.2 What constitutes a good PRO?  
Developing a PRO is not a “do it yourself” project. It is labourintensive, necessitating meticulous 
methodology, and requires a collaborative team of clinicians, scientists, statisticians and patients. 
Excellent methodological guidance is offered by the article series published in “Value in Health”11. 
Before developing a new PRO, clinicians should consider using existing ones. Electronic databases, such 
as PROQOLID or PROMIS offer a quick and comprehensive overview of existing instruments. So far, 
however, instruments capturing the patient’s experience of ITP almost exclusively focus on QoL, often 
applying generic instruments such as the Short Form36 and the EQ5D in adults, and the PedsQL and 
KINDL in children10. Three diseasespecific QoL measures are also available: the ITP-patient 
administered questionnaire for adults, the Kids' ITP Tool and the ITP-Quality of Life for children 12.  
If a PRO instrument is available, each clinician should answer five key methodological 
questions 5, 11 before adopting it in research or practice.  
3.2.3 Does the instrument provide a conceptual definition?  
Several PRO instruments are published that do not describe what the instrument aims to measure, or 
do not provide the conceptual framework that is underpinning the items. One should check that what 
you are trying to measure fits well with the concept and items outlined in existing PRO instruments. 
For instance, if you would like to understand the impact of ITP on a person’s social and professional 
functioning you should check whether the PRO you are considering addresses these issues. If that is 
not the case, the search for a more appropriate instrument should continue.  
3.2.4 For which patient population was the PRO instrument developed? 
Instead of hastily choosing a self-report instrument off the shelf, one should carefully look at the 
sample characteristics: for whom was the questionnaire designed? Are these patients similar to the 
study population one has in mind? Even if the concept measured is the same, a PRO instrument 
measuring side effects of immunosuppressive drugs in transplantation might not be applicable to 
patients taking immunosuppressive drugs for rheumatic conditions. Also, will subjects be able to 
complete the questionnaire? Think of vision problems, cognitive impairments or literacy levels. If 
questionnaires are designed in a different language, culturally sensitive translations, following rigo-
rous protocols are mandatory, to make sure items and instructions are clear to patients with a different 
geographical or cultural background.  
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3.2.5 Was there sufficient patient input in the PRO instrument development process?  
Strictly speaking, if no patients were involved in the development process, it is not really a PRO instru-
ment. Patient involvement is recommended at three possible occasions5. First of all, if no conceptual 
definition exists, qualitative interviews with the patient group of interest, are helpful to understand how, 
for instance, patients conceptualize side effects of pharmacological treatment (e.g. patients might talk 
about frequency of occurrence, distress experienced and impact on their daily functioning as dimensions 
of the concept ‘side effects’). Also, interviewing patients allows to identifying the symptoms which they 
deem to be important. Secondly, interviews with patients can be conducted to define items in line with 
the conceptual definition. An instrument on side effect experience, for instance, would not be a good 
instrument if it only assesses the occurrence of side effects but not the severity, or if the list of side 
effects measured is incomplete. When developing items, it is recommended that instrument developers 
stay as close as possible to the patients’ wordings. Patients will for instance talk about wind or gas and 
not flatulence, or hair growth and not hirsutism. Finally, once the instrument is drafted, the 
appropriateness of recall period and response options, as well as the clarity of instructions and items 
needs to be evaluated with patients (also called cognitive debriefings).  
3.2.6 Is the instrument’s reliability and validity well established? 
Validity and reliability testing is an ongoing process which involves many different test procedures 
that need to be conducted in the study population of interest. When selecting an instrument, one should 
ask if and to what extent it has been validated in a population that is similar to the one of interest. If 
treatment related improvement of PROs is a primary research goal, it is also good to know if the 
instrument is responsive to change. Many types of validity (e.g., content, concurrent, construct) and 
reliability (e.g., internal consistency, testretest) can be tested. The interested reader can find an 
overview of terminology related to psychometric testing in the paper of Kimberlin and colleagues13.  
3.2.7 How to interpret the collected PRO data? 
Interpretability means the degree to which one can assign easily understood meaning to an instrument’s 
quantitative score, and represents one of the most complicated challenges in PRO measurement14. 
Optimally, test developers give clear information about scoring and interpretation and if not there exists 
evidence guiding scoring interpretation15. Even more important is the distinction between “statistically 
significant” and “clinically relevant” differences. For instance, differences in QoL between stable 
chronic ITP patients taking romiplostim therapy and those with no treatment might be statistically 
significant, but an individual patient might not actually feel a ‘2 points scale difference’ in daily life. 
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3.2.8 Integrating PROs in clinical research and practice 
At present, the systematic use of PRO instruments in clinical care and research is rare, because of both 
clinician and patient factors. Although most clinicians agree that PROs are important to capture the 
patient’s experience, their integration in clinical workflows is thought to be burdensome, labor-intense 
or will increase administrative costs. However, PRO instruments can be successfully implemented in 
clinical processes by using thorough planning, training of personnel and pilot-testing. They can 
present clinicians with real-time information that are relevant for patient communication, decision 
making, and interdisciplinary collaboration. There is also a concern about patients’ willingness and 
ability to fill out questionnaires. In particular, the longitudinal use of PROs decreases patients’ 
motivation to engage actively, especially if they do not get adequate feedback. The easier to complete 
and interpret, and the more relevant the PRO assessed, the higher the likelihood that both clinicians 
and patients will benefit of it. As a future trend, several institutions facilitate real-time electronic PRO 
(e-PRO) symptom reporting and combine them with electronic health records16. Features of these e-
PRO reporting systems include simple interfaces for patients, automated reminders, clear reports for 
clinicians that illustrate longitudinal illness trajectories, and real-time alerts when alarming symptoms 
are reported. The routine use of e-PRO data in the ITP setting could create a rich data source to enable 
understanding of the patient experience and link this to clinical and economic outcomes. 
3.3 Conclusions 
The use of PROs adds to the understanding how patients are affected by ITP and of the treatment and 
health care provided. PROs can help in deciding whether to modify specific treatment elements such 
as medications, consultant care, patient education, or support services. The purpose of including PROs 
in clinical studies is to understand the patient’s perspective on what is gained or lost from treatment. 
Optimally, clinical practice and research should combine objective diagnostics with PRO instruments. 
This approach will contribute to patient care quality by detecting health changes and nascent problems 
undetectable via clinical observations, leading to early treatment and hence to improved patient 
outcomes. 
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4.1 Abstract 
Purpose: The aim of this sequential mixed methods study was to develop a PRO-CTCAE (Patient-
Reported Outcomes version of the Common Terminology Criteria for Adverse Events)-based measure 
of the symptom experience of late effects in German speaking long-term survivors of allogeneic stem 
cell transplantation (SCT), and to examine its content validity. 
Methods: The US National Cancer Institute’s PRO-CTAE item library was translated into 
German and linguistically validated. PRO-CTCAE symptoms prevalent in ≥50% of SCT survivors 
(n=15) and identified as important by SCT experts (n=9) were identified. Additional concepts relevant 
to the symptom experience and its consequences were elicited. Content validity of the PROVIVO 
(Patient-Reported Outcomes of long-term survivors after allogeneic SCT) instrument was assessed 
through an additional round of cognitive debriefing in 15 patients, and item and scale content validity 
indices by 9 clinical experts.  
Results: PROVIVO is comprised of 49 items capturing the experience of physical, emotional 
and cognitive symptoms. To improve the instrument’s utility for clinical decision-making, questions 
soliciting limitations in activities of daily living, frequent infections, and overall well-being were 
added. Cognitive debriefings demonstrated that items were well understood and relevant to the SCT 
survivor experience. Scale CVI (0.94) and item CVI (median = 1; range 0.75-1) were very high. 
Conclusions: Qualitative and quantitative data provide preliminary evidence supporting the 
content validity of PROVIVO and identify a PRO-CTCAE item bundle for use in SCT survivors. 
Studies to evaluate the measurement properties of PROVIVO, and to examine its capacity to improve 
survivorship care planning, is underway.  
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4.2 Introduction 
Allogeneic hematopoietic stem cell transplantation (SCT) has become a standard therapy for patients 
with a variety of hematologic disorders 1. However, its adverse symptom profile is prominent due to the 
use of high-dose chemotherapy and/or radiotherapy and high prevalence of acute and chronic graft-
versus-host disease (cGVHD). With improved survival, there has been increased attention given to late 
post-transplant adverse effects (effects that develop or persist one year and beyond post-transplant), 
including major organ system dysfunction, secondary malignancy, side effects of immunosuppression 
required to treat cGVHD, and infections related to delayed or abnormal immune reconstitution 2. These 
complications can cause substantial morbidity, adversely affect quality of life, and contribute to late 
mortality 3. Tailored and targeted preemptive and supportive care management based on a patient-
centered comprehensive assessment can favorably affect clinical outcomes and the survivorship 
experience 4, 5. Systematic use of PROs in clinical practice can strengthen care-planning 6, facilitate 
communication between patients and health care workers 7, and optimize symptom management 8. 
The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) 
in the internationally accepted system for grading transplant-related adverse effects in trials 9, and may 
also be used in clinical settings 10. Although the CTCAE provides a standard method for clinician 
grading of treatment-related adverse effects, additional evaluation from the patient perspective is 
warranted since approximately 10% of the adverse effects listed in the CTCAE are subjective 
symptoms that can be best evaluated by gathering information directly from patients. A recent 
systematic review confirms that clinicians often underestimate the incidence, severity and distress of 
the symptoms experienced by cancer patients 11. Patient-reported outcomes (PROs) capture the 
patient’s perspective directly and have had increasing use in both research and clinical practice 12.  
To better capture symptomatic adverse treatment effects from the patients’ perspective, the US 
National Cancer Institute (NCI) has developed the Patient-Reported Outcomes version of the CTCAE 
(PRO-CTCAE). It is designed to complement the CTCAE and to improve precision and reliability in 
gaging symptomatic toxicities of cancer treatment 13. The PRO-CTCAE item library is comprised of 
124 PRO items reflecting 78 symptom terms, with each term assessed relative to one or more 
attributes, including presence/absence, frequency, severity, and/or interference with usual or daily 
activities. It includes items that capture the full range of symptomatic treatment effects that may be 
experienced across a variety of disease sites and cancer treatment modalities, however to date PRO-
CTCAE has had limited testing in SCT settings. 
SCT-specific PRO measures include the MDASI-BMT14, FACT-BMT15, and EORTC-HDC29 
16, however these instruments focus on the acute phase, measure a broad range of HRQoL constructs, 
and address only a subset of the symptoms that can occur in long-term SCT survivors. For instance, 
none of these instruments captures symptoms such as muscle cramping, blurred vision or skin rash, 
symptoms that are common in long-term post-transplant survivors. Similarly, while the Lee Chronic 
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GVHD Symptom Scale has demonstrated validity for the assessment of cGVHD symptoms 17, 
symptoms caused by late effects other than cGVHD (for example palpitations and sensory neuropathy) 
are not addressed by this measure. Wood et al (2013) determined that PRO-CTCAE is feasible for 
evaluating SCT-related symptomatic toxicities in the early post-transplant setting; however it is not 
currently known which items are most suitable to capture symptoms in the later post-transplant period 18. 
In addition, while the PRO-CTCAE item bank has been developed in English and translated into 
Spanish, no German translation currently exists.  
Therefore, the objectives of this study were to: (I) translate and linguistically validate the 
PRO-CTCAE item library in the German language; (II) identify a PRO-CTCAE-based item bundle 
relevant for survivors ≥1 year after allogeneic SCT and elicit additional concepts that should be 
incorporated into PROVIVO, a new measure of the symptom experience designed to improve 
supportive care management in SCT survivors; and (III) evaluate the comprehensibility and content 
validity of the PROVIVO measure using mixed methods.  
4.2.1 Design and Methods  
This sequential mixed methods study 19 is the first phase of a larger PROVIVO project that will 
investigate Patient-Reported Outcomes of long-term survivors after allogeneic SCT (NCT01275534). 
The three specific aims of the present study were accomplished, using a sample of 30 SCT survivors 
and 18 haematology experts. As shown in Figure 1, the PRO-CTCAE items were translated into 
German in accordance with recommended approaches 20, 21. Mixed methods were used to identify a 
bundle of PRO-CTCAE symptoms relevant for survivors ≥1 year after allogeneic SCT, and these 
items were supplemented to create the PROVIVO instrument, a new measure of the symptom 
experience of late effects and their impact on daily life. Human subject approval was provided by the 
Ethics Committees of the cantons Zurich and Basel. 
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Figure 1: Study proces 
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4.3 Aim I: German translation and linguistic validation of PRO-CTCAE  
item library 
Authorization was received from the US National Cancer Institute to translate the PRO-CTCAE item 
library into German. Two bilingual translators independently translated the 78 PRO-CTCAE symptom 
terms and response options into German. Translations were compared to detect literal and conceptual 
inconsistencies. Reconciliation of terms resulted in one final translation of each item, which was used for 
the conceptual back translation carried out by a third translator. Subsequently, the first two translators 
reviewed the back translation, discussed inconsistencies and refined some translations. All documen-
tation pertaining to the translation, including item history, cognitive debriefing and decisions made, were 
provided to the National Cancer Institute Outcomes Research Branch for review, and the final version of 
the PRO-CTCAE-German was approved by the US National Cancer Institute. The German language 
PRO-CTCAE items were subsequently examined through cognitive debriefing, an interview method that 
evaluates respondents’ comprehension of terminology, phrasing, response options, and format of a PRO 
measure 22. Maximum variation sampling 23 was used to select two heterogeneous samples each 
comprised of 15 adults post-allogeneic SCT based on following variables (1) wide age range (2) gender; 
(3) different time points after SCT (1-2, 3-5, ≥6 years); (4) educational level; and (5) presence/absence of 
cGVHD which is known to be a main cause for worsening chronic health conditions after SCT 24. 
Excluded participants were those who were younger than 18 years of age, did not speak German, had 
visual and/or hearing impairment, were currently hospitalized, had a life expectancy <4 weeks, or 
suffered from a psychiatric illness that in the opinion of the treating haematologist prevented them from 
participating meaningfully in the study. Eligible participants were identified by physicians and nurses 
working at two outpatient clinics. The investigators contacted eligible patients by phone to explain the 
study aims and procedures, and those willing to participate signed an informed consent document. 
Interviews took place either in the outpatient clinic or at the patient’s home and were audiotaped and 
transcribed. Participant characteristics are summarized in Table 1.  
Characteristics Interview group 1* n=15 (%) ± 
Interview group 2┼ 
n=15 (%) 
Age in years, mean (SD; range) 49.7 (11.4; 34-66) 48.6 (13.6; 23-69) 
Male gender, (n, %) 8 (47%) 7 (53%) 
Native Language (n, %)     
 German 13 (87%) 12 (80%) 
 Other 2 (13%) 3 (20%) 
Marital status (n, %)     
 Married/cohabiting 10 (67%) 14 (93%) 
 Single/widowed/separated 5 (33%) 1 (7%) 
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Education (n, %)     
 Compulsory school or less  4 (27%) 3 (20%) 
 Upper secondary school/high school  10 (67%) 5 (33%) 
 University or corresponding level  1 (7%) 7 (47%) 
Current working status (n, %)     
 Full time  2 (13%) 4 (27%) 
 Part-time 5 (33%) 5 (33%) 
 Not working 6 (40%) 3 (20%) 
 Retired 2 (13%) 3 (20%) 
Diagnosis (n, %)     
 Acute myeloid leukemia  5 (33%) 4 (27%) 
 Acute lymphoblastic leukemia 1 (7%) 3 (20%) 
 Chronic myeloid leukemia  1 (7%) 2 (13%) 
 Chronic lymphoblastic leukemia 1 (7%) 1 (7%) 
 Hodgkin or Non-Hodgkin Lymphoma 5 (33%) 3 (20%) 
 Myelodysplastic syndrome 1 (7%) 1 (7%) 
 Myeloproliferative disease 1 (7%) 2 (13%) 
Years after SCT (n, %)     
 1-2 years 7 (47%) 4 (27%) 
 3-5 years 5 (33%) 4 (27%) 
 6-9 years 2 (13%) 3 (20%) 
 ≥ 10 years 1 (7%) 4 (27%) 
NIH Chronic GVHD Global Severity Score# (n, %) 
 None 5 (33%) 8 (53%) 
 Mild 7 (47%) 4 (27%) 
 Moderate 2 (13%) 2 (13%) 
 Severe 1 (7%) 1 (7%) 
Duration of interviews in minutes, mean (SD) 86 (38) 62 (18) 
Table 1: Participant characteristics 
A semi-structured interview guide was used to evaluate patients’ comprehension of the translated 
PRO-CTCAE symptom terms and response options Patients were provided with a stack of cards, each 
listing one of the 78 translated symptom terms, and asked to perform the following tasks. First, they 
were encouraged to ‘think aloud’ and describe the meaning of each symptom in their own words. If 
patients believed that the symptom phrasing was not accurate, they were asked to suggest a better 
term. Next, they sorted each symptom card into one of the following categories: 1) “I presently have 
this symptom”; 2) “I had this symptom in the past”; 3) “I never experienced this symptom”. Feedback 
concerning the clarity and comprehensiveness of the response options was also elicited. Because the 
PRO-CTCAE uses four different question types (severity, occurrence, frequency and interference with 
daily activities) patients were asked whether the response options were understandable to them. 
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Finally, patients were asked to list any other symptoms they had experienced that were not mentioned 
on the cards. Field notes were taken and a report summarizing the interview topics and the difficulties 
participants had in responding to PRO-CTCAE items was prepared for each interview. 
Continuous content analysis was used to evaluate the clarity of the symptom terms on an item-
by item basis 22. SCT survivors’ descriptions of the meaning of each symptom term were summarized 
and problems with comprehension were flagged. Based on these summaries, translations and potential 
refinements were re-evaluated after the fifth, tenth and last interview. Additionally, the occurrence of 
symptoms (present now or had in the past ≥1 year after SCT) was documented. Additional symptoms 
experienced by SCT survivors but not represented in the PRO-CTCAE item library were captured.  
4.3.1 Results 
The comparison of the two independent forward translations revealed literal (‘same words’) and 
conceptual equivalence (‘same conceptual meaning’) for 21 of the 78 PRO-CTCAE symptom terms 25; 
conceptual agreement was reached for 51/78 terms. For 6 symptom terms there was minor conceptual 
disagreement. Reconciliation through translator discussion resulted in one final translation of each 
term, which was used for the back translation. The back translation resulted in 26 symptom terms with 
complete literal and conceptual equivalence to the original English language source, and 52 symptom 
terms with conceptual equivalence. The translators examined the 52 terms where there was conceptual 
equivalence only, and either improved the translation or proposed alternative terms that were 
comparatively tested in the subsequent cognitive debriefing.  
Cognitive debriefing revealed that participants were generally satisfied with the proposed 
German language phrasing of PRO-CTCAE symptom terms; feedback prompted adjusted phrasing of 
23 terms. The PRO-CTCAE response categories were generally perceived as easy to understand. 
However, four patients indicated a preference to use numerical response categories (e.g. 1-2 times a 
week, 3-4 a week) instead of labels (e.g. rarely or frequently) for frequency questions.  
Symptom prevalence in the sample is displayed in Table 3. Of the 78 symptom terms, 27 were 
experienced by more than 50% of the patients. Respondents suggested 57 additional topics which were 
not covered by the PRO-CTCAE, but were thought to be important for the SCT-survivor population. 
4.4 Aim II: Derive, validate and refine a PRO-CTCAE-based item bundle for 
long-term SCT survivors 
To address this aim, we derived a PRO-CTCAE-based item bundle for SCT survivors, evaluated the 
content validity of the proposed bundle in a sample of patients and experts, and elicited additional 
concepts important to the provision of follow-up care to SCT survivors and that should be incorpora-
ted into the PROVIVO instrument.  
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4.4.1 Materials and methods 
A convenience sample of 9 multidisciplinary experts in SCT follow-up care were surveyed to assess the 
relevance of the 78 PRO-CTCAE symptom terms to late effects assessment and management and 
survivorship care delivery for patients ≥1 year post-SCT. Participating experts (nurses and physicians) 
were required to have ≥5 years of experience in SCT, including a minimum of 3 years in outpatient care, 
and be proficient in both German and English. The chairpersons of the European Group for Blood and 
Marrow Transplantation (EBMT) national nurses groups of Switzerland, Germany and Austria suggested 
names of eligible expert nurses. Senior physicians were identified based on their active participation in 
the EBMT and their scientific contributions to SCT research. Ten experts were invited to participate; 
informed consent to participate was obtained from nine, and surveys were distributed by surface mail 
with an enclosed postage-paid return envelope. All nine experts who agreed to participate returned the 
questionnaire within four weeks. Characteristics of the experts are summarized in Table 2.  
Characteristics Expert group 1 N=9; n. (%)* 
Expert group 2 
N=9; n (%) 
Profession; (n, %)  
 Physician 5 (56%) 5 (56%)
 Nurse 4 (44%) 4 (44%) 
Male gender; (n, %) 4 (44%) 5 (56%)
Age  
 30-39 2 (22%) 3 (33%)
 40-59 7 (78%) 4 (44%) 
 ≥ 60 2 (22%) 
Years of working experience in follow-up 
care (mean, SD) 12.2 5.9 12.9 7.6 
Total work load; (n, %)  
 60-75 2 (22%) 1 (11%)
 80-100 7 (78%) 8 (89%) 
Workload in direct clinical follow-up care; (n, %)  
 75% or less 2 (22%) 1 (11%)
 80-100% 7 (78%) 7 (78%) 
 Not indicated 1 (11%) 
Number of allogeneic SCT done at the centre per year; (n, %)
 20-39 2 (22%) 1 (11%)
 40-79 5 (56%) 5 (55%) 
 ≥80 2 (22%) 3 (33%) 
Table 2: Demographic characteristics of the two expert panels 
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Experts were asked to rate the relevance of each PRO-CTCAE symptom term for the care of patients 
who are ≥1 year after SCT using a four-point Likert scale (1 = not relevant, 2= rather not relevant, 3= 
relevant, 4 = highly relevant). They had the option to provide additional comments regarding the 
terminology used and to suggest additional symptoms and topics believed to be important for a 
clinically useful PRO measure designed to evaluate the symptom experience in SCT recipients with 
and without cGVHD. Topics mentioned within the free text responses were summarized using content 
analysis; The Item Content Validity Index (I-CVI) was computed as the number of experts giving a 
rating of either 3 or 4 divided by the total number of experts. According to Polit & Beck (2006) items 
with an I-CVI of ≥.78 are considered to have good content validity. 38 items of the PRO-CTCAE 
symptom terms received an I-CVI ≥ 0.78 establishing them as relevant for SCT survivors. Experts 
suggested 26 additional topics (see Figure 1).  
Items to comprise a PRO-CTCAE item bundle for SCT survivors were included if two a priori 
criteria were met: (i) at least 50% of the patient sample (used to accomplished Aim 1) endorsed 
currently experiencing a symptom or experiencing it at any point 1 year or more after SCT; and (ii) 
SCT experts’ I-CVI rating of that item was ≥0.78. If neither criterion was met an item was excluded. If 
one criterion was met, a decision whether to include or exclude the symptom was made by two senior 
hematologists (JH & GS) and one expert nurse scientist (MK). Decisions about including a symptom 
were made based on these experts’ opinions about the clinical meaningfulness of the symptom in the 
post-transplant setting, and relevant literature. 
4.4.2 Results 
Twenty-three symptom terms met both selection criteria and were incorporated into the PRO-CTCAE 
SCT item bundle. Thirty-seven symptoms did not meet either of the two selection criteria and were 
excluded. Of the remaining 18 symptoms, the research team retained 13 symptoms. Ten out of these 
13 symptoms had a prevalence ≤50%, yet a high clinical relevance, meaning that they are potentially 
related to less common but important late effects (e.g. Unexpected or excessive sweating during the 
day or night-time may reflect infection or relapse) Three symptoms (anxiety, insomnia including 
difficulty falling asleep, staying asleep or waking up early and pounding or racing heartbeat) had a 
prevalence ≥50%, but an I-CVI <0.78 suggesting that experts may have underestimated the 
importance of these symptom concerns for patients.  Given that more than 50% of the SCT survivors 
indicated that they were experiencing or had previously experienced these symptoms, they were 
retained within the SCT survivor item bundle. Five items were excluded from the PRO-CTCAE SCT 
item bundle because of insufficient relevance for SCT follow-up care (e.g. frequent urination) or 
conceptual overlap with other included items (e.g. headache overlapping with pain).  
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The 57 additional topics suggested by patients and the 26 topics suggested by experts were 
compared using content analysis. After removing conceptual overlap, 37 additional candidate topics 
remained (see Box 1). These topics were considered for inclusion in the draft PROVIVO instrument. 
Experts were asked to rate the relevance of each PRO-CTCAE symptom term for the care of patients  
Topics in bold were included in the PROVIVO instrument  
Box 1: Additional topic suggestions by experts and patients 
Seven physical symptom terms (muscle cramps, light sensitivity of the eyes, dry eyes, joint stiffness, 
teeth problems (such as cracking, caries, and tooth sensitivity), tremors; and changes in the skin of the 
penis) were incorporated into the PROVIVO instrument, based on the authors’ clinical expertise and 
relevant literature. Eight additional items reflecting the effects of symptoms on daily living (partner–
ship and family, professional life/education/school, financial issues, social contacts (e.g. friends, 
Physical Symptoms 
Photosensitivity (light sensitivity of the eyes) 
Dry eyes 
Joint stiffness 
Teeth problems 
Muscle cramps  
Tremors 
Decreased flexibility of muscles and skin (e.g. 
problems to stretch muscles) 
Speech problems (e.g. problems with word finding) 
Urgent need for defecation 
Cellulite-like changes to the skin and soft tissues 
Runny nose 
Sensitivity of the gums / mouth 
Hearing loss 
Weight loss 
Skin changes  
Males:  Change in the skin of the penis 
 
Emotional symptoms 
Stress  
Frustration 
Changes in body image 
 
Comorbidities 
Frequent infections 
Osteoporosis 
Osteonecrosis 
Joint replacement 
Occurrence of skin tumours / changes in moles 
Solid tumours 
 
Functional problems 
Social problems 
Problems in work life  
Problems in family life, marriage and relationship 
Fertility concerns 
Financial problems  
Social support problems  
Help for self-help 
Problems with medications 
 
General condition 
Overall well-being 
Self-perceived physical fitness and endurance 
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public), family planning/fertility concerns); frequent infections, and two open-ended questions asking 
about current well-being and concerns the patient would like to discuss at the annual follow-up visit 
were also included in the PROVIVO instrument to inform follow-up care planning. Although these 
items address concerns beyond symptoms, both patients and experts perceived that the issues were 
salient to a full understanding of the symptom experience.  
4.5 Aim III: Evaluate the comprehensibility and content validity of the 
PROVIVO instrument  
Based on data derived from Aims I and II, the 52-items PROVIVO instrument was drafted. Self-
regulation theory was chosen as the underlying conceptual framework for the PROVIVO instrument, 
and shaped investigators’ decisions that items should capture both symptom occurrence (measured in 
terms of frequency or severity) and the associated symptom distress 26. The frequency response 
options (Never/Rarely/Occasionally/Frequently/Almost constantly) and severity response options 
(None/Mild/Moderate/Severe/Very severe) were derived from PRO-CTCAE.  An additional set of 
response options were developed to gauge how much distress (Not at all/A little bit/Somewhat/Quite a 
bit/Very much) was experienced in association with each symptom. To diminish respondent burden, 
PRO-CTCAE interference items were not included in the PROVIVO instrument. The PROVIVO 
measure incorporated the 7-day recall period used by PRO-CTAE.  
4.5.1 Materials and methods 
The comprehensibility of the 52 items, response options and instructions for the PROVIVO measure 
were evaluated in cognitive debriefings with 15 additional SCT survivors. Sample selection and 
recruitment procedures were comparable to those described previously.   
For this second round of debriefing, survivors first completed the PROVIVO instrument on 
their own. Subsequently, the interviewer instructed them to read aloud the introduction, the 
instructions and the items with their respective answers. Participants were then debriefed using a semi-
structured interview that focused on four aspects of comprehension: 
1. Are the introduction and the instructions clear? (e.g. Could you please repeat the instructions in 
your own words?) 
2. Are the items understood? (e.g. Could you please explain in your own words what this question 
means to you?) 
3. Are the response options well chosen? (e.g. Do these response options make sense to you?) 
4. Is item concept saturation reached? (e.g. Are there any items missing which should have been 
included in the questionnaire?) 
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Content analysis was used to summarize comprehension difficulties with the questionnaire introduc–
tion and instructions, and the items and response options.  
To evaluate the content validity of the PROVIVO items and the overall instrument, 9 additional 
experts were recruited using previously described eligibility criteria. Experts rated the relevance of each 
symptom term using a four-point Likert scale, and indicated any concerns about the questionnaire layout, 
introduction, instructions, items, and response options. Two CVI parameters were calculated: the pre-
viously described I-CVI, and the content validity index of the overall scale (S-CVI/Ave), which is com-
puted by summing the I-CVI’s from all items and dividing this sum by the number of items. I-CVI ≥0.78 
and S-CVI/ave ≥0.90 are considered to reflect acceptable content validity 27. 
4.5.2 Results 
Most PROVIVO items were well understood, although for 8 items minor adjustments to phrasing of 
the symptom terms were suggested, mostly with regard to word order. Five of these 8 were symptom 
terms that were added based on the unique symptom concerns experienced by SCT survivors (e.g. 
muscle cramping, dry eyes, light sensitivity of the eyes). Three PRO-CTCAE items (increased sun-
sensitivity of the skin, aching muscles and aching joints) were not well understood, and these items 
were eliminated from the final PROVIVO instrument. Specifically, respondents were unsure if 
increased sun-sensitivity referred to having a higher risk for developing skin cancer because of 
previous cancer treatment or if it was the increased risk of getting a sunburn even with minimal sun 
exposure. Other patients stated that they did not test their skin’s sun-sensitivity, but endorsed the 
presence of sun sensitive skin because they were aware that they were at risk for photoxicity due to 
medications and GVHD. Given these perspectives, the research team decided to exclude this item 
from the PROVIVO measure because it was felt that photosensitivity reflects a toxicity that is best 
identified by a clinician. With regard to aching muscles and aching joints (such as elbows, knees, 
shoulders) several respondents experienced difficulty answering these questions because they could 
not distinguish the discomfort caused by aching muscles vs. aching joints. For the PROVIVO 
measure, the investigators elected to gather information about pain more generally using the PRO-
CTCAE pain item, and to provide a free text option for the patient to specify the quality of the pain 
and a figure to mark the location.  
Although the chosen recall period of 7 days was well-accepted by a majority of the respondents, 
some indicating that they would have liked the option of a longer recall period in order to be able to 
communicate their past experiences. Because the PROVIVO measure is intended to capture the current 
symptom experience, and supported by evidence that there is an inverse relationship between length of 
recall period and accuracy of recall 28, the 7-day recall period was retained. Favourable feedback on the 
instructions for self-administration and the layout was received, suggesting that no changes were needed. 
Slight adjustments were made to the phrasing of the questionnaire introduction.  
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Themes/Item┼ 
Symptom prevalence 
(%)± in patient inter-
view round I: (n=15) 
I-CVI in 
expert 
group I* 
I-CVI in 
expert 
group II 
Physical symptoms 
Pounding or racing heart beat (palpitations) 9 (60%) 0.67 0.78 
Vomiting 8 (53%) 0.78 0.89 
Nausea 11 (73%) 0.78 1.00 
Loose or watery stools (diarrhea) 6 (40%) 0.78 1.00 
Arm or leg swelling 7 (47%) 0.89 0.89 
Unexpected or excessive sweating during the day or 6 (40%) 0.67 0.75 
Fatigue, Tiredness, or lack of energy 15 (100%) 0.89 1.00 
Shortness of breath 13 (87%) 1.00 1.00 
Cough 11 (73%) 1.00 0.89 
Blurred vision 11 (73%) 1.00 1.00 
Watery eyes (tearing) 5 (33%) 1.00 1.00 
Decreased appetite 13 (87%) 0.78 1.00 
Problems with tasting food or drinks 14 (93%) 0.78 1.00 
Difficulty swallowing 12 (80%) 0.78 0.89 
Mouth or throat sores 13 (87%) 1.00 0.89 
Dry mouth 12 (80%) 0.89 1.00 
Dry skin 12 (80%) 1.00 1.00 
Rash 9 (60%) 1.00 1.00 
Unusual darkening of the skin 7 (47%) 0.89 0.89 
Itchy skin 7 (47%) 1.00 1.00 
Numbness or tingling in your hands or feet 10 (67%) 0.89 1.00 
Insomnia including difficulty falling asleep, staying 10 (67%) 0.67 1.00 
Increased skin sensitivity to sunlight# 12 (80%) 0.89 - 
Pain 11 (73%) 1.00 1.00 
Aching joints# 10 (66%) 0.89 - 
Aching muscles# 7 (47%) 0.89 - 
Muscle cramps / / 0.89 
Tremors / / 0.89 
Photo sensitivity (Light sensitivity of the eyes) / / 0.78 
Dry eyes / / 1.00 
Teeth problems (such as / / 0.89 
Stiffness of joints / / 1.00 
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Emotional & cognitive symptoms    
Sad or unhappy feelings/Feeling that nothing could 9 (60%) 0.89 1.00 
Anxiety or worry 11 (73%) 0.67 1.00 
Problems with concentration 12 (80%) 0.89 1.00 
Problems with memory 10 (67%) 0.89 1.00 
Male & female urogenital symptoms    
Male (n=7)    
Change in the skin of the penis / / 0.75 
Ejaculation problems 4 (57%) 0.78 0.78 
Difficulty getting or keeping an erection 3 (43%) 0.89 0.89 
Female (n=8)    
Vaginal dryness 9 (100%) 1.00 1.00 
Unusual vaginal discharge 2 (25%) 0.78 0.89 
Pain during vaginal sex 4 (50%) 1.00 1.00 
Both genders    
Decreased sexual interest 13 (87%) 0.89 0.89 
Pain or burning with urination 2 (13%) 0.78 0.89 
Additional items for follow-up care planning    
Partnership and family / / 1.00 
Professional life/ education / school / / 1.00 
Financial concerns / / 1.00 
Social contacts (e.g. friends, public) / / 1.00 
Family planning /fertility concerns / / 1.00 
General well-being / / 0.89 
Frequent infections / / 0.89 
Current main concerns to discuss at next follow-up visit / / 1.00 
±    Prevalences are rounded 
┼  Cell colours indicate whether the item was retrieved from the PRO-CTCAE or if it was added 
PRO-CTCAE   additional item 
*  Item Content Validity Index 
# Excluded items in revised questionnaire version 
Table 3: Prevalence of symptoms in patients and CVI ratings of included items during the instrument development 
Twenty-nine of 49 PROVIVO items received an I-CVI of 1.00 indicating that all experts found these 
items to be quite or very relevant. Fifteen items received I-CVIs of 0.89 and three items received an  
I-CVI of 0.78. Two items, specifically pounding or racing heartbeat and light sensitivity of the eyes 
had an I-CVI of 0.75. Despite their slightly suboptimal CVI, it was decided to retain these two items 
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as both reflect symptom concerns identified by SCT survivors as important. The overall PROVIVO 
instrument received a S-CVI/Average of 0.94, indicating strong content validity as perceived by 
experts. The layout, introduction and respondent instructions were viewed favorably, and judged to be 
easy to comprehend. A majority expressed no concerns about the response options, although three 
experts mentioned that different response scales (e.g. Visual analogue scales, numeric scales) could 
have been considered. Since the team wished to incorporate the validated response options provided in 
PRO-CTCAE, no changes to the response options were made. 
4.6 Discussion 
We report the German language translation and linguistic validation of the PRO-CTCAE item bank, and 
describe the evidence supporting the content validity of a new measure designed to assess the symptom 
experience of allogeneic SCT survivors who are a year or more post-transplant. A subset of the PRO-
CTCAE symptom terms were identified by patients and clinician experts as relevant for symptom 
surveillance in SCT survivors. Additional symptom domains important to SCT survivors were identified 
by a panel of clinician experts, and through cognitive debriefing of SCT survivors, and included 
symptoms such as muscle cramping, joint stiffness, and dry eyes. Debriefing interviews confirm that the 
item phrasings, response choices, and general instructions are clear and comprehensible. All items but 
two exceeded an I-CVI >0.78, consistent with high relevance to SCT survivors. Data substantiate an 
empirically-derived PRO-CTCAE SCT survivor item bundle that can be used in prospective studies, and 
support the content validity of the German language PROVIVO instrument.  
Given the multifactorial etiology of late effects and the need to screen for a variety of 
symptoms with overlapping causes, the broad range of included symptoms is a particular strength of 
the newly developed PROVIVO instrument. It reflects symptoms that may be related to the underlying 
disease, persistent and late treatment effects, and comorbid conditions. Our goal with PROVIVO was 
to construct a PRO measure that predominantly focuses on symptom experience and to augment it 
with questions guiding survivorship care planning. Using the PRO-CTCAE item library was an 
efficient approach for the identification of an SCT-specific item bundle broadly applicable for 
symptom screening, and the resultant data are immediately actionable. As an alternative, an existing 
SCT-specific PRO measure (e.g. FACT-BMT, EORTC-HDC29 and the MDASI symptom burden 
scale (BMT & cGVHD versions) 14-16, 29, 30 could have been tailored to for use in the PROVIVO 
instrument. However, these instruments have had limited testing in long-term SCT survivors, and to 
our knowledge only, Velikova and colleagues involved survivors ≥1 year after SCT in the 
development of the EORTC-HDC-29, as is recommended 31, 32. Furthermore, the items included in 
these QoL instruments reflect only a narrow range of common symptoms (such as nausea, pain, and 
fatigue) and may neglect a number of the important and clinically actionable symptoms that can occur 
in long-term SCT survivors.  
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cGVHD and the immunosuppressive agents used to treat it may cause a wide range of compli-
cations that can amplify symptom distress and impair functional performance 33. Since the PROVIVO 
instrument, however, was not specifically created to identify and grade cGVHD, in patients with 
cGVHD, we recommend that the PROVIVO measure be used in conjunction with the Lee cGVHD scale 
17. To avoid overlap in the content of these two measures, electronic reporting systems using conditional 
branching could be applied to customize assessment pathways based on respondents’ answers.  
Several limitations should be considered in interpreting our findings. We recognized that the 
two criteria defined a priori for the inclusion of items were relaxed in making the final selection of 
items. Decisions about the topics included in the PROVIVO instrument reflect triangulation of the 
mixed methods data sources, including patient and clinician perspectives concerning the topics that are 
important to optimize the delivery of SCT survivorship care. It is possible that our results were 
influenced by our small sample size or by socio-linguistic factors. Although standard German is the 
official language in Switzerland, the Swiss-German dialect is commonly spoken in everyday life 34. 
Validity testing of the PRO-CTCAE German item library in a large sample of patients recruited from 
cancer treatment centres in Germany is ongoing to establish the generalizability of these linguistic 
validation findings35. The validity and responsiveness of the PROVIVO measure are also being 
examined in a study of approximately 300 Swiss-German speaking SCT survivors, with diverse 
characteristics with respect to age, underlying diagnosis, and severity of cGVHD manifestations.  
With additional testing in both the German language and in other languages, the PROVIVO 
instrument and the empirically derived PRO-CTCAE item bundle offer promising tools to improve the 
delivery of SCT survivorship care. Our findings provide preliminary evidence supporting an SCT 
survivor-specific PRO-CTCAE item bundle, and identify additional PRO-CTCAE symptom terms 
such as muscle cramping and tremor that should be included in future versions of the NCI PRO-
CTCAE item library. PROs may have utility to direct follow-up care delivery and can help survivors 
and their clinicians efficiently identify symptoms and other concerns that are actionable during clinic 
visits. Prospective studies are warranted to define the sensitivity of PROVIVO and the PRO-CTCAE 
SCT survivor item bundle to detect late effects such as avascular necrosis and new onset of pulmonary 
compromise, particularly in long-term survivors who may be seen less frequently at their transplant 
centre yet require life-long surveillance for a range of chronic health concerns 36. Additional research 
is needed to determine how to incorporate the information derived from PROs to inform the 
development of survivorship care plans, strengthen care delivery, and improve outcomes for this 
vulnerable group of survivors.  
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5.1 Abstract  
Background: Following allogeneic haematopoietic stem cell transplantation (SCT), patients remain 
permanently at risk of late effects, many of which manifest as symptoms. To measure patients’ symptom 
experiences, the PROVIVO instrument (Patient Reported Outcomes of long-term SCT surVIVOrs) was 
developed. This paper describes several refinements to the initial version, followed by validity and 
reliability testing. 
Objective: To refine the newly developed PROVIVO instrument and examine its validity and 
reliability. 
Methods: A cross-sectional study was performed using a 376-patient convenience sample ≥1 
year after allogeneic SCT in two Swiss university hospitals. Following American Educational 
Research Association guidelines, we tested the questionnaire on three evidence levels: construct 
validity based on internal structure was tested by an exploratory factor analysis; and Cronbach’s 
alphas and inter-item correlations were calculated to examine internal consistency reliability. Relations 
to other variables were tested based on a set of evidence-based hypotheses.  
Results: Based on performance testing, four original PROVIVO items were dropped. The 
exploratory factor analysis revealed an eight-factor model explaining 57.05% of variance. Internal 
consistency reliability was good for the entire scale (Cronbach's alphas .90), but only acceptable for 
the eight factor scores. Additional evidence supports relations between variables, e.g., between the 
number of symptoms and cGVHD occurrence, number of late and performance status.  
Conclusion: Initial evidence for the validity of the PROVIVO symptom experience scale was 
provided. The PROVIVO questionnaire may be useful to identify late effect symptoms warranting 
further testing.  
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5.2 Background 
Allogeneic hematopoietic stem cell transplantation (SCT) is an intensive curative treatment for many 
haematological diseases. However, patients remain at a life-long increased risk of developing various 
adverse side effects. These “late effects” 1 may appear months or years after treatment has ended, can 
persist chronically and may be experienced as distressing and burdensome symptoms 2. Therefore, it is 
essential to assess symptom experience. According to Leventhal’s self-regulation theory, symptoms 
can be adequately assessed on two dimensions: the cognitive, i.e., symptom occurrence (frequency and 
severity), and the emotional, i.e., symptom distress 3. Thus, it is necessary to measure, document, and 
monitor symptom experience based on patient-reported outcomes (PROs). As a data collection 
method, PROs have become increasingly important to both clinical research and practice over the last 
decades. For example, before approving new therapeutic agents, the US Food and Drug 
Administration (FDA) and the European Medicines Agency recommend that research provides ample 
patient-reported evidence of their benefits 4, 5.  
As few long-term post-SCT studies have simultaneously measured symptom occurrence and 
distress, little is known of patients’ symptom experiences 6-8. However, it has been shown that vision 
problems, sexual dysfunction, tiredness, anxiety and changes of taste are experienced by more than 50% 
of survivors and can be very distressing 7. Also, as may be expected, patients who have chronic graft 
versus host disease (cGVHD) suffer more distressing symptoms than those who have no cGVHD 9-11. 
Greater symptom distress has been associated with worse psychological functioning, i.e., greater degrees 
of depression and anxiety 12-14, worse post-transplant physical functioning 15-17, and more post-transplant 
comorbid conditions (≈late effects) 18. Most importantly, lower symptom distress is a positive predictor 
of survival 8. Figure 1 illustrates the interplay between this study’s theoretical framework of symptom 
experience and the current evidence presented in the literature.  
 
 
 
 
 
 
 
 
Figure 1. Symptom experience of late effects 
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Optimally, research on late effects should be based on a combination of PRO data and objective 
diagnostics. However, to date, most studies on late effects have relied only on clinician-rated adverse 
event forms or checklists 19, 20. Full assessment of late effect symptom experiences requires the 
development of a valid and reliable PRO instrument. Although various SCT-specific PRO instruments, 
including the MDASI-BMT 21, FACT-BMT 22, and EORTC-HDC29 23 already exist, these were 
specifically designed either for the acute treatment phase, or, in the case of the Lee Chronic GVHD 
scale 24, for the assessment of cGVHD symptoms. Similarly, generic instruments such as the 
Rotterdam Symptom Checklist 25 or the Symptom Distress Scale 26 may only address subsets of the 
symptoms that can occur in long-term SCT survivors.  
Consequently, to assess specific symptom experiences relating to post-SCT late effects, we 
followed FDA state-of-the-art PRO guidelines to develop the PROVIVO questionnaire 5. As a basis 
for symptom selection we used the U.S. National Cancer Institute’s PRO-CTCAE – an item library 
comprised of 78 symptom terms relevant to all types of cancer treatment. The iterative development 
process involved both quantitative and qualitative research methods, and included two rounds of 
patient cognitive debriefings (n=30) and clinical expert review (n=18). Preliminary content validity 
testing revealed excellent content validity in both the scale (scale-CVI: 0.94) and its individual items 
(median item-CVI= 1; range 0.75-1) 27. However, as a subsequent step, instrument refinement and 
psychometric testing in a larger sample of long-term SCT survivors is warranted.  
Level of evidence Hypothesis or research question 
Evidence on construct 
validity based on 
internal structure 
H1 The symptom occurrence items build a meaningful symptom structure in the exploratory factor analysis. 
Internal consistency 
reliability H2 The PROVIVO instrument shows good internal consistency. 
 H3 Symptom occurrence items of the PROVIVO instrument show high correlations within its respective factor 
Relation to other 
variables H4 
Symptom occurrence items of the PROVIVO instrument show high 
correlations within its respective factor 
 H5 
Having depressive symptomatology based on the HADS (score>8) is 
related to higher symptom occurrence and symptom distress. 12-14 
 H6 
Having a lower performance status (Karnofsky <80) is associated with 
higher symptom occurrence 15-17 
 H7 
Having more late effects is associated with higher symptom 
occurrence and symptom distress. 
Abbreviations:  
H = Hypothesis, cGVHD = chronic Graft versus Host Disease, according to the National Institute of Healtth criteria (I-III) 
Table 1: Hypotheses of the validation study 
CHAPPTER 5 
- 65 - 
As cancer patients usually simultaneously experience multiple disease- and treatment-related 
symptoms, many of which also influence each other, the validation of a symptom experience scale is 
especially complex 28. The standards for educational and psychological testing set by the American 
Educational Research Association (AERA) define validation as the process of developing a sound 
argument for how to interpret scores on a test and the relevance of the test to its proposed use 29. The 
purpose of this validation study was (1) to describe preliminary data of the newly developed 
PROVIVO instrument, (2) refine the newly developed instrument and (3) to explore its psychometric 
properties based on the AERA Standards. Hypotheses to rigorously check the validity and reliability 
of the instrument are listed in Table 1. 
5.3 Methods 
5.3.1 Design, sample, setting 
To validate the PROVIVO instrument we used data collected for a cross-sectional study using a 
convenience sample of 376 patients ≥1 year after allogeneic SCT at the Basel and Zürich University 
Hospital outpatient clinics (NCT01275534). Inclusion criteria were a minimum age of 18 years and 
the ability to read and write German. Patients who were hospitalized or in a terminal illness state were 
excluded, as were those with psychiatric disorders that, in the opinion of the treating haematologist, 
would prevent them from participating in the study. 
5.3.2 Variables and measurement 
Symptom experience  
The PROVIVO instrument measures 31 physical symptoms, 4 emotional and cognitive symptoms, 
three gender-specific symptoms for women (vaginal dryness, unusual vaginal discharge, pain during 
vaginal sex), and three more for men (difficulty getting or keeping an erection, ejaculation problems, 
changes in the skin of the penis). The reporting period for each is the last 7 days. Each symptom is 
scored in view of symptom occurrence (severity or frequency) and distress. For symptom severity, a 5-
point rating scale ranging from 0 (none) to 4 (very severe) is used. Frequency is assessed from 0 
(never) to 4 (nearly every time), and distress from 0 (not at all distressing) to 4 (extremely distressing). 
For follow-up care planning at the survivorship clinic, 5 additional items reflect the symptoms’ effects 
on aspects of daily life (partnership and family, professional life/education/school, financial issues, 
social contacts (e.g., friends, public), family planning/fertility concerns). Each of these effects is also 
assessed regarding severity and distress, using the above-mentioned Likert scale responses. To further 
facilitate follow-up care planning, one item asking about frequency of infections, and two open-ended 
questions asking about current well-being and supportive care needs/topics the patient would like to 
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discuss at the annual follow-up consultation. Because these items are primarily aimed at enhancing 
care planning and do not strictly belong to the concept of symptom experience, they are not included 
in the psychometric testing procedures; still, the current report gives descriptive results for the 5 items 
reporting influence on daily living. Results of the two open-text items are reported elsewhere 30. The 
time frame of all items is the last seven days. 
Anxiety and depression 
Anxiety and depression were measured using the Hospital Anxiety Depression Scale (HADS) 31, 
consisting of 14 items evaluated on a 4-point Likert scale. The HADS is divided into two separately-
summed scales, i.e., 7 items measure anxiety and 7 measure depression. On the anxiety scale, a total 
score of greater than 10 indicates a clinical diagnosis of anxiety, scores of 8 to 10 are borderline, and 
those below 8 are interpreted as clinically insignificant or normal. Similar interpretations apply to the 
depression scale. Both scales can be interpreted independently of one other. The HADS is widely 
validated in diverse populations 32. The German language version (HADS-D) is validated in the 
general German-speaking population 33. 
Demographic and clinical variables  
Patients provided information about marital status (married or living with partner; not married or ed), 
education (no completed school or professional education; mandatory school; apprenticeship or full-
time vocational school; higher professional education; university degree) and employment (full-time 
(working ≥80%), part-time, or not employed). 
Clinical data were retrieved from the transplant database and patient records. Variables included: 
age; years after transplantation; haematological diagnosis; transplant source (peripheral stem cells, bone 
marrow, cord blood); total body irradiation (yes/no); number of transplantations; donor relationship 
(related matched, related mismatched, syngeneic, unrelated), status of haematological disease at annual 
control (remission, not in remission/relapse); grade of cGVHD (none, mild, moderate, severe) 34; and 
Karnofsky index (physician’s rating of an individual's health and well-being, based on a criteria-related 
performance index of physical ability rated from 100% (normal function) to 10% (moribund)) 35.  
5.3.3 Data collection 
In the month before their annual follow-up visits, a research assistant phoned all eligible SCT 
recipients, informed them about the study and inquired whether they were interested in participating. 
Those who were interested received the study information letter, informed consent form and 
questionnaire per postal mail. Patients either gave the completed materials to their treating physicians 
at their annual follow-up visits or via regular mail. Clinical and demographic data were collected from 
the transplant database and patient records. Data was anonymised and entered in a database. 
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5.3.4 Data analysis 
For our first aim, to describe preliminary data collected by the newly developed PROVIVO instru-
ment, we used descriptive statistics (means and standard deviations for normally distributed and 
interval scaled data as well as medians and interquartile ranges (IQR) for skewed interval scaled data 
and ordinal scaled data). For data visualisation we used a scatterplot matching mean item severity/ 
frequency scores and mean item distress scores. 
Our analysis used all available data, handling missing data via pairwise deletion. Data were 
screened for outliers and normal distributions by considering boxplots and histograms. All data were 
analysed using IBM SPSS Statistics 21 (SPSS, Inc., Chicago, IL). Statistical significance was set at p<0.05. 
For our second aim, the refinement of the instrument, a-priori defined criteria guided our 
decisions. Items with the following characteristics were considered for removal/refinement:  
1. More than 5% missing responses;  
2. Ceiling or floor effects (respectively, ≥80% or ≤20 of patients experiencing a symptom); and 
3. Redundancy of an item as demonstrated by a strong correlation with another item (r≥0.70).  
A fourth criterion, useful for both item reduction and refinement, resulted from an exploratory 
factor analysis (EFA) with oblique rotation (Promax rotation method (assumes correlated factors)) and 
principal axis factoring extraction. This used all but three interval-scored symptom severity/frequency 
items. The exceptions were the gender-specific items. Because of their different (male vs. female) sam-
ple characteristics, these items were subjected to separate factor analyses, i.e., one for each gender. Bas-
ed on the factor loadings, items were considered for deletion or refinement either if they failed to load on 
exactly one factor with a value of ≥0.4, i.e., they loaded on no factor with a value ≥0.4 or if they loaded 
on two or more factors with values of ≥0.4. For item reduction, the clinical relevance of each item was 
also considered.  
For our third aim, the exploration of the psychometric properties based on the AERA Stand-
ards, to test the revised instrument’s internal structure (hypotheses 1), a second EFA was conducted 
with the adjusted number of items. 
To test hypothesis 2 and 3 (Table 1), the instrument’s internal consistency reliability was 
examined. Cronbach’s alpha was calculated for each factor of the PROVIVO symptom scale, with 
values >0.60 indicating adequate internal consistency 36. Additionally, to confirm the internal consist-
ency, inter-item correlations and correlations between individual items and corresponding factor 
scores were calculated. An acceptable coefficient for item-total correlations, indicating that the item 
contributes significantly to the measure, is >0.30. For interitem correlations, coefficients of >0.30 and 
<0.70 are acceptable. An item coefficient of ≤0.30 indicates no significant contribution; a coefficient 
of ≥0.70 indicates redundancy. 
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Evidence concerning relations to other variables was assessed with Spearman correlations. 
Based on the evidence from the literature, we proposed hypotheses 3-7 (displayed in Table 1).  
5.4 Results 
5.4.1 Demographics 
A total of 376 completed questionnaires were returned (overall response rate: 61.6%). On average, 
patients were 50.3 (SD 12.7) years old, with a median post-SCT follow-up period of 7.1 years (IQR 
8.9). Most had been treated for an acute or chronic myeloid leukaemia. Detailed socio-demographic 
and clinical characteristics are shown in Table 2. 
Characteristics n % 
Gender, male (%) 207 (55.1%) 
Age in years, mean (s.d.) 50.3(12.7) 
Initial Diagnosis (%)  
 Acute & chronic myeloid leukemia 180 (47.8%) 
 Acute & chronic lymphoid leukemia 73 (19.4%) 
 Plasma cell disorder 21 (5.6%) 
 Hodgkin or Non Hodgkin lymphoma 40 (10.6%) 
 Myelodysplastic or  Myeloproliferative syndrome 44 (11.7%) 
 Non-malignant haematologic disease 18 (4.9%) 
Years after transplantation, median 7.1 (IQR 8.9, range 1-33) 
Source of transplant (%)  
 Bone marrow 117 (31.1%) 
 Peripheral blood 258 (68.6%) 
 Umbilical cord blood 1 (0.3%) 
Conditioning regimen (%) a  
 Myeloablative 286 (76.9%) 
 Reduced intensity 86 (23.1%) 
Total Body Irradiation with ≥12 Gray (%) 220 (58.5%) 
Donor relationship (%)  
 Matched related 226 (60.1%) 
 Syngen 8 (2.1%) 
 Mismatched related 9 (2.4%) 
 Unrelated 133 (35.4%) 
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Current stage of disease (%) b 
 Complete remission 347 (94.8%)
 Not in remission/Relapse 19 (5.2%)
Chronic GVHD (%)
 None 206 (54.8%)
 Mild 101 (26.8%)
 Moderate 36 (9.6%)
 Severe 12 (3.2%)
 No information available 21 (5.6%)
Karnofsky Score (%) c 
 100 - 90% 297 (84.2%)
 <90 - 80 35 (9.9%)
 <80 21 (5.9%)
Education (%) d 
 Compulsory schooling 52 (14.1%)
 Secondary education 204 (55.3%)
 Tertiary education 113 (30.6%)
Partnership (%) e  
 Married or cohabiting 292 (78.3%)
 Single, not cohabiting 81 (21.7%)
Employment (%)  
 Full-time (≥80%) 130 (34.6%)
 Part-time 127 (33.8%)
 Not working 119 (31.6%)
a missing n = 4; b missing n = 10; c missing n = 23; d missing = 7; e missing= 3;  
Table 2: Sample characteristics (N=376) 
5.4.2 Results for aim 1: Preliminary description of results of the newly developed PROVIVO 
instrument  
The median number of symptoms/problems per patient was 13 (IQR 13; range: 0-36). The most often 
reported symptom was fatigue, tiredness or lack of energy (74.2%) followed by problems with memory 
(68.8%) and dry skin (67.8%). Six more symptoms were reported by more than 50% of all patients: pain 
(58.0%), problems with concentration (54.8%), light-sensitivity of the eyes (54.0%), muscle cramps 
(51.6%), dry eyes (51.1%), and insomnia (50.0%). While no items showed ceiling effects, i.e., 
prevalences above 80%, six showed floor effects, i.e., prevalences below 10%: vomiting (9.8%), pain or 
burning with urination (2.7%), ejaculation problems (8.5%), change in the skin of the penis (2.4%), 
unusual vaginal discharge (2.9%) and pain during vaginal sex (6.6%). Distributions of symptom 
occurrence and distress items were skewed.  
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Median occurrence scores ranged from 1.89 (vomiting) to 3.47 (child wish/family planning) 
while median distress scores ranged from 1.25 (unusual vaginal discharge) to 3.14 (family planning/ 
child wish). A scatter plot of mean symptom severity/frequency scores (Figure 2) shows the classifi-
cation of symptoms into four categories. Symptoms in the lower left quadrant are both less severe/ 
frequent and less distressing (n=13); those in the upper left quadrant are more severe/frequent but less 
distressing (n=6); in the upper right quadrant they are both more severe/frequent and more distressing 
(n=19), and symptoms in the lower right quadrant are less severe/frequent but more distressing (n=9).  
Legend 
Physical symptoms   Gender symptoms 
1 Fatigue, tiredness, or lack of energy 20 Tremors 19♂♀ Decreased sexual interest 
2 Dry skin 21 Teeth problems 37♂ Difficulty getting or keeping 
3 Pain 22 Watery eyes (tearing)  an erection 
4 Light sensitivity of the eyes 23 Nausea 38♂ Ejaculation problemserection 
5 Muscle cramps 24 Problems with tasting food/drinks 39♂ Change in the skin of the penis 
6 Dry eyes 26 Rash 40♀ Vaginal dryness 
7 Insomnia including difficulty falling, 27 Decreased appetite 41♀ Unusual vaginal discharge 
 asleep, staying asleep 28 Mouth or throat sores 42♀ Pain during vaginal sex 
8 Unexpected or excessive sweating  29 Difficulty swallowing 
 during the day or night time 30 Unusual darkening of the skin Influence on daily life 
9 Blurred vision 31 Vomiting 43 Partnership and family 
10 Dry mouth 32 Pain or burning with urination 44 Professional life/education/school 
11 Shortness of breath   45 Financially 
12 Cough Emotional/cognitive symptoms 46 Social contacts (e.g. friends, public) 
13 Numbness or tingling in hands or feet 33 Problems with memory 47 Family planning /child wish 
14 Stiffness of joints 34 Problems with concentration 
15 Itchy skin 35 Sad or unhappy feelings  
16 Loose or watery stools (diarrhea) 36 Anxiety or worry  
17 Arm or leg swelling  
18 Pounding or racing heart beat    
Figure 2: Mean symptom severity/frequency and distress score per item (N = 376) 
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 Frequency Symptom occurrence 
Symptom 
distress 
 n % Median (IQR) Median (IQR) 
Physical symptoms     
Fatigue, Tiredness, or lack of energy 279 74.2% 2.85 (1.70) 3.00 (2.08) 
Dry skin 255 67.8% 2.88 (1.68) 1.94 (1.62) 
Pain 218 58.0% 3.31 (1.55) 2.83 (2.72) 
Light sensitivity of the eyes 203 54.0% 2.70 (1.61) 2.60 (1.89) 
Muscle cramps 194 51.6% 2.63 (1.47) 2.89 (1.90) 
Dry eyes 192 51.1% 3.12 (1.91) 2.76 (1.95) 
Insomnia including difficulty falling asleep, staying 
asleep, or waking up early) 188 50.0% 2.86 (1.70) 2.94 (2.04) 
Unexpected or excessive sweating during the day or 
night time (not related to hot flashes) 143 38.0% 2.51 (1.44) 2.32 (1.67) 
Blurred vision 143 38.0% 2.36 (2.36) 2.96 (1.95) 
Dry mouth 139 37.0% 2.78 (1.66) 2.57 (1.85) 
Shortness of breath 138 36.7% 2.57 (2.57) 2.71 (1.88) 
Cough 135 35.9% 2.14 (2.14) 1.84 (1.49) 
Numbness or tingling in your hands or feet 133 35.4% 2.76 (1.75) 2.64 (1.94) 
Stiffness of joints 124 33.0% 2.71 (1.53) 2.83 (1.70) 
Itchy skin 118 31.4% 2.00 (2.00) 2.34 (1.65) 
Loose or watery stools (diarrhea) 115 30.6% 2.41 (1.38) 2.57 (2.05) 
Arm or leg swelling 112 29.8% 2.81 (1.55) 2.57 (1.89) 
Pounding or racing heart beat (palpitations) 110 29.3% 2.37 (1.34) 1.96 (1.43) 
Decreased sexual interest 101 26.9% 2.62 (1.43) 2.00 (1.80) 
Tremors 91 24.2% 2.42 (1.35) 2.17 (1.79) 
Teeth problems 89 23.7% 2.16 (2.16) 2.56 (1.73) 
Watery eyes (tearing) 87 23.1% 2.50 (2.50) 2.23 (1.72) 
Nausea 86 22.9% 2.23 (2.23) 2.56 (1.72) 
Problems with tasting food or drinks 76 20.2% 2.83 (1.70) 2.93 (2.21) 
Rash 75 19.9% 2.55 (2.55) 2.74 (1.98) 
Decreased appetite 69 18.4% 2.52 (2.52) 2.03 (1.71) 
Mouth or throat sores 68 18.1% 2.23 (2.23) 2.5 (1.73) 
Difficulty swallowing 52 13.8% 2.28 (2.28) 2.79 (1.92) 
Unusual darkening of the skin 41 10.9% 2.32 (2.32) 1.82 (1.72) 
Vomiting 37 9.8% 1.89 (1.89) 2.91 (2.2) 
Pain or burning with urination 10 2.7% 2.40 (1.40) 2.50 (2.17) 
Emotional and cognitive symptoms       
Problems with memory 258 68.6% 2.58 (1.42) 2.78 (2.14) 
Problems with concentration 206 54.8% 2.52 (1.42) 2.66 (2.03) 
Sad or unhappy feelings 172 45.7% 2.19 (2.19) 2.30 (1.69) 
Anxiety or worry 118 31.4% 2.18 (2.18) 2.23 (1.57) 
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Male symptoms 
Difficulty getting or keeping an erection 81 21.5% 2.92 (1.62) 2.50 (1.87) 
Ejaculation problems 32 8.5% 2.83 (1.43) 2.53 (1.96) 
Change in the skin of the penis 9 2.4% 2.95 (1.43) 2.7 (1.57) 
Female symptoms 
Vaginal dryness 159 42.3% 2.57 (1.43) 2.13 (1.95) 
Unusual vaginal discharge 11 2.9% 2.58 (1.52) 1.25 (1.25) 
Pain during vaginal sex 25 6.6% 2.61 (1.53) 2.80 (1.80) 
Influence on daily life       
Partnership and family 117 31.1% 2.51 (2.51) 2.90 (1.89) 
Professional life/ education / school 105 27.9% 2.75 (1.72) 2.90 (1.87) 
Financially 86 22.9% 2.58 (1.52) 2.76 (1.72) 
Social contacts (e.g. friends, public) 72 19.4% 2.65 (1.64) 3.02 (1.99) 
Family planning /child wish 40 10.6% 3.47 (2.27) 3.14 (2.14) 
Heat intensity mapping was used to represent the median scores for symptom occurrence and distress varying from light to 
dark grey (i.e., the darker the grey colour the larger the median score, the lighter the grey color the lower the mean score).  
 ≥75 Percentile ≥ 50 percentile  < 50 percentile 
Abbreviations: IQR = Interquartile range 
Table 3: Symptom prevalence, median symptom occurrence and distress scores (N=376) 
5.4.3 Aim 2: Refinement of the scale 
A missing value analysis indicated 4-items with more than 5% missing values (range: 0–7.2%): 
“decreased sexual interest”, “pain or burning during urination“, “problems at work/training/school”, 
and “problems with child wish/family planning” 
The item-to-item correlations were all below 0.80, with the closest association indicated was 
between nausea and vomiting (r=0.624), indicating a conceptual similarity. Subsequently, the EFA 
was conducted including all 35 non-gender-specific physical and emotional/cognitive symptom items. 
This yielded 10 factors with eigenvalues ranging from 8.301 to 1.012, explaining 59.4% of the 
variance. Twenty-seven items clearly loaded on one of the 10 factors, with loadings ranging from .403 
to .903. Of the remaining 8, two cross-loaded: blurred vision, with factor loadings of .587 on factor 2 
(dry eyes, light-sensitivity) and .517 on factor 10 (watery eyes); and problems with tasting food or 
drinks, with factor loadings of .480 on factor 3 (cough, numbness or tingling in your hands or feet, 
shortness of breath) and .485 on factor 7 (vomiting, nausea, decreased appetite). Six items failed to 
load significantly on any factor. 
Based on these preliminary results, we adapted the PROVIVO scale according to our pre-
defined criteria for item retention and clinical meaningfulness. As the vomiting item had a floor effect 
and a high item-to-item correlation with nausea, we combined the two items into nausea or vomiting. 
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Also, we observed double loadings in two factors related to eye problems, watery eyes and dry eyes. 
As both are manifestations for abnormal tearing production (potentially related to a damage of the 
conjunctivas or cataract) we also combined them into a single item, abnormal tearing (too dry or 
watery eyes). Further, we changed one item, skin rash into changes of the skin (including skin rash) 
and deleted two others entirely – unusual darkening of the skin, which showed a floor effect, and pain 
or burning with urination, which had both 5.6% missing data and a floor effect. Other items with floor 
effects were left unchanged, as, from a clinical point of view, they would prevent errors in the 
detection of clinically important symptoms.  
5.4.4 Construct validity and internal consistency reliability 
 
Factor 
1 2 3 4 5 6 7 8 
Decreased appetite .750 
         
Nausea & vomiting .741 
Loose or watery stools (diarrhea) .404 
Pounding or racing heartbeat (palpitations) .402 
Abnormal tearing of eyes (too dry or watery) .795 
Eye sensitivity to light .745 
Blurred vision .714 
Cough .711 
Numbness or tingling in your hands or feet .618 
Problems with tasting food or drinks .567 
Shortness of breath .468 
Skin rash or abnormal changes of skin .836 
Itchy skin .767 
Dry skin .553 
Arm or leg swelling .672 
Muscle cramps .611 
Stiffness of joints .514 
Pain .486 
Mouth or throat sores .636 
Dental problems .635 
Dry mouth      .403   
Difficulty swallowing      .401   
Sad feelings -.722 
Problems concentrating -.708 
Problems with memory -.682 
Anxiety -.663 
Decreased sexual interest        .844 
Fatigue, tiredness, or lack of energy 
Tremors         
Insomnia (including difficulties falling 
asleep, or waking up early)         
Unexpected or excessive sweating during the 
day or nighttime (not related to hot flashes)         
Table 4: exploratory factor analysis 
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After reducing the number of items as described above, the EFA of the adjusted 34-item instrument yielded 
8 factors explaining 57.05% of the total variance. The Kaiser-Meyer-Olkin measure of sampling adequacy 
produced a figure of 0.824, showing that the data are suitable for factor analysis. Eigenvalues ranged from 
8.069 to 1.103. Factor loadings are presented in Table 4. Five items did not load adequately on any factor. 
The EFA for the male symptoms yielded one factor with an eigenvalue of 1.785, explaining 59.52% of the 
variance; the factor loadings ranged from .483 to .883. The female symptoms yielded one factor with an 
eigenvalue of 1.936, explaining 64.42% of the variance; loadings ranged from .568 to .926. 
As predicted in hypothesis 1, the 8-factor model yielded acceptable/good reliability values, 
with Cronbach’s alphas varying from 0.53 to 0.82 (Table 5). For the male and female symptom 
factors, Cronbach’s alphas were respectively 0.65 and 0.72.  
Factors of PROVIVO Eigenvalue Cronbach’s alpha 
Inter-item 
correlation 
Item to factor 
correlation, range 
Ingestion symptoms (4 items) 8.069 0.66 .340 .368–.599 
Eye symptoms (3 items) 1.885 0.72 .465 .538–.545 
Symptoms of neurological & 
pulmonary toxicity/morbidity (4 
items) 
1.695 0.62 .295 .348–.454 
Skin symptoms (3 items) 1.462 0.67 .428 .457–.575 
Skeletal, connective tissue symptoms 
& pain (4 items) 
1.348 0.66 .333 .366–.477 
Symptoms of the mouth & dental 
problems (4 items) 
1.117 0.53 .230 .284–.355 
Emotional & cognitive symptoms  
(4 items) 
1.103 0.82 .526 .564–.736 
Decreased sexual interest 1.015 n.a n.a. n.a. 
Table 5: Reliability characteristics of the eight factors  
5.4.5 Relations to other variables 
Testing evidence based on relations to other variables confirmed four literature-based hypotheses. As 
hypothesized, any grade of cGVHD was associated with a higher number of physical symptoms  
(r =.304; p<=0.00); depressive symptomatology was related to both higher number of emotional/ cog-
nitive symptoms (r=.474; p=.000) and higher emotional/cognitive symptom distress (r=.596; p=.000). 
Also more anxiety symptomatology was related to more emotional/cognitive symptoms (r=.595; 
p=.000) and higher emotional/cognitive symptom distress (r=.527; p=.000). Symptom occurrence was 
higher both in patients with lower performance status (Karnofsky <80) (r=-.417; p=.000) and in those 
with more late effects (r=.189; p=.000). 
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5.5 Discussion 
The PROVIVO instrument appears to be a useful measure of late effect symptom experience following 
SCT. In this initial psychometric evaluation, item refinement and reduction resulted in the final 34-item 
symptom experience scale including three gender specific items each for women and men. Eight addi-
tional items are included to guide follow-up care planning. The questionnaire’s measurement properties 
were supported, with findings suggesting good internal structure, adequate consistency, and reliability, 
along with evidence for validity related to other variables. This study provides initial evidence regarding 
measurement of long-term allogeneic SCT survivors late effect symptom experiences. The minimal 
incidence of missing data from the submitted PROVIVO questionnaires suggests ease of use and 
comprehensibility. 
From our factor analysis examining construct validity, logical patterns of symptoms emerged, 
i.e., symptoms which typically occur frequently in combination also loaded together 37. For instance, as 
abnormal tearing of eyes, light-sensitivity of the eyes and blurred vision might appear more frequently in 
patients with eye-related problems such as cataract or sicca syndrome of the conjunctivas 38, 39. However, 
five items did not load on any factor: fatigue, tiredness or lack of energy, tremors, insomnia, unexpected 
or excessive sweating during the day or night. Since inter-item correlations of these symptoms showed 
relations to various symptoms, a possible explanation for their failure to load significantly is that they co-
appear with a variety of conditions and therefore cannot be clearly related to any single symptom factor. 
As an example, while fatigue is a symptom very commonly related to numerous co-morbidity conditions 
after SCT 40-42, it did not load significantly on any specific factor.  
It is acknowledged that performing factor analyses on a symptom questionnaire is a difficult 
undertaking 43, 44. Regarding the current study, any of a number of particularities, including the hetero-
geneity of symptom profiles, differences in the occurrence and severity of symptoms, or the overall he-
terogeneity of the study sample could have skewed the results. This may also explain our low Cronbach 
alphas and item to factor correlations. In contrast to scales measuring very distinct constructs such as 
anxiety, “late effect symptom experience” is more manifold on a patient level and therefore more 
difficult to assess.  
Further research should therefore examine the eight revealed factors in view of their predictive 
validity for specific late effects. For example, it would be useful to investigate whether the factor inclu-
ding arm or leg swelling, muscle cramps, stiffness of joints and pain predicts late skeletal system effects. 
This information would be particularly valuable to determine the PROVIVO’s predictive validity for 
specific late effects’ symptom factor scores, and to determine whether sub-scores can be calculated for 
the PROVIVO instrument. Currently we recommend scoring the instrument using two separate sum 
scores – one for the number of symptoms (physical and emotional/cognitive) and one for symptom 
distress. Regarding symptom occurrence and distress, scores can also be calculated on the item level. 
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Moreover, as the current study’s patients reported a high number of symptoms (median 13 (IQR 
13) – considerably more than those in previous studies (median <10) 6, 18 – the PROVIVO instrument’s 
preliminary results underscore the importance of symptom assessment in long-term survivors. 
Differences may be related to the researchers’ choices of measures, or to variations in sample 
characteristics, or even data collection time points. Bevans et al.’s prospective study of 171 patients 
(minimum post-SCT follow-up time 3 years) reported an average of 8 (SD 5) to 10 symptoms (SD 6.6) 
across time. For Larsson et al., one year after transplantation, patients evaluating their health status 
reported symptoms with an adapted 23-item version of the symptom distress scale. Based on this self-
evaluation, patients were divided into those with poor health status (n=9), with a median of 10 symptoms 
(range: 6-14) and those with good health status (n=21), with a median of 3 symptoms (range 0-10) 6. The 
differences between our results and previous studies might result from the difference in sample size 
and/or the measurements used. 
Other long-term post-SCT studies used health related quality of life questionnaires to survey 
patients’ perspectives. However, symptom assessment is only one aspect of these questionnaires, and 
not be well captured. Therefore, evidence on the symptom experience for SCT recipients is often 
extrapolated from broader HRQoL instruments which use only limited subsets of items with a 
unidimensional question format (e.g., “Do you have nausea?”). Although symptoms are embedded in 
the common HRQoL dimensions of a questionnaire, a more comprehensive assessment is required 
before suggesting interventions. This seems obvious for the physical symptoms routinely assessed in 
allogeneic SCT follow-up, wherein a healthcare provider would immediately expand assessment of 
nausea if reported by a patient (e.g., “How much does it distress you?”). The PROVIVO instrument 
systematizes this process, minimizing response biases to compile a full list of symptoms, their 
incidence and the distress they cause. Given the clear need for patient reports of their symptom 
experiences, then, the PROVIVO instrument is a promising tool for the development and evaluation of 
symptom management interventions  
This study has to be viewed in the light of following limitations. First, our sample size might 
have been underpowered 45. Along with the heterogeneity of our patient sample characteristics, this 
may have contributed to our moderate results in terms of internal structure. Second, our study included 
only one measurement point; therefore, future longitudinal studies are suggested.  
The validation of PRO instruments is an on-going process, and confidence in a questionnaire 
develops based on the long-term accumulation of psychometric data46. Therefore, despite encouraging 
preliminary results, the current study should be considered only as an initial step in validating the 
PROVIVO instrument. Subsequent steps should include examining the instrument's responsiveness to 
change over time and developing interpretation guidelines such as the minimally important difference 47.  
In sum, the refined PROVIVO demonstrated reliability and validity as a PRO measure that 
allows for a brief yet comprehensive assessment of symptom experience from the patient perspective. 
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6.1 Abstract 
Little is known of health-relevant behaviours among long-term survivors of haematological disorders treated 
with haematopoietic stem cell transplantation. This comparative cross-sectional multicentre study aimed (1) to 
explore the prevalence of selected behaviours in this group and (2) to compare them with those of the general 
population. Self-reported data of 376 survivors (mean age: 50.4 (s.d.=12.8); median 7 years post-allogeneic 
SCT (IQR=8.9; range 1-33) were compared with controls derived from the Swiss Health Survey 2007 by pro-
pensity score matching. Survivors were more physically inactive (26.8% vs. 12.5%; p=<.001) and consumed 
fewer portions of vegetables (≥ 3 pieces: 10% vs. 21.6%; p<.001), fruits (≥ 3 pieces: 6.5% vs. 10.6%; p<.001), 
and fish (31.2% vs. 60.9% weekly fish dish; p<.001). More consumed dairy products daily (92.5% vs. 62.9%; 
p<.001), used sun protection regularly (94.5% vs. 85.3%, p<.001) and had received influenza vaccinations in 
the last year (58.4% vs. 21.5%; p<.001); fewer smoked (13.4% vs. 35.4%; p<.001). Survivors’ weekly alcohol 
consumption was lower (median 1.5 servings (IQR 4) vs. median 4.5 (IQR 10.3); p<.001). Of those taking 
immunosuppressants, 65.7% were non-adherent. Similar to the general population, survivors experience 
problems executing several health-enhancing behaviours, warranting corrective interventions.  
6.2 Introduction  
Haematopoietic stem cell transplantation (SCT) is an established treatment for patients with severe disorders 
of the haematopoietic system. Although many patients can be cured of their initial disease, up to two-thirds 
develop chronic conditions, including cGVHD, heart problems, endocrine disorders, neurocognitive 
impairment, musculoskeletal disorders and secondary malignancies 1. Since these conditions require life-long 
management 2 the majority of SCT survivors can be regarded being chronically ill. Research in chronic 
illness patients as well as in the general population indicates that favourable health behaviours prevent some 
chronic illnesses, delay progression of existing conditions and decrease mortality rates 3. In particular, four 
health behaviours – adequate physical activity, healthy diet, non-smoking, and moderate alcohol 
consumption – contribute to a longer, healthier life 4. Ford’s large prospective study in the general population 
(N= 23.125) linked engagement in these behaviours with a reduced risk for early death from cancer and 
cardiovascular diseases 3. In Switzerland, cancer survivors, including SCT recipients, are therefore 
encouraged to follow the same national health recommendations for these four key health behaviours 5-9. 
Additional recommendations include sun protective measures 10, scheduled vaccinations 11, 12 and close 
adherence to any medication regimen 13 (see also table 1 for overview). 
While the literature on health behaviours in cancer survivors is growing 14,15, little is known about 
how many SCT survivors succeed in following a healthy lifestyle. Studies from the United States show that 
29-36% of survivors exercised for at least 20-30 minutes three times per week compared to 30-45% of 
matched controls 16, 17. Overweight was observed 52% of survivors and 47% of controls; and only 5% of 
survivors reported eating a healthy diet, i.e., one low in fat and high in fruits and vegetables 17. Survivors 
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were also less likely than controls to drink more than 2 servings of alcohol per day (15% vs 25%) 17, and 
high-risk drinking was less prevalent in survivors (9.5%) than in controls (13.3%) 18. In the reported studies 7 
to 14% of survivors currently smoked 16-18. Survivors were more likely than controls to have received 
seasonal influenza vaccinations (59.7% vs. 32.7%), especially those aged over 65 years (95% vs. 73%) 17.  
To date no study has examined sun-protective behaviours and medication intake in the long term 
following SCT. Further, knowledge is lacking as to whether health behaviours among European SCT 
survivors differ from those of the general population; and previous research focused on small sets of 
behaviours. Therefore, the present study aimed  
1. to determine the prevalence of 8 health behaviours in Swiss SCT survivors (i.e., physical activity, 
dietary habits and weight control, alcohol intake, smoking, influenza vaccination, sun protection, and 
medication adherence)  
2. to compare Swiss SCT survivors’ health behaviours with those of matched controls from the general 
population 
6.3 Subjects and methods 
6.3.1 Design 
This cross-sectional comparative observational study is part of the mixed-methods multicentre PROVIVO 
project investigating Patient Reported Outcomes of long-term survivors after allogeneic SCT (NCT01275534). 
Data from the PROVIVO study and the 2007 Swiss Health Survey (SHS) were used. The PROVIVO study was 
approved by the Basel and Zurich ethical committees. 
6.3.2 Setting, sample and data collection procedures 
Convenience sampling was used to recruit allogeneic SCT recipients from the University Hospitals of Basel 
and Zurich from November 2011 until November 2012. Inclusion criteria were at least one year post- 
transplantation and an age of at least 18 years. Exclusion criteria were an inability to read German, current 
hospitalization or a diagnosed end-of-life stage. Patients with visual and/or hearing impairment or severe 
psychiatric disorders (e.g., suicidal tendencies, acute psychosis) were also excluded. In the month before their 
annual follow-up visits, a research assistant phoned all eligible SCT recipients, informed them about the study 
and inquired whether they were interested in participating. They were also asked if they were taking any type of 
immunosuppression medication. Those who were interested received the study information letter, an informed 
consent form and an appropriate questionnaire (version A for patients with immunosuppressants or version B 
for patients without) per postal mail. Patients returned the completed study materials to their treating physician 
at their annual follow-up visit or returned them via post. Clinical and demographic data were collected from the 
transplant database and patient records. Data was anonymised and entered in a database. 
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6.3.3 Selection of case-matched controls from the SHS sample 
Controls were selected from the 2007 dataset of the Swiss Health Survey (SHS). The national representative 
health survey is repeated in 5-year intervals and consists of a telephone interview and a written question-
naire. In addition to questions about physical, mental and social health, symptoms, co-morbidities, accidents, 
and disabilities, participants were asked about their health behaviours, living conditions and resources which 
would potentially affect their health. The 2007 survey involved a sample of 30.179 Swiss households with 
telephone landlines. From each participating household, one person aged over 15 years was randomly 
chosen. With a response rate of 66%, the final sample included 18.760 participants 19.  
Propensity score (PS) matching was used to match each survivor with one control from the SHS. The 
following covariates were matched: gender, age, education, and residence, i.e., the Swiss region (7 regions) and 
urbanisation zone (9 types) of residence 20. Each PS value was allocated a score between 0 and 1 to express the 
probability of one participant having a perfect match when their observable characteristics are given. Using the 
minimum distance method, each patient was linked with the control group subject with the nearest PS value.21 
The area under the curve (c-statistic) of the logistic model to calculate the propensity scores was 0.74 (95%; 
CI=0.72-0.76), indicating appropriate matching. 
6.4 Variables and measurement 
6.4.1 Socio-demographic and clinical data 
The following socio-demographic variables were documented for both patients and controls: gender, age, 
education (compulsory schooling, secondary education, tertiary education), Swiss living region and urbani-
sation zone (not displayed in this article), partnership (married or cohabiting/single or not cohabiting), and 
employment (full time (working ≥80%), part-time, or not employed). Table 2 gives an overview about the 
clinical characteristics of SCT survivors. 
Health behaviours assessed in survivors and in SHS population 
To allow comparison with the general population, health behaviours were measured with standardised 
questions, almost all of which were drawn from the SHS. On-going data quality controls concerning item 
clarity and validity were performed by the Swiss Federal Statistical Office 19. Table 1 displays health 
behaviour recommendations, variables of interest and categorizations used.  
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Health behaviour Recommendations5-13 Study variables, measurement and categorization
Physical activity 
(3 items) 
 
 Engage in at least 30 
minutes of daily 
moderate activity (e.g. 
cycling, brisk walking) 
or a total of 2 ½ hours of 
moderate physical 
activity per week 
or 1 ¼ hours or high-
intensity activity per 
week (e.g. jogging, 
playing tennis) 
Physically active (yes/no); if yes: frequency (days), 
duration (minutes) and intensity (very easy, easy, 
moderate, strong, very strong). 
Categorization in three levels: Inactive (less than once 
weekly, 30 minutes of physical activity with 
moderate or strong intensity); partially active (at least 
once weekly, 30 minutes activity with a moderate 
intensity or once with strong intensity regardless of 
duration); and active (at least on 5 days weekly, 
moderate physical activity for 30 minutes each time 
or 3 times with strong intensity) 
Dietary habits  
(5 items) and  
weight control 
(indicated by BMI) 
 
 
 Eat 5 or more servings 
of a variety of 
vegetables and fruits 
each day.  
 Limit intake of pro-
cessed and red meats 
 Eat (preferable three) 
dairy products daily 
 Achieve and maintain a 
healthy weight (BMI 
18.5-24.9) 
Numbers of consumed vegetables and fruits (per 
day), dairy products (per day), meat and fish servings 
(per week); frequency of weekly visits to fast food 
restaurants (only survivors). 
Categorization: Meeting the 5-a-day recommendation 
(to consume 5 daily servings of fruits and vegetables) 
(yes/no).  
Body mass index (BMI) was used as an indicator for 
adequate weight control and was calculated based on 
the self-reported weight and height22, divided into 
underweight (BMI <18.5 kg/m2), normal (BMI 18.5-
24.9 kg/m2), overweight (BMI 25-29.9 kg/m2) and 
obese (BMI ≥ 30 kg/m2) 
Alcohol consumption 
(5 items) 
 Limit the intake to ≤ 2 
drinks per day for men 
and ≤1 drink per day 
for women  
Frequency of alcohol consumption (never, ≤ 2 times per 
month, 1-2 times per week, 3-6 times per week, daily); if 
individuals indicated drinking alcohol average weekly 
amount of alcoholic drinks (number of glasses of beer 
(3dl), wine (1dl), liquor and spirits (4cl). Categorization 
in critical alcoholic intake: women ≥ 1 alcoholic 
beverage per day, or >7 per week, and for men ≥ 2 
alcoholic beverages per day or >14 per week 
Smoking 
(2 items)  
 Do not smoke Smoking status (never; former or current smoker), 
and daily number of cigarettes for smokers (1-9 
cigarettes, 10-19 cigarettes, ≥ 1 pack, not daily)  
Sun protection  
(3 items) 
 
 Protect yourself from 
UV light. Stay in the 
shade between 10 AM 
to 4 PM, wear protec-
tive clothes and wear 
sunscreen (Factor> 20)  
The use of sun protective measures was assessed 
differently in the survivor population and the SHS; 
therefore, answers from survivors were recoded to 
allow comparison. SHS respondents were asked if they 
regularly apply sun protective measures (yes/no). 
Survivors were asked how strictly they adhere to three 
sun protective measures: using sunscreen, staying in 
shade between 10 AM and 4 PM and wearing protec-
tive clothes (never, rarely, sometimes, often, and al-
ways). Survivors’ responses to the three questions were 
dichotomized (often and always = yes; never, rarely 
and sometimes = no). If at least one question was 
answered yes, a patient was categorised as using sun 
protective measures regularly.  
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Vaccination  
(1 item) 
 Receive a yearly in-
fluenza vaccination 
Received an influenza vaccination in the last year 
(yes/no). 
Medication adherence 
(6 items) 
 Adhere to your health 
care professionals’ 
recommendation with 
respect to timing, 
dosage, and frequency 
of medication-taking 
during the prescribed 
length of time 
Basel Assessment of Adherence with Immuno-
suppressive Medication Scale (BAASIS©)  
(only measured in survivors) 
During the past four weeks, the BAASIS evaluates 
the different dimensions of non-adherent medication 
taking behaviour referring to the acknowledged ABC 
taxonomy which is described as followed 23: Im-
plementation of medication adherence: taking 
(omission of single doses), drug holidays (omission 
of successive doses), timing (deviation > 2 h) on a 
six-point scale; and dose reduction (deviation from 
prescribed amount) (yes/no). Discontinuation 
(stopping treatment too early) is measured by one 
item (yes/no). Overall medication (non-)adherence 
is measured in two ways: dichotomously, i.e., any 
self-reported medication nonadherence on any of the 
five aforementioned items is considered 
nonadherence; and continuously, indicating self-
perceived overall medication adherence on a Visual 
Analogue Scale (VAS) ranging from 0% (never took 
medications as prescribed) to 100% (always took 
medications as prescribed) 24. Patients taking 
immunosuppressants received the full version of the 
BAASIS©; those taking any other medications 
received adapted versions, which ask the same 
questions for any kind of oral medications and omits 
the timing dimension of medication intake. Content, 
concurrent and predictive validity of the BAASIS© 
have been reported in solid organ transplantation 25, 26. 
Table 1: Health behaviour recommendations, study variables and measurements 
6.5 Data analysis 
Descriptive statistics included frequencies, percentages and proportions, means and standard deviations, or 
medians and inter-quartile ranges (IQR). Missing data were excluded pairwise for the statistical analysis. 
Clinical characteristics of respondents and non-respondents in the SCT sample were compared using inde-
pendent t-tests, Chi-Square tests and the Mann-Whitney-U test. In order to compare the prevalence of health 
behaviours in survivors to those of their matched SHS subjects, we used McNemar or Wilcoxon signed-rank 
paired testing methods as appropriate 27. Influenza vaccination rates were compared between the survivor 
and control groups, including a subgroup analysis comparing survivors with controls over the age of 65, for 
whom a yearly influenza vaccine is recommended 12. All calculated p-values were adjusted (upwards) to 
correct for multiple testing. To limit the expected number of false positive findings with an alpha level of 
0.05 to below 5% we used the false discovery rate procedure (reported as q-values in tables) 28. Analyses 
were performed with IBM SPSS software© version 21 and SAS version 9.3.1. 
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6.6 Results 
6.6.1 Characteristics of survivors and controls 
Of the 638 survivors identified as eligible, 610 (95.6%) were contacted successfully. Of these, 376 (61.6%) 
were included in the final sample for analysis (figure 1). Compared with all nonparticipants (those 
unreachable, withdrawn from the study, or declined), participants were more likely to be older at the date of 
transplantation (aged 41.3 (s.d. 14.5) years vs 36.9 (16.5) years; p < .03), and to be at an early follow-up 
stage (median follow-up 7.1 (range 1-33) vs 9.0 (range 1-35) years; p < .01). 
 
 
 
 
 
 
 
 
 
 
Figure 1: Flow of participants 
Among survivors; 39.6% showed some form of cGVHD but most (84.2%) were highly functional (Karnof-
sky Index Score ≥ 90%). The primary disease was active in 5.2% (Table 2). 
Characteristic n (%)a 
Initial Diagnosis (%) (n=376)  
AML 119 (31.6%) 
ALL 58 (15.4%) 
CML 61 (16.2%) 
CLL 15 (4%) 
Plasma cell disorder 21 (5.6%) 
Hodgkin or Non Hodgkin lymphoma 40 (10.6%) 
Myelodysplastic syndrome 31 (8.2%) 
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Myeloproliferative syndrome 13 (3.5%) 
Non-malignant haematologic disease 18 (4.9%) 
Years after transplantation, median 7.1 (IQR 8.9, range 1-33)  
Source of transplant (%) (n=376)  
Bone marrow 117 (31.1%) 
Peripheral blood 258 (68.6%) 
Umbilical cord blood 1 (0.3%) 
Conditioning regimen (%) (n=372)  
Myeloablative 286 (76.9%) 
Reduced intensity 86 (23.1%) 
Total Body Irradiation with ≥12 Gray (%) (n=376) 220 (58.5%) 
No. of transplantations (%) (n=376)  
1 305 (81.1%) 
> 1 71 (18.9%) 
Donor relationship (%) (n=376)  
Matched related 226 (60.1%) 
Syngen 8 (2.1%) 
Mismatched related  9 (2.4%) 
Unrelated 133 (35.4%) 
Current stage of disease (%) (n=366)  
Complete remission 347 (94.8%) 
Not in remission/Relapse 19 (5.2%) 
Chronic GVHDb (%) (n=376)  
None 206 (54.8%) 
Mild 101 (26.8%) 
Moderate 36 (9.6%) 
Severe 12 (3.2%) 
No information available 21 (5.6%) 
Karnofsky Score (%) (n=353)  
100 - 90% 297 (84.2%) 
<90 – 80 35 (9.9%) 
<80 21 (5.9%) 
Table 2: Clinical characteristics of survivors 
Table 3 compares the demographic characteristics of survivors and controls. More survivors were married or 
cohabiting (78.3% vs 67.2%, p <.001); fewer had a full-time employment (34.6% vs 53.1%), and in contrast 
more than double a part-time job (33.8% vs 14.4%) while the proportion of individuals not working was 
similar in both groups. 
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 Survivors Case-matched controlsb  
 Na n % Na n % p- q-valuec
Gender, male (%) (n=376) 207 (55.1%) (n=376) 207 (55.1%) n.a. 
Age in years, mean (s.d.) (n=376) 50.3(12.7) (n=376) 50.5 (12.7) n.a. 
Education (%) (n=369) (n=376)  n.a. 
Compulsory schooling  52 (14.1%) 51 (13.6%)  
Secondary education  204 (55.3%) 212 (56.4%)  
Tertiary education  113 (30.6%) 113 (30.1%)  
Nationality (%) (n=376) (n=376)  .368 .504
Swiss  328 (87.2%) 337 (89.6%)  
Foreign nationality  48 (12.8%) 39 (10.4%)  
Partnership (%) (n=373) (n=375)  .001 .002
Married or cohabiting  292 (78.3%) 252 (67.2%)  
Single, not cohabiting  81 (21.7%) 123 (32.8%)  
Employment (%) (n=376) (n=369) <.001 <.001
Full-time (≥80%)  130 (34.6%) 196 (53.1%)  
Part-time  127 (33.8%) 53 (14.4%)  
Not working  119 (31.6%) 120 (32.5%)  
Table 3: Demographic and clinical characteristics 
6.6.2 Comparison of health behaviours between survivors and controls 
Table 4 summarizes the health behaviours of survivors and their controls. Compared to the general popu-
lation, survivors were more likely to report inactivity (26.8% vs. 12.5%, p <.001). Only 11.2% of survivors 
had the recommended 5 servings of fruits and vegetables per day–in contrast to 24.2% of controls (p <.001). 
Survivors were less likely to have at least one weekly serving of fish (31.2% vs. 60.9%; p<.001). Compared 
to controls, fewer survivors ate meat on more than 5 days per week (17.8% vs. 26.6%; p <.001) and more 
consumed dairy products on a daily basis (92.5% vs. 62.9%; p <.001). No significant differences arose in 
BMI distribution. Overweight and obesity were present in 26.4%, respectively 10.2% of survivors and 
29.4%, respectively 12.4% of controls. Survivors reported consuming significantly lower numbers of 
alcoholic beverages per week (median 1.5 (IQR 4) vs. 4.5 (IQR 10.3); p <.001), yet critical amounts of 
alcohol (i.e. >21 standard beverages per week for men, 14 for women) were consumed by 14 survivors 
(3.7%; 8 men, 6 women). Despite reporting similar rates of ever having smoked, significantly fewer 
survivors currently smoked (13.4% vs. 35.4%; p <.001). Survivors made more regular use of sun protection 
(94.1% vs. 85.3%; p <.001) – the most common method being sunscreen (with 79.1% using it often or 
always), followed by staying in shaded areas between 10 AM and 4 PM (73.6%) and wearing sun-protective 
clothes (71.1%). Survivors (58.4%) were more likely than controls to have received influenza vaccinations 
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(21.5%); this was also true for the 56 survivors over the age of 65 compared to their matched controls, for 
whom the vaccine was also recommended (76.8% vs. 32.3%; p=.002). 
Behaviour Survivors Controls   
 Na n % Na n % p-value 
q-
valueb 
Physical activity (n=354)   (n=376)   <.001 <.001 
Inactive  95 (26.8%) 47 (12.5%)  
Partially active  112 (31.6%) 163 (43.4%)  
Active  147 (41.5%) 166 (44.1%)  
Diet         
Number of daily fruit 
servings c (n=371)   (n=375)   <.001 <.001 
None or less than  
once a day  54 (14.5%)  61 (16.3%)   
1 – 2   280 (75.5%)  233 (62.1%)   
≥3   37 (10.0%)  81 (21.6%)   
Number of daily 
vegetable servings c (n=372)   (n=376)   <.001 <.001 
None or less than  
once a day  27 (7.3%)  54 (14.4%)   
1-2  321 (86.3%)  282 (75.0%)   
≥ 3  24 (6.5%)  40 (10.6%)   
Daily dairy products 
consumption d (n=374)   (n=375)   <.001 <.001 
Yes  346 (92.5%)  236 (62.9%)   
Number of weekly fish 
servings  (n=375)   (n=376)   <.001 <.001 
Never  36 (9.6%)  30 (8.0%)   
Less than once a week  222 (59.2%)  117 (31.1%)   
≥1 a week  117 (31.2%)  229 (60.9%)   
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Number of weekly meat 
servings (n=376)   (n=376)   <.001 <.001 
Never or less than  
once a week  47 (12.5%)  24 (6.4%)   
1-3   132 (35.1%)  152 (40.4%)   
4-5  130 (34.6%)  100 (26.6%)   
≥ 6  67 (17.8%)  100 (26.6%)   
Frequency of eating at a 
fast food restaurant per 
week  
(n=363)      n.a.  
Never or less than  
once a week  310 (85.5%)      
≥ once a week  53 (14.5%)      
Body mass index (n=322)   (n=371)   .067 0.111 
Underweight  24 (7.5%)  12 (3.2%)   
Normal   180 (55.9%)  204 (55.0%)   
Overweight   85 (26.4%)  109 (29.4%)   
Obese   33 (10.2%)  46 (12.4%)   
Alcohol drinking (n=374)   (n=375)   <.001 <.001 
Abstinent  68 (18.2%)  48 (12.8%)   
Less than once a-week  137 (36.6%)  92 (24.5%)   
1-6 times a-week  154 (41.2%)  173 (46.1%)   
Daily  15 (4.0%)  62 (16.5%)   
Number of alcoholic 
beverages per week 
(Median; IQR) e 
(n=374) 1.5 (0-4) (n=375) 4.5 (0.3-10.6) <.001 <.001 
Smoking  (n=367)   (n=376)   <.001 <.001 
Never  201 (54.8%)  143 (38%)   
Previous smoker  117 (31.9%)  100 (26.6%)   
Current smoker  49 (13.4%)  133 (35.4%)   
Number of cigarettes per 
day for smokers      .001 .002 
1-9 cigarettes  22 (44.9%)  20 (16.0%)   
10-19 cigarettes  9 (18.4%)  28 (22.4%)   
≥ 1 pack  9 (18.4%)  38 (30.4%)   
Not daily  9 (18.4%)  39 (31.2%)   
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Received an influenza 
vaccination in the last year (n=366)   (n=299)   <.001 <.001 
Yes  219 (58.4%)  64 (21.4%)   
Regular sun protective 
measures  (n=375)   (n=374)   <.001 <.001 
Yes  353 (94.1%)  319 (85.3%)   
Yes  353 (94.1%)  319 (85.3%)   
a  Number of survivors and controls available for analysis 
b Q value adjustments were made for multiple comparisons 
c  1 portion = size of a fist or circa 120 g 
d 1 portion = 2dl milk, yoghurt, quark or 30-60g cheese   
e  One alcoholic beverage = 0.3 dl beer; or 1 dl wine; or 4 cl Spirits or liquor 
Table 4: Prevalence of health behaviours among survivors and controls 
6.6.3 Medication nonadherence in patients taking immunosuppressants or other medications 
Of 376 participants, 107 required no medications and 170 required non-immunosuppressant medications. 
The remaining 99 were using immunosuppressants, of whom 65 (65.7%) reported nonadherence to at least 
one dimension of their medication regimens. Nonadherence in the implementation of the prescribed medical 
regimens was observed in 64 patients (64.6%). Thirty-three (33.3%) had failed to take at least on dose in the 
past four weeks and 61.2% had had timing deviations of more than two hours. Four (4.1%) reported having 
reduced their dosages without consulting a physician and three (3.2%) had taken drug holidays. Further three 
patients had stopped their immunosuppressant intake early and were therefore regarded as non-persistent 
with the therapy. The median self-perceived overall adherence (reported via the VAS) was 95.0% (IQR: 15).  
One hundred and seventy patients took non-immunosuppressant medications. For this group, the 4-
week prevalences of the 4 measured dimensions of nonadherence (taking nonadherence, dose reduction, drug 
holidays and non-persistence) were 37.6%, 7.3%, 12%, and 2.4%, respectively. Their average VAS rating for 
self-perceived adherence was 98.0% (IQR 5).  
6.7 Discussion 
To our knowledge, this is the first study to compare a comprehensive set of health behaviours in SCT 
survivors with those of matched controls. We observed that survivors were more likely to be inactive, and 
showed more unfavourable nutrition habits with regard to vegetable, fruit and fish consumption. However, 
survivors were less likely to be current smokers and drank less alcohol. They were also more likely to 
receive influenza vaccinations and to protect themselves from UV radiation. Our findings indicate that, 
overall, survivors engage less often in active health behaviours (e.g., physical activity and dieting) aimed at 
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preventing new diseases. However, they more often avoid health-impairing habits such as smoking and 
drinking. These innovative insights warrant evaluation in the light of existing evidence.  
Although the proportion of active individuals is similar in both groups, twice as many patients were 
inactive compared to matched controls. The following hypotheses might explain these low percentages: 
Many survivors suffered from some form of cGVHD and certainly from various other late effects, potentially 
inhibiting their physical performance 29. Moreover, many survivors complain about fatigue, which can persist 
far beyond treatment. Interestingly, although fatigue is a barrier to exercise, it can be reduced by regular 
physical activity 30. Therefore, given that recent research has showed that regular activity not only reduced 
fatigue but might also attenuate the risk of developing diabetes and cardiovascular conditions (including 
hypertension) after SCT 31, 32, interventions are needed to improve survivors’ physical activity.  
Another health behaviour that might lower the risks of co-morbidities such as diabetes and 
dyslipidaemia is a diet rich in fruits and vegetables 32. Although consistent with earlier reports showing that 
cancer survivors often fail to adhere to dietary guidelines 33, the low fruit and vegetable intake in our study is 
particularly worrisome. To some extent, our findings concerning dietary habits might be linked to oral 
cGVHD-related factors such as xerostomia, mucosal and hypopharyngeal inflammation (which cause painful 
burning sensations in the mucous membranes). Other late effects such as dental problems might cause 
problems with chewing and swallowing food, which might explain the lower meat consumption. Further 
reasons for dietary intolerances or aversions might be food allergies, taste changes, medication-related 
nausea or a low-bacteria diet (e.g., avoiding raw seafood and vegetables) 34, 35. Mean BMIs did not differ 
significantly between survivors and controls, indicating that overweight and obesity in survivors are as 
common as in the general population. Since the 1990s, obesity has almost doubled in the Swiss population 36, 
and also appears problematic in the survivor group, potentially increasing the risks of several complications 
and non-relapse mortality 37, 38. Using focus group interviews, Jim et al. showed that survivors desire more 
information regarding post-transplant quality of life aspects and in particular in regard to late complications, 
as these often arise unexpectedly and threaten the ongoing sense of recovery 39. Giving information about 
potential benefits of healthier lifestyle choices should be also an integral part of survivor care. Admittedly, at 
the time of data collection, no comprehensive lifestyle counselling was included in either of the two 
hospitals’ follow-up services. The higher dairy product consumption in our survivor sample remains difficult 
to explain. One possibility is that beneficial effects of dairy products on skeletal and dental health might have 
been delivered more frequently (although in a non-standardized manner), yet this is only a hypothesis. 
More than three quarters of our participants reported regular use of sun protective measures a 
proportion much higher than in the matched control group. Survivors also seem to be more aware of this factor 
than solid organ transplant groups, among which only one-third of patients wear protective clothing and two-
thirds regularly use sunscreen 40. Also, survivors were less likely than their controls to smoke: a substantial 
number had quit smoking. Nevertheless, while consistent with previous research (7-13%) 16-18, the prevalence 
of smokers is still problematic, given the known relationship between smoking and the high risk for 
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malignancies due to exposure to alkylating agents, bleomycin, radiation, TBI, and cGVHD 41. Therefore, 
regular smoking cessation programs should be offered.  
Unfortunately, our study revealed a high rate of immunosuppressive nonadherence (65.7%). This pre-
valence is higher than numbers found in solid organ transplant groups, although comparisons are complicated 
by differences in operational definitions and measurement methods 42. Evidence from solid organ transplan-
tation has linked even minimal deviations from the prescribed medication schedule (>5%) to negative clinical 
consequences (e.g., graft loss, rejection) 43,44. This underpins our stringently chosen cut-off for nonadherence. 
However, a clear need exists for further research identifying a clinically meaningful definition for medication 
nonadherence in SCT. Hence, a prospective study is recommended to assess the impact of subclinical medica-
tion nonadherence on clinical outcome, especially in terms of cGVHD. The influenza vaccination rate among 
our participants was higher than in the normal population. However, it is not yet satisfactory given that 
influenza may cause severe disease and mortality in SCT survivors. As patients’ motivation to vaccinate might 
depend on the practice patterns of their transplant centres, transplant teams should actively educate them and 
their families. 
The findings of this cross-sectional study allow no causal relationships and must be interpreted in the 
context of potential limitations. For example, we used survey data with the potential to underestimate true 
health behaviour prevalences. Socially undesirable behaviours such as smoking are prone to underreporting–
particularly in a cancer survivor population, in which smoking is mostly undesirable 45. Only German-
speaking patients participated, as the questionnaire was only available in this language. In order to enhance 
the participation of high-risk foreign language speakers 46, we recommend using multi-lingual questionnaires 
and the assistance of professional translators as appropriate. Additionally, hospitalized patients were not 
included. Therefore it is possible that those who participated were in better physical condition, making them 
more likely to engage in health behaviours such as physical activity. Also, we did not ask patients taking IS 
about their adherence to other medications; therefore, it remains unclear whether differences exist in their 
taking behaviour between IS and other medication. A future study should examine medication-taking 
behaviour regarding the entire medical regimen, optimally triangulating patient self-report with other 
vigorous assessment methods such as electronic monitoring, blood assay and physician estimations.  
Despite these limitations, this study had the strength of a case-match control design. Even taking into 
account the low prevalence (i.e., lower than the OECD average) of unhealthy behaviours in Switzerland’s 
general population 47, this allows a sound comparison with other European populations. In the context of the 
growth and increasing longevity of the SCT survivor population, our work has several important clinical 
implications. First, given the high prevalence of suboptimal health behaviours, regular screening throughout 
follow-up is warranted, and preventive and remediating strategies are indicated. It is crucial to recognize this 
population’s health behaviour practices and to use the information from this and other studies both to assist 
survivors with their disease self-management practices, and to allow practitioners to develop accurately-
targeted behavioural interventions. In particular, physical inactivity, poor nutritional practices, medication 
nonadherence and lack of influenza vaccinations were problematic in our group. Interventions on physical 
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activity and diet have been tested in cancer survivors, including SCT recipients, resulting in observable short- 
and medium-term of improvements in health behaviours 48. Further investigations are needed to examine the 
relationship between programs’ content and delivery and their sustainable effects on clinical outcomes. 
6.8 Conclusions 
This study provides population-based measures of health behaviours among SCT survivors in Switzerland. 
Survivors are most likely to adopt beneficial health behaviours regarding not smoking and low alcohol con-
sumption. Yet, relative to the general population, a considerable group still engage in unfavorable behaviours. 
Our findings indicate a need for investigating the effectiveness of interventions to increase survivors’ positive 
health behaviours, including medication adherence.  
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7.1 Abstract  
Following allogeneic stem cell transplantation (SCT), adherence to immunosuppressants (IS) is essen-
tial to prevent and treat chronic GVHD (cGVHD), which is associated with reduced quality of life and 
increased morbidity, mortality, and overall healthcare needs.  
This secondary analysis of data from a multicentre cross-sectional study included a conve–
nience sample of 99 IS-prescribed patients. Its aims were to determine the prevalence of medication 
nonadherence (MNA) in post-SCT patients, to examine its correlates, and to explore its associations with 
cGVHD. MNA measurement combined patients’ and physicians’ (collateral) reports. Descriptive 
statistics and logistic regressions were applied. Self-reported taking and timing MNA prevalences were 
33.3% and 61.2%, respectively; discontinuation occurred in 3.1% of cases. Combining these data with 
the physicians-reported prevalence (18.9%) yielded a composite MNA rate of 68.7%. MNA correlated 
with higher numbers of IS [odds ratio (OR):1.42; p=0.011] and fewer co-medications (OR:0.85; 
p=0.02). MNA was significantly associated with higher grades of cGVHD (OR: 3.01; p = 0.012). 
Patients with higher grades of cGVHD were more likely to have problems in the implementation of 
the medication regimen (OR:2.60; CI:1.14-5.91; p=0.023); in particular regarding taking (OR:2.46; 
p=0.028) and self-initiated dose reduction (OR:15.57; p=0.022). This study indicates high levels of 
MNA in SCT patients, calling for adherence-enhancing interventions.  
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7.2 Introduction 
For many haematological malignancies, allogeneic haematopoietic stem cell transplantation (SCT) is the 
only curative treatment available; the frequency of transplants continues to increase worldwide. How-
ever, while Allo-SCT usually causes a beneficial graft-versus-leukemia effect, a major source of morbi-
dity and mortality in the long-term after treatment is chronic graft-versus-host disease (cGVHD) 1-3. In 
particular, moderate and severe cGVHD are major causes of transplant-related functional impairments, 
reduced patient-reported quality of life 4, 5, higher morbidity 6, worse late non-relapse mortality and 
inferior overall survival 4. Immunosuppressant (IS) intake is essential, but increases the risk of severe 
infections and reduces the graft-versus-tumour effect 7. Therefore, taking IS as prescribed can be 
challenging for many patients 8. However, significant deviations from optimal intake, i.e., medication 
nonadherence (MNA), may increase the risk of poor clinical outcomes, resulting in re-hospitalisation, the 
use of multiple services, higher medical and healthcare costs 9, 10.  
MNA is defined as any deviation from the prescribed medication regimen sufficient to adversely 
influence the regimen’s intended effect 11. This can occur in the following situations or combinations: 
late- or non-initiation of the prescribed treatment; suboptimal implementation of the dosing regimen; or 
early discontinuation of treatment 12. The process of medication adherence starts with initiation of the 
treatment, when the patient takes the first dose of a prescribed medication. It continues with 
implementation of the dosing regimen, i.e., the extent to which a patient’s actual dosing corresponds to 
the prescribed dosing regimen, from initiation until the final dose is taken. Discontinuation means that 
the patient terminates the treatment earlier than recommended and does not restart 12.  
Developing methods to promote adherence to complex treatment regimens demands an 
understanding of the reasons behind nonadherence. MNA is influenced by a number of factors 
recognized by the WHO’s ‘Five dimensions of adherence’. The PROVIVOmed study framework (see 
Figure 1) integrated Vrijens et al.’s taxonomy of adherence 12 as well as the risk factors of the five-
dimensional WHO adherence model 13.  
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Figure 1: The PROVIVOmed adherence model (adapted from Vrijens et al., 2012 12 and Sabaté, 2003 13) 
To date, few studies have examined MNA post-SCT. One notable exception is the cross-sectional 
PROVIVO study, which examined medication adherence, along with various other health behaviours. 
Out of 99 patients using IS, two-thirds (65.7%) reported nonadherence over the past month to at least 
one dimension of their medication regimens 14.  
The aims of this study were (1) to describe MNA along the different dimensions of Vrijens’ 
taxonomy, (2) to examine associations between MNA and potential influencing factors and (3) to 
explore the association between patient-reported immunosuppressive MNA and cGVHD. 
7.3 Patients and Methods 
7.3.1 Design, setting and sample  
This report is a secondary data analysis of the multicentre PROVIVO study, investigating patient 
reported outcomes of long-term survivors after Allo-SCT (NCT01275534). Convenience sampling was 
used to recruit Allo-SCT recipients from the University Hospitals of Basel and Zurich (Switzerland). 
Inclusion criteria were an age of at least 18 years, a post-transplantation period of ≥1 year and current IS 
intake. Exclusion criteria were an inability to read German, current hospitalization, a diagnosed end-of-
life stage, severe visual impairment or severe psychiatric disorders (e.g., suicidal tendencies, acute 
psychosis).  
CHAPTER 7 
- 105 - 
7.3.2 Variables and measurements  
MNA was assessed via a combination of patient self-reports and physician collateral reports.  
Patient reported MNA  
The six-item “Basel Assessment of Adherence to Immunosuppressive Medication Scale (BAASIS©)” 15 
was used to measure medication adherence to IS over the preceding four weeks. In accordance to Vrijens 
et al.’s taxonomy 12, the BAASIS© evaluates implementation of medication adherence according to four 
items: taking (omission of single doses); drug holidays (omission of successive doses); timing (deviation 
> 2 h) [rated on a six-point scale ranging from never (0) to more than four times or almost every day (5)]; 
and dose reduction (deviation from prescribed amount – YES/NO). Discontinuation (stopping treatment 
too early) is measured by one item (YES/NO). A patient is considered to be overall nonadherent if 
he/she has shown nonadherence on any of the five aforementioned items. Additionally, self-perceived 
overall medication adherence in the past four weeks is measured by a Visual Analogue Scale (VAS) 
ranging from 0% (never took medications as prescribed) to 100% (always took medications as 
prescribed 15. Concurrent (r=0.65) and predictive validity of the BAASIS© have been established in 
kidney 16 and liver transplantation 17.  
Physician reported MNA 
Patients’ medication adherence was also assessed by physicians’ collateral reports. The treating senior 
physicians who were aware of the patient’s GVHD symptomatology were provided with a list of all 
patient names and, separately, the assayed IS drug level of each. Based on this information and their 
personal knowledge of patient’s medication intake behaviour, physicians judged each patient’s 
medication adherence in a single dichotomous score (YES=adherent / NO=nonadherent).  
7.3.3 Composite nonadherence score 
In a second step, as combining reporting sources provide greater sensitivity than self-reports alone, we 
combined patient reported MNA with that reported by physicians 18, 19. Patients were classified as 
nonadherent if they fulfilled at least one criteria of the BAASIS© and/or the physician collateral report 
(adherent=0 / nonadherent=1) listed them as nonadherent.  
7.3.4 Adherence correlates  
In order to examine associations between MNA and potential correlates we applied variables in 
accordance with the five dimensions of the WHO adherence model 13.  
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Three social/economic factors were retrieved from patient records: nationality, age and gender. 
Marital status, education level and patients’ employment status were collected via self-report 
questionnaire.  
For patient-related factors we included depressive symptomatology, measured via the sevenitem 
depression subscale of the German version of the Hospital Anxiety Depression Scale (HADS) 20. The 
HADS uses a four-point (0-3) Likert scale. Subscale scores were calculated by summing the individual 
item scores. A total score of ≥8 indicates depression symptoms. The HADS is widely validated in 
different populations including cancer patients 21 and has been used in several SCT studies 22-25. As an 
indicator for treatment side effects, i.e., potential barriers to taking IS, we included symptom intensity of 
nausea in our analysis. Nausea was assessed by a single self-report item on a five-point rating scale 
ranging from one (none) to five (very severe) during the last seven days 26. The Karnofsky Performance 
Status was graded by the treating physician 27.  
Therapy-related factors assessed were treatment regimen, number of transplantations, TBI 
(yes/no), stem cell source, years after SCT, and medication specific variables including immuno-
suppressive regimen (calcineurin inhibitor/steroids/others/combination), daily number of IS pills, as 
well as number of co-medications were retrieved from the transplant database or patient records.  
As a health care team & system-related factor we considered the treating centre (Basel/ 
Zurich) in our analysis.  
Condition-related factors included haematological diagnosis, status of haematological 
disease at annual control, donor relationship were extracted from participants’ medical records. For 
the analysis, cGVHD was scored according to the NIH criteria (none, mild, moderate, severe) 28.  
7.4 Data collection 
Patients were recruited for the PROVIVO study between November 2011 and November 2012; detail-
ed data collection procedures are described elsewhere 14. Clinical and demographic data were collected 
from the transplant database and patient records. Data was anonymised and entered in a database. The 
PROVIVO study was approved by the Ethics Committees of Basel and Zurich.  
7.5 Data analysis  
Depending on measurement levels and data distributions, detailed descriptive statistics were perfor-
med using frequencies, proportions, measures of central tendency and dispersion as appropriate. For 
the statistical analysis, missing data were excluded pairwise.  
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MNA prevalence was depicted for the overall patient sample and for nonadherent patients. Cor-
relates of the composite MNA score were initially determined using univariate binary logistic regression 
(see Table 5). Factors arising from the univariate analysis which revealed significant p-values (<0.05) 
were entered in an additional multivariate binary logistic regression model. In this second model, as no 
multilevel analysis was indicated for two clusters, “transplant centre” was treated as a confounding 
factor.  
The association between the composite MNA score and cGVHD grade was assessed with an 
ordinal logistic regression. Here “donor relationship” and “centre” were controlled as they might be 
confounding factors for the occurrence of cGVHD. Additionally, we carried out a series of post-hoc 
sensitivity analyses to determine the impacts of the different MNA dimensions on cGVHD grade. 
Therefore we used again the ordinal logistic regression model with cGVHD grade as outcome variable 
and entered the different MNA dimensions (taking, timing, drug holidays, dose reduction, disconti-
nuation) successively as independent variables.  
Data analysis was performed using IBM SPSS® Statistics for Windows, Version 21.0 and SAS 
9.1.3. Armonk, NY: IBM Corp. Statistical significance was set at alpha = 0.05 and q-values were used 
to control for false positive results.  
7.6 Results  
7.6.1 Patient characteristics  
Of 638 eligible SCT recipients, 376 (58.9%) took part in the PROVIVO study. Of these, 99 (26.3%) 
were currently taking IS and were therefore included in the PROVIVOmed substudy (Figure 2).  
Median patient age was 51 years (range: 20–72 years), with a median of 3.9 years (range: 1–29 
years) post-transplant. Participants were mostly male (61.6%), were Swiss citizens (88.9%), had an ave-
rage of 15.9 years of education and were predominantly married or cohabited (75.8%). Nearly half did 
not work professionally (46.5%). Seventy-five (77.3%) had documented diagnoses of cGVHD (40.2% 
mild, 27.8% moderate and 9.3% severe) according to the NIH consensus criteria. Half (50.5%) took a 
single calcineurin inhibitor, mostly CYA, 32.6% were receiving combined calcineurin inhibitor-steroid 
therapies, and 11.6% were receiving steroids alone. The total daily number of IS pills ranged from 1 to 
12 and of co-medications from 1 to 22. Sample characteristics are summarized in Tables 1 and 2.  
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Figure 2: Flowchart for the PROVIVOmed study sample 
Characteristics 
Total Non-adherent1 Adherent  
N = 99 n = 65 n = 34 
Age, median (IQR; range) 51.0  51.0  53.0  
Years after SCT, median (IQR; range) 
3.9  
(2.1 - 7.1; 
1.0 - 29.0) 
4.0  
(2.3 - 7.0; 
1.0 - 29.0) 
3.9  
(1.7 - 7.6; 
1.0 - 26.0) 
Gender; male, n (%) 61 (61.6) 42 (64.6) 19 (55.9) 
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Marital status, n (%) 
Married or cohabited 
 
75 (75.8) 
 
49 (75.4) 
 
26 (76.5) 
Nationality, n (%) 
Swiss 
Others 
 
88 (88.9) 
11 (11.1) 
 
57 (87.7) 
8 (12.3) 
 
31 (91.2) 
3 (8.8) 
Education level, n (%) 
Not completed school orcompulsory schooling 
Secondary education 
Tertiary education2 
Not reported 
 
13 (13.4) 
38 (39.2) 
46 (47.4) 
2 (2.0) 
 
10 (15.4) 
22 (33.8) 
33 (50.8) 
0 (0.0) 
 
3 (9.4) 
16 (50.0) 
13 (40.7) 
2 (5.9) 
Employment status, n (%) 
Working full-time3 
Working part-time 
Unemployed 
 
16 (16.2) 
37 (37.4) 
46 (46.5) 
 
12 (18.5) 
23 (35.4) 
30 (46.2) 
 
4 (11.8) 
14 (41.2) 
16 (47.1) 
Abbreviations: IQR = interquartile range  
1 Nonadherence is any YES answer on any of the five items.  
2 Tertiary education includes high school, higher professional education, college and university.  
3 Full-time engagement means working at least 33.6 h per week. 
Table 1: Demographic data 
Characteristics 
Total Non-adherent1 Adherent
N = 99 n = 65 n = 34
Haematological diagnosis, n (%) 
AML 
ALL 
CML 
CLL 
Hodgkin or Non Hodgkin lymphoma 
Myelodysplastic syndrome 
Multiples Myeloma 
Myeloproliferative syndrome 
Autoimmune disease  
 
28 (28.3) 
21 (21.2) 
10 (10.1) 
8 (8.1) 
15 (15.1) 
11 (11.1) 
4 (4.0) 
1 (1.0) 
1 (1.0) 
 
17 (26.2) 
16 (24.6) 
6 (9.2) 
4 (6.2) 
10 (15.4) 
8 (12.3) 
3 (4.6) 
0 (0.0) 
1 (1.5) 
 
11 (32.4) 
5 (14.7) 
4 (11.8) 
4 (11.8) 
5 (14.7) 
3 (8.8) 
1 (2.9) 
1 (2.9) 
0 (0.0) 
Status of haematological disease, n (%)  
Complete remission 
 
92 (92.9) 
 
63 (96.9) 
 
29 (85.3) 
Treatment regimen (conditioning), n (%)  
Myeloablative 
Reduced intensity 
Not documented  
 
75 (76.5) 
23 (23.5) 
1 (1.0) 
 
52 (81.3) 
12 (18.8) 
1 (1.5) 
 
23 (67.6) 
11 (32.4) 
0 (0.0) 
Stem cell source, n (%)  
Peripheral blood  
Bone marrow 
 
88 (88.9) 
11 (11.1) 
 
59 (90.8) 
6 (9.2) 
 
29 (85.3) 
5 (14.7) 
TBI2, n (%)  
Yes 
Not documented  
 
65 (66.3) 
1 (1.0) 
 
44 (68.8) 
1 (1.5) 
 
21 (61.8) 
0 (0.0) 
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Number of transplantations, n (%)  
1 
≥ 2 
 
81 (81.8) 
18 (18.2) 
 
51 (78.5) 
14 (21.5) 
 
30 (88.2) 
4 (11.8) 
Donor relationship, n (%)  
Unrelated  
Identical sibling or matched related 
Mismatched related  
 
52 (52.5) 
44 (44.4) 
3 (3.0) 
 
35 (53.8) 
29 (44.6) 
1 (1.5) 
 
17 (50.0) 
15 (44.1) 
2 (5.9) 
cGVHD3, n (%) 
Yes 
Mild 
Moderate 
Severe 
No 
Not documented 
 
75 (77.3) 
39 (40.2) 
27 (27.8) 
9 (9.3) 
22 (22.7) 
2 (2.0) 
 
54 (84.4) 
26 (40.6) 
20 (31.3) 
8 (12.5) 
10 (15.6) 
1 (1.5) 
 
21 (63.6) 
13 (39.4) 
7 (21.2) 
1 (3.0) 
12 (36.4) 
1 (2.9) 
Karnofsky Performance Status4, n (%) 
100% 
90% 
80% 
< 80% 
Not documented 
 
38 (39.2) 
25 (25.8) 
17 (17.5) 
17 (17.5) 
2 (2.0) 
 
27 (42.9) 
17 (27.0) 
11 (17.5) 
8 (12.7) 
2 (3.1) 
 
11 (32.4) 
8 (23.5) 
6 (17.6) 
9 (26.5) 
0 (0.0) 
Immunosuppressive regimen, n (%) 
Steroids5 only 
CNI (CYA or tacrolimus) only 
Others (mTOR inhibitor or mycophenolate) 
Combination (+ steroids5) 
Not documented 
 
11 (11.6) 
48 (50.5) 
5 (5.3) 
31 (32.6) 
4 (4.0) 
 
3 (4.8) 
33 (52.4) 
3 (4.8) 
24 (38.1) 
2 (3.1) 
 
8 (25.0) 
15 (46.9) 
2 (6.3) 
7 (21.9) 
2 (5.9) 
Number of IS pills, median (IQR; range) 
 
Not documented 
2.5  
(2-4.25; 1-12) 
5 
3.0 
(2.0-5.0; 1-10) 
3 
2.0 
(1.25-3.75;1- 2) 
2 
Number of co-medications, median (IQR; range) 
 
Not documented 
8.0 
(5.0-10.0; 1-
22) 
3 
8.0 
(5.0-10.0; 1-14) 
2 
9.0 
(6.0-11.0;1-22) 
1 
Abbreviations: cGVHD = chronic graft-versus-host disease; CNI = calcineurin inhibitor; mTOR = mammalian target of 
rapamycin; IS = immunosuppressants; IQR = interquartile range  
1 Nonadherence is any YES answer on any of the five items of the BAASIS©.  
2 Prevalence of patients who had a total body irradiation in the conditioning regime with 12 Gray.  
3 cGVHD was rated by the physician with the cGVHD grading scheme recommended by the National Institutes of Health 
consensus development project on criteria for clinical trials in cGVHD.  
4 Karnofsky Performance Status was determined by the physician at the annual follow-up visit and comprises an 
individual’s health and physical functionality, based on a criteria related performance index rated from 100% (normal 
function) to 10% (morbid).  
5 Prednisone with a dosage of at least 2.5 mg 
Table 2: Clinical characteristics 
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7.6.2 Prevalence of MNA  
MNA according to dimensions of the BAASIS© 
Total sample  
(N = 99) 
Non-adherent patients  
(N = 65) 
Implementation, n (%)  
Taking nonadherence, n (%)  
Drug holidays1, n (%) 
Timing nonadherence2, n (%) 
Dose reduction3, n (%) 
64 (64.6) 
33 (33.3) 
3 (3.2) 
52 (61.2) 
4 (4.1) 
64 (98.5) 
33 (50.8) 
3 (4.6) 
52 (80.0) 
4 (6.2) 
Discontinuation3, n (%) 3 (3.1) 3 (4.6) 
Overall medication (non-)adherence  
Overall nonadherence on any of the 5 BAASIS© 
items, n (%) 
Overall adherence rated on VAS in %, median (IQR)4 
 
65 (65.7) 
 
95 (90 - 100) 
 
n.a. 
 
90 (80 -95) 
Physician-reported MNA (N = 95)5  
Nonadherence, n (%)  18 (18.9) 15 (23.1) 
Composite adherence score (N = 99)   
Nonadherence, n (%)  68 (68.7) n.a 
Abbreviations: MNA = medication nonadherence; BAASIS© = The Basel Assessment of Adherence to 
Immunosuppressive Medication Scale; VAS = Visual Analogue Scale; IQR = interquartile range  
14 missings (4.0%), 214 missings (14.1%); from which 8 patients (missings) took only steroids, 31 missing (1.0%),  
43 missings (3.0%), 54 missings (4.0%) 
Table 3: Prevalence of patient- and physician-reported MNA 
Table 3 shows the prevalence of patient and physician reported MNA for the overall sample as well as 
for patients with no/mild cGVHD and for those with moderate/severe cGVHD. Combining patients’ 
self-reported MNA on any items of the BAASIS© with physicians assessment of MNA yielded an 
overall nonadherence prevalence of 68.7% across the entire sample, 62.2% in patients with no/mild 
cGVHD, and 80.2% in patients with moderate/severe cGVHD.  
7.6.3 Correlates of MNA  
The univariate binary logistic regression model (Table 4) indicates that MNA is associated with higher 
numbers of IS pills (p=0.022), and with immunosuppressive therapies using either CNI alone (p=0.030) 
or CNI-steroid combinations (p=0.011), and with lower numbers of comedications (p=0.035).  
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Univariate binary logistic regression(N = 99)1 Adjusted model for centre 
 OR (95% CI) Df p-value q-value 
Age 0.985 (0.952–1.019) 1 0.373 0.4747 
Gender 0.533 (0.220–1.289) 1 0.162 0.2835 
Time after SCT  0.984 (0.903–1.073) 1 0.714 0.7689 
Number of IS pills 1.328 (1.042–1.694) 1 0.022 0.0672 
Immunosuppressive regimen 
CNI (CYA or tacrolimus) only2  
Others (mTOR inhibitor or mycophenolate)2 
Combination (+ steroids)3 
 
5.513 (1.175–25.857) 
2.650 (0.253–27.781) 
8.560 (1.623–45.159) 
3 
1 
1 
1 
0.067 
0.030 
0.416 
0.011 
 
0.0700 
0.4853 
0.0560 
Number of co-medications 0.871 (0.766–0.990) 1 0.035 0.0700
Karnofsky Performance Status4  1.016 (0.98–1.047) 1 0.282 0.4387
Depression  0.860 (0.271–2.733) 1 0.798 0.7980
Nausea severity 0.801 (0.519–1.235) 1 0.314 0.4396 
Multivariate binary logistic regression (N = Adjusted model for centre 
 OR (95% CI) df p-value q-value 
Number of IS pills 1.422 (1.083–1.867) 1 0.011 0.0560 
Number of co-medications  0.852 (0.742–0.979) 1 0.024 0.0672 
Centre 0.174 (0.055–0.553) 1 0.003  
Abbreviations: MNA = medication nonadherence; OR = odds ratio; CI= confidence interval; df = degrees of 
freedom; IS = immunosuppressants; CNI = calcineurin inhibitor; mTOR = mammalian target of rapamycin 
1 Outcome variable for the regression analyses were the composite MNA adherence score  
For the univariate binary logistic regression correlates were selected based on the WHO adherence model and 
evidence of the literature from adherence research in CML patients. 29, 31, 33, 44, 46, 60-63  
2 Reference category: Steroids  
3 Prednisone with a dosage of at least 2.5 mg  
4  Karnofsky Performance Status was determined by the physician at the annual follow-up visit and comprises 
an individual’s health and physical functionality, based on a criteria related performance index rated from 
100% (normal function) to 10% (morbid). 
Table 4: Correlates of MNA in the univariate and multivariate analysis 
Multivariate binary logistic regression analysis results revealed that MNA is associated with higher 
numbers of IS pills (odds ratio (OR):1.422; 95% confidence interval (CI):1.083-1.867; p=0.011), as 
well as with a lower number of co-medications (OR:0.852; CI:0.742-0.979; p=0.024). The explained 
variance of the adjusted model is acceptable (Nagelkerke R2: 22.7%). 
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7.6.4 Association of MNA with cGVHD  
The ordinal logistic regression indicated a positive association between composite MNA and higher 
grades of cGVHD (OR:3.01; CI:1.27-7.14; p=0.012). 
Ordinal logistic regression (N = 99) 
Adjusted model for centre and donor relationship 
OR (95% CI) df p-value 
Composite MNA  3.007 (1.267 - 7.135) 1 0.012 
Centre 0.209 (0.083 - 0.526) 1 0.001 
Donor relationship 
Identical sibling or matched related 
Mismatched related 
Unrelated1 
 
1.184 (0.550 - 2.547) 
10.034 (1.047 - 96.255) 
 
 
1 
1 
 
 
0.666 
0.046 
 
Abbreviations: MNA = medication nonadherence; cGVHD = chronic graft-versus-host disease; OR = odds ratio; 
CI = confidence interval; df = degrees of freedom; BAASIS© = The Basel Assessment of Adherence to Immuno-
suppressive Medication Scale 1This parameter is set to zero because it is redundant.  
Table 5: Association of MNA with cGVHD 
Further our post-hoc sensitivity analyses revealed that, patients with higher grades of cGVHD, reported 
significantly more problems relating to the implementation of the medication regimen (OR:2.60; 
CI:1.14-5.91; p=0.023). In particular, with higher grades of cGVHD there was a higher risk for taking 
nonadherence (OR:2.46; CI:1.10-5.50; p=0.028) and dose reduction (OR:15.57; CI:1.49-162.72; 
p=0.022), respectively, see Table 6. 
Ordinal logistic regression (N = 99)  
Adjusted model for centre and donor relationship 
OR (95% CI) df p-value 
Implementation  2.60 (1.14 - 5.91) 1 0.023 
Taking nonadherence 2.46 (1.10 - 5.50) 1 0.028 
Drug holidays 1.60 (0.19 - 13.57) 1 0.667 
Timing nonadherence 0.91 (0.97 - 2.10) 1 0.826 
Dose reduction  15.57 (1.49 - 162.72) 1 0.022 
Discontinuation 3.03 (0.22 - 41.18) 1 0.406 
Abbreviations: MNA = medication nonadherence; cGVHD = chronic graft-versus-host disease; OR = odds ratio; CI = 
confidence interval; df = degrees of freedom 
Table 6: Post-hoc sensitivity analyses MNA with cGVHD 
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7.7 Discussion 
This is the first study to show a relationship between cGVHD and MNA. It also indicates a high 
prevalence of nonadherence, particularly regarding timing and taking. Furthermore, not only patients 
taking more IS agents, but also, surprisingly, those taking lower numbers of comedications were more 
likely to be nonadherent.  
For the first time, our study showed a significant association between MNA and cGVHD as a 
clinical outcome. Nonadherent patients were more likely to have higher grades of MNA. More 
specifically taking nonadherence and dose reduction were more common in patients with higher 
grades of cGVHD. These results need further exploration. Research in patients with chronic myeloid 
leukemia showed that the consequences of MNA to Imanitinib were fatal since taking nonadherence 
was significantly related to poor cytogenetic and molecular response 29-32 and poor survival 32, 33.  
In fact, while evidence in solid organ transplantation indicates clear associations between 
small deviations from prescribed medication schedules and poor clinical outcomes 34, 35 (e.g., more 
than 5% deviation from dosing schedules has been associated with higher incidences of graft loss or 
late acute rejections in renal and heart transplant recipients), however no information is available on 
how much timing deviation is tolerable in SCT. Further research is needed to identify a clinically 
meaningful definition of IS MNA in the stem cell transplant population. To develop such a definition, 
a prospective cohort study design assessing subclinical MNA levels and its relationship with clinical 
outcomes would be most appropriate. 
Although extensive research has examined genetic and biophysiological factors behind cGVHD 
36-39 its behavioural influences remain unexplored. To the existing knowledge base, the current study 
adds that MNA as a behavioural factor is linked to cGVHD. Given the increasing global number of 
transplantations using mobilized peripheral blood stem cells, the increasingly frequent use of reduced 
conditioning regimens, mismatched and unrelated donors, and older SCT recipients, larger numbers of 
patients with GVHD can be expected in the near future 40. Yet, while numerous efforts have been made 
to improve the staging and treatment of cGVHD 28, its management remains puzzling. Challenges to 
clinical practice and research include the heterogeneous nature of the disease [e.g., variable organ invol-
vement, patient risk factors (age, gender) and treatment-related factors (conditioning regimens, cGVHD 
treatment and SCT type)] and the absence of a clear consensus about second- and third-line management 
options 37, 39, 41-43. Therefore, to clarify our understanding of cGVHD pathogenesis, it is recommended 
that researchers routinely combine patient reported outcome instruments (such as the BAASIS©) and 
objective measurements (e.g. electronic monitoring systems) in prospective multicentre studies.  
In accordance with our theoretical model, we revealed that two therapy-related factors –
“number of IS pills” and “number of co-medications” – are strongly associated with MNA. While we 
did not assess underlying reasons for patients’ nonadherence, the present results are consistent with 
those of previous studies from hemato-oncology settings, which have associated higher numbers of 
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medications (≈ higher medication doses) with higher MNA 29, 31, 44-46. Research in solid organ 
transplantation 47 indicates that barriers to adherence are often unintentional (e.g., Forgetfulness/ 
Interruption of daily routine) or determined by patients’ attitude (e.g., the belief that not all IS are 
necessary to prevent rejection). 48 Such explanations might also be relevant to our study population. 
For instance, clinicians might recognize that patients consciously or unconsciously reduce or omit IS 
intake, potentially leading to cGVHD exacerbation. Clinical experience shows that some patients with 
treatment refractory disease eventually lose their belief in their medications’ effectiveness (“the drugs 
don’t work”). Further practical barriers to IS intake might include the unpleasant smell and taste of 
pills or cGVHD involvement of the mouth, which can make pill intake difficult. Surprisingly, though, 
while one might expect that higher numbers of co-medications would result in greater MNA, we found 
a negative relationship. Here a possible explanation could be that patients with fewer concomitant 
medications pay less attention to their medication. However, these hypotheses need to be further 
studied in prospective studies.  
As western healthcare systems are shifting from a strictly acute treatment system to one that 
embraces effective long-term management of chronic conditions 49, the current study has notable 
clinical implications. Supporting patients’ medication management is a key task for transplant teams – 
one for which multidisciplinary teams are under growing pressure to develop innovative solutions 50. 
And while educational strategies appear to be most commonly used for medication adherence in SCT 
patients 51, information alone may not be sufficient. Therefore, combinations of cognitive/ behavioural 
and psychological interventions, drawing upon skill development and consolidation of favourable 
behaviours, may more effectively engage patients in their own medication management 52-55. For 
example, a nurse-coordinated intervention program could offer an excellent opportunity to assess 
medication taking behaviours and initiate individually tailored adherence enhancing interventions with 
components proven effective against MNA, e.g., brief (maximum one page) written medication 
adherence instructions, electronic reminders to take medications regularly, dose modifications, special 
packaging, self-monitoring, and medication side effect management 52-55. Additional use of electronic 
monitoring could provide feedback data for patients to track their medication taking progress 56, 57. 
Finally, considering the overall increase of chronically ill patients on complex medication regimens, 
the topic of MNA demands greater awareness among healthcare professionals and should be a major 
component of continuous professional education. 
The findings of this secondary analysis must be interpreted in the context of this study’s 
potential limitations. The small sample size permits only low analytic sensitivity, inclusion of a small 
set of study variables and limited statistical power, possibly resulting in undetected reliable 
relationships between variables. Our ordinal regression analysis revealed a significant effect for the 
control variable “centre” which can be explained by the fact that one centre had considerable more 
patients with higher grades of cGHVD because of their higher performance in HLA-mismatched 
transplantations. Admittedly, our cross-sectional study design does not allow inferences of causality. 
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Therefore, the impact of MNA as a potential behavioural risk factor for cGVHD should be assessed as 
a component of prospective cohort studies. Such a longitudinal study could clarify if patients who 
show complete medication adherence have less cGVHD over time and therefore have to take lower IS 
doses for a shorter time periods. Also, although depression and illness severity are possible risk factors 
for MNA, patients with psychiatric disorders and in-patients were excluded 44, 58. And concerning 
measurement accuracy, while combining self-report questionnaires with physicians’ collateral reports 
results in greater sensitivity than either alone, the additional use of electronic monitoring would have 
provided the greatest possible sensitivity 19.  
Clearly, further research will be needed to confirm and expand the current study’s findings and 
to transpose the knowledge acquired here into clinical practice 59. A qualitative interview study would be 
particularly helpful to understand patients’ reasons for taking and particularly timing MNA, as well as to 
tailor and deliver effective individual support. Further research will then be needed to investigate the 
effectiveness of adherence-enhancing interventions. This will be particularly useful to assess the impact 
of early post-transplant interventions on the occurrence and severity of both acute and chronic GVHD. 
Given the knowledge that MNA is not entirely patient-driven but is also influenced by the healthcare 
team/system related factors (quality of patient-physician communication, reimbursement of medication 
costs, and regularity of follow-up) this will have to be examined in future studies.  
To conclude, this is one of the first studies demonstrating the high magnitude of MNA in a 
SCT population. For the first time, associations clearly link MNA and cGVHD as a clinical outcome, 
while its associations with medication-specific variables (numbers of IS pills and co-medications) 
have been shown in SCT recipients. Our findings indicate a strong need for a meaningful definition of 
MNA regarding SCT. 
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8.1 Abstract 
Recipients of stem cell transplants (SCT) must accurately manage multiple medications as 
nonadherence jeopardizes treatment benefits. There is an evidence base for the efficacy of adherence 
enhancing interventions, however level of clinical implementation is unknown.  
This study aimed to identify patterns of practice in assessing medication adherence, screening 
for risk factors of nonadherence, interventions used in SCT to improve adherence and how nurses 
perceive the effectiveness of such interventions.  
A convenience sample of 143 European nurses completed a 29-item questionnaire measuring 
the frequency and perceived effectiveness of assessment/screening methods for adherence and three 
types of intervention (educational/cognitive, counselling/behavioural, and psychological/affective). 
Questioning patients about adherence was the most regularly used assessment method 
(51.5%). Nurses used a median of 7 interventions (IQR: 6) ‘frequently’, the most popular being 
provision of reading materials (79%). The interventions perceived as most effective were; providing 
individual patient/family with teaching and reading materials.  
This is the first study exploring patterns of practice relating to adherence in SCT. Educational 
interventions were the most frequently employed style of intervention, which is at odds with recent 
data suggesting limited efficacy with this style of intervention. Combining educational, behavioral and 
psychological interventions would more accurately embrace current understanding. 
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8.2 Introduction 
Stem cell transplantation (SCT) is routinely used as an intensive treatment for haematological malig-
nancies as well as selected solid tumours and non-malignant diseases. It requires prolonged medication 
regimens and clinical follow-up 1. Patients must take numerous oral medications, including immuno-
suppressing drugs and infection prophylaxis treatments for 6 months or longer depending on the type of 
transplant. The success of such medical treatment depends partly on patients’ ability and willingness to 
take medications correctly. As shown in other chronically ill patient populations, not taking medications 
as prescribed is a major issue jeopardizing the benefits of a pharmacological treatment 2. Medication 
nonadherence is defined as ‘a deviation from the prescribed medication regimen sufficient to adversely 
influence the regimen’s intended effect’ 3. While one might expect that the diagnosis of a potentially 
fatal illness would ensure medication adherence, the evidence indicates otherwise. Where self-admini-
stration of oral medications is required for cancer treatment, 20% to 100% of patients fail to execute their 
prescribed drug regimens correctly 4-8. Given the possible magnitude of the issue and consequences of 
non-adherent behaviour, healthcare professionals should take advantage of their unique position to 
assess, monitor and support patients’ management of self-medication. However, extent and content of 
adherence support between clinical settings varies tremendously and patterns of practice do not always 
reflect the state-of-science regarding adherence enhancing interventions 9, 10.  
Important first steps in dealing with nonadherence include routinely assessing patients’ 
adherence in clinical practice and screening them for nonadherence risk factors 11. For patients 
identified as nonadherent or at risk of nonadherence, there are three different types of adherence 
enhancing interventions described in the literature, which healthcare professionals can integrate into 
their care practice. Educational/cognitive interventions present information or knowledge individually 
or in a group setting, delivering it verbally, in a written format, and/or audio-visually. Counselling/ 
behavioural interventions target, shape and/or reinforce behaviour, empowering patients to participate 
in their own care, while positively changing their skill levels or normal routines. Psychological/ 
affective interventions focus on patients' feelings and emotions or relationships and social support. 
Mixed interventions combine any two or more of these intervention types 11.  
Using this terminology, Berben et al. 9, 10 have assessed healthcare professionals' patterns of 
practice regarding medication adherence in areas of cardiovascular care (N=137) and solid organ 
transplantation (N=85). In both studies, healthcare professionals relied more on educational interven-
tions than on counselling/behavioural and psychological/affective interventions. However, a 2009 
meta-analysis showed that the frequently used educational interventions have limited efficacy in 
bringing about behaviour change which results in substantial improvements in patients’ knowledge 12. 
Multi-level interventional approaches combining educational/cognitive interventions with counselling/ 
behavioural interventions and/or psychological/affective interventions appear to be more efficient in 
improving patient medication taking behaviour 11-16. In other words, combinations of interventions 
appear to be more effective than single interventions. In particular, a combination of measures such as 
NURSES’ PRACTICE PATTERNS IN RELATION TO ADHERENCE-ENHANCING INTERVENTIONS IN SCT CARE 
- 126 - 
special medication packaging, dose modifications, participant monitoring of medication effects/side 
effects and the use of succinct written instructions indicated considerable potential value 12. Further 
promising approaches are interventions that are likely to shape behaviour by simple interactions; for 
instance, reminder systems (SMS, smart phone applications, alarm clocks) or direct feedback loops 
based on electronic monitoring (a medication bottle containing a microchip which registers the date 
and time of every bottle opening) 17, 18. 
To date, no information is available looking at practice patterns relating to medication 
adherence in the field of SCT. It is unknown which interventions are perceived as most efficient. 
Moreover, there is no information regarding which patterns of practice are congruent with the state-of-
science adherence enhancing interventions. 
The aims of this study were therefore  
1. To assess practice patterns of assessment/screening methods and interventions used to enhance 
medication adherence  
2. To determine nurses’ perceived efficacy of used assessment/screening methods and 
adherence-enhancing interventions 
8.3 Materials and Methods 
8.3.1 Design, setting and sample 
This study survey used a methodology previously developed by Berben et al. 9, 10. A convenience 
sample of nurses was recruited in April, 2011 during the Annual Conference of the European Group 
for Blood and Marrow Transplantation (EBMT) Nurses Group in Paris (France). The survey was 
approved by the EBMT General Board. Inclusion criteria were: employment as a nurse providing 
direct care for autologous or allogeneic SCT patients, and the ability to understand and read English. 
Informed consent was presumed with the return of the completed questionnaire.  
8.4 Measurements and Variables 
8.4.1 Demographic information 
Respondents’ demographic information was collected by self-report and included: gender; age in 
years; total years of working experience in nursing; years of clinical experience in SCT care; highest 
level of education (Diploma, Bachelor, Master, Doctorate/PhD); and current involvement in direct 
SCT patient care. Furthermore, data were collected on respondents' working environments regarding: 
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the age range of patients treated (children, adults, or both); the work setting (inpatient, outpatient, or 
both); the kind of transplants performed (allogeneic, autologous or both); and the country where the 
centre was located (Table 1). 
  Total (N=143)
Gender; n (%)1  
 Female 124 (87.3)
Age; mean (SD) 39.4 (8.3)
Years of working experience as a nurse; mean (SD) 15.9 (8.1)
Years of working experience in SCT care; mean (SD) 11.0 (6.6)
Professional qualification in nurses; n (%) 2
 Diploma 58 (41.1)
 Bachelor 43 (30.5)
 Master 39 (27.7)
 Doctorate/PhD 1 (0.7)
Kind of transplants performed at the centre; n (%)
 Allogeneic & autologous  119 (84.4)
 Autologous 11 (7.8)
 Allogeneic 11 (7.8)
Primary workplace; n (%)1 
 Inpatient 80 (55.9)
 Outpatient 26 (18.2)
 Inpatient and outpatient 34 (23.8)
 Home care 2 (1.4)
Kinds of patients treated at the centre; n (%)
 Children 30 (21.0)
 Adults 102 (71.3)
 Children and adults 11 (7.7)
Region where department is located3  
 Western Europe 62 (43.3)
 Northern Europe  53 (37.1)
 Southern Europe 15 (10.5)
 Eastern Europe 3 (2.1)
 Asia 9 (6.3)
 Northern America 1 (0.7)
1 missing n=1; 2 missing n=2; 3 Classification according United Nations Statistics Division 
http://unstats.un.org/unsd/methods/m49/m49regin.htm#europe 
Table 1: Demographic characteristics of respondents and characteristics of SCT centres 
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8.4.2 Adherence assessment and intervention strategies 
This study used an English-language instrument developed by Berben et al. 9, 10. The questionnaire's 
content validity was established based on experts’ opinion, evidence from state-of-the-art adherence 
literature and pilot-testing. 
The frequencies with which adherence assessment strategies and screening for risk factors 
were utilized was measured through responses to the following three items looking at 
1.  Questioning patients about nonadherence during follow-up 
2.  Screening for nonadherence risk factors during follow-up 
3.  Using electronic monitoring devices to assess nonadherence. 
The regularity with which participants utilized 26 different adherences-enhancing interventions 
within the categories of educational/cognitive (6 items), counselling/behavioural (11 items), and 
psychological/affective (9 items) interventions was explored using items presented in table 2. For each 
assessment/screening method and intervention, nurses were asked to indicate their frequency of utilizing 
it, using a Likert scale scored from 0 (‘never’) to 5 (‘all the time’). In addition, nurses were asked to rate 
the perceived effectiveness of their reported assessment/screening methods and interventions using a 
scale scored from 0-3 (0 = Don’t know’; 1 = ‘Not at all’; 2 = ‘Somewhat’; 3 = ‘Extremely’). 
8.5 Data collection 
All nurses who attended the opening session of the EBMT meeting were invited by the President of 
the EBMT Nurses Group to participate in the survey. When delegates entered the conference hall to 
attend the opening session, five members of the EBMT Nurses Group research subcommittee 
distributed the questionnaires and printed information about the survey. Completed questionnaires 
were either collected after the session or were returned to a designated collection box at the EBMT 
stand during the conference.  
8.6 Data analyses 
Descriptive statistics were used as appropriate (i.e., frequencies, percentages, means/standard deviations 
and medians/interquartile ranges). To describe assessment/screening methods and adherence-enhancing 
interventions, we calculated the prevalence of each strategy at the item level, using frequencies and 
percentages. Because most items yielded skewed answer patterns, the Likert scale responses for the 
frequencies of screening/assessment methods and interventions were regrouped into 3 values: never = 0 
(originally ‘never’); seldom = 1 (originally ‘occasionally’ and ‘sometimes’); and frequently and all the 
time = 2 (originally ‘frequently’ and ‘all the time’). For each of the three intervention categories 
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(education/cognitive, counselling/behavioural, and psychological/affective), we calculated the mean 
percentage of interventions that nurses reported using it ‘frequently’, ‘seldom’ and ‘never’. In order to 
show how many interventions are used frequently by nurses, the median and IQR for the total number of 
interventions nurses reported using ‘frequently’, as well as the number used within each of the three 
intervention categories was calculated. To estimate how many nurses used a variety of different 
intervention types, we calculated the number and proportion of participants who reported using one or 
more interventions from each of two or more intervention categories ‘frequently’. To assess the average 
perceived effectiveness of each of the three intervention categories, we calculated mean and standard 
deviations based on the effectiveness ratings (0-3) of all items reported used in that category. Prior to 
examining the relationship between the respondents' reported frequencies of using assessment/screening 
methods and adherenceenhancing interventions, along with their perceived effectiveness, we calculated 
frequency and effectiveness scores for each of the four domains: assessment/screening methods and 
three intervention categories. Analyses were performed using IBM SPSS Statistics (version 19.0.1; IBM 
Inc., Armonk, NY, USA) and Microsoft Office Excel 2008. 
8.7 Results 
A total of 481 questionnaires were distributed, of which 173 (35.6%) were returned. Seventeen re-
spondents reported providing no direct patient care; 13 had not filled-out large parts of the question-
naire. These 30 were therefore excluded from further analysis, leaving a final sample of 143 (29.7%) 
nurses with a mean age of 39.4 years (SD 8.3); 87.3% were female. The majority (71.3%) cared for 
adult patients; 81.6% cared for both autologous and allogeneic SCT recipients. Nurses had a mean 
working experience of 11 years (SD 6.6) in the SCT field. The characteristics of the sample and the 
SCT centres are presented in Table 1. 
8.7.1 Practice patterns in view of strategies for the assessment of nonadherence and risk 
factors in daily practice 
Just over two-thirds (67.8%) of participants reported ‘frequently’ asking patients about nonadherence 
during follow-up. Fewer than half (44.8%) reported the same level of screening for nonadherence risk 
factors during follow-up; and only 11.2% reported frequent use of electronic monitoring devices for 
nonadherence assessment.  
8.7.2 Practice patterns in view of adherence enhancing interventions 
Educational/cognitive adherence-enhancing interventions were most commonly used: 36.4% of nurses 
reported using them ‘frequently’, followed by counselling/behavioural interventions (26.6%) and 
psychological/affective interventions (23.1%). Nurses reported using a median of 7 (IQR 6) ad-her-
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ence-enhancing interventions ‘frequently’ in the daily care of SCT-patients. Regarding individual in-
tervention types, they used a median of 2 (IQR 2) educational/cognitive, 2 (IQR 3) counselling/be-
havioural and 2 (IQR 3) psychological/affective interventions. Most nurses (n=121, 84.4%) reported 
using a variety of interventions from all three categories (educational/cognitive, counselling/behaviou-
ral, and psychological/affective).  
Examining the data at the item level revealed that providing reading materials (79%) and 
printed medication instructions (58.7%) were the most frequently used educational interventions. Less 
used educational interventions included showing video tapes (11.2%), offering educational classes 
(9.1%) and using computer assisted educational programs (3.5%). Of the counselling/behavioural 
interventions, 66.4% of respondents reported ‘frequently’ training patients during their inpatient stay 
regarding correct medication intake; and 39.9% reported ‘frequently’ providing adherence reminders 
during clinic visits. The most regularly used psychological/affective measures focused on involving 
family or support persons in adherence enhancing interventions (51.1%) and establishing partnerships 
with patients (49%). Few nurses indicated ‘frequently’ utilizing support groups such as peer mentor 
programs (4.9%) or those focused solely on adherence (2.1%). 
8.7.3 Perceived effectiveness of assessment strategies and interventions 
The assessment strategy perceived as being most effective was questioning patients about medication 
adherence during follow-up visits; 44.7% of participants who used this intervention rated this as ‘ex-
tremely effective’. Involving family members in the teaching process and providing reading materials 
were perceived as the most effective of the used adherence-building educational/cognitive interventions 
(Table 2). Of the respondents who reported their use, 57.4% rated them as ‘extremely effective’. Among 
behavioural/counselling interventions, training patients how to take their medications correctly during 
inpatient stays was rated as the most effective, with 53.2% of users considering it as ‘extremely 
effective’. For psychological/affective approaches, both involving family or support persons in education 
and behavioural interventions (52.9%) and establishing a partnership with patients and significant others 
(51.9%) were rated by their users as ‘extremely helpful’. Comparing the interventions’ perceived 
effectiveness indicated no significant differences between the three categories. Whereas educational/ 
cognitive interventions (2.60; SD 0.36) were rated slightly higher than the psychological/affective group 
(2.47; SD 0.37), the counselling/behavioural group (2.43; SD 0.32) fell very slightly below. 
  
 Frequency of  method/intervention (N=143) 
Total number of 
nurses having 
utilized the method/ 
intervention1 
Perceived effectiveness  
of interventions used2 
 Frequently n (%) 
Seldom 
n (%) 
Never 
n (%) 
Not 
applicable/ 
missing 
n (%) 
n Extremelyn (%) 
Somewhat
n (%) 
Not at all 
n (%) 
Don’t 
know/ 
missing 
n (%) 
Adherence assessment/screening methods 
Questioning patient about medication adherence 
during follow-up visits 97 (67.8) 17 (11.9) 10 (7) 18 (13.3) 114 51 (44.7) 47 (41.2) 0 16 (14.1) 
Screening patients for risk factors for NA during 
follow-up 64 (44.8) 44 (30.8) 16 (11.2) 19 (13.3) 108 43 (39.8) 40 (37) 1 (0.9) 24 (22.3) 
Using an electronic monitoring device 16 (11.2) 8 (5.6) 103 (72) 16 (11.2) 24 6 (25) 11 (45.8) 0 7 (29.2) 
Educational/ cognitive interventions 
Providing reading materials 113 (79) 16 (11.2) 5 (3.9) 7 (4.9) 129 74 (57.4) 38 (29.5) 2 (1.6) 15 (11.7) 
Providing printed medication instructions 84 (58.7) 39 (27.3) 14 (9.8) 6 (4.2) 123 60 (48.8) 44 (35.8) 1 (0.8) 18 (14.6) 
Providing individual patient/family teaching 81 (56.6) 41 (28.7) 16 (11.2) 5 (3.5) 122 70 (57.4) 34 (27.9) 0 18 (14.7) 
Showing video tapes 16 (11.2) 22 (15.4) 93 (65) 12 (8.4) 38 15 (39.5) 15 (39.5) 0 8 (21.0) 
Offering educational classes 13 (9.1) 23 (16.1) 91 (63.6) 16 (11.2) 36 13 (36.1) 13 (36.1) 1 (2.8) 9 (25.0) 
Using computer-assisted educational programs 5 (3.5) 22 (15.4) 104 (72.7) 12 (8.4) 27 7 (26) 9 (33.3) 0 11 (40.7) 
Counselling/ behavioural interventions 
Training patients during inpatient recovery how 
to take medications 95 (66.4) 31 (21.7) 8 (5.6) 9 (6.3) 126 67 (53.2) 40 (34.7) 0 19 (15.1) 
Teaching patients to use cueing 49 (34.3) 57 (39.7) 28 (19.6) 10 (6.4) 106 36 (34) 51 (48.1) 0 19 (17.9) 
Reducing the complexity of the medication regimen 33 (23.1) 72 (50.3) 27 (18.9) 11 (7.1) 105 31 (21.7) 55 (38.5) 1 (1.0) 18 (17.1) 
Tailoring medication regimen to patient’s lifestyle 44 (30.8) 60 (42) 26 (18.2) 13 (9.1) 104 44 (42.3) 40 (38.5) 1 (1.0) 19 (18.2) 
Providing adherence reminders during clinic visits 57 (39.9) 39 (27.3) 24 (16.8) 23 (16.1) 96 35 (36.4) 40 (41.7) 2 (2.1) 19 (19.8) 
Providing dispensers for organizing medications 28 (19.6) 61 (42.7) 43 (30.1) 10 (7.7) 91 32 (35.6) 38 (42.2) 2 (2.2) 19 (20.0) 
Behavioural counselling intervention 37 (25.9) 47 (32.9) 33 (23.1) 26 (18.2) 84 26 (31) 38 (45.2) 0 20 (23.8) 
Recommend reminder systems 21 (14.7) 57 (39.9) 54 (37.8) 11 (7.7) 78 17 (21.8) 41 (52.6) 1 (1.3) 19 (24.3) 
  
Medical counselling by a clinical pharmacist 28 (19.6) 31 (21.7) 72 (50.3) 12 (8.4) 59 25 (42.4) 22 (37.3) 0 12 (20.3) 
Establishing adherence contracts with patients 17 (11.9) 36 (25.2) 76 (53.1) 14 (9.8) 53 17 (32.1) 25 (47.2) 0 11 (20.7 ) 
Using reports from electronic monitoring devices 
as a feedback system 9 (6.3) 7 (4.9) 111 (77.6) 16 (11.2) 16 4 (25.0) 5 (31.3) 0 7 (43.7) 
Psychological/ affective interventions 
Involving family or support persons in education 
and behavioural interventions 73 (51.0) 46 (32.2) 12 (8.4) 12 (8.4) 119 63 (52.9) 40 (33.6) 1 (0.8) 15 (12.6) 
Providing telephone assistance if needed 63 (44.1) 48 (33.6) 24 (16.8) 8 (5.6) 111 51 (45.9) 41 (36.9) 0 19 (17.2) 
Establishing a partnership with patient and 
significant other 70 (49.0) 36 (25.2) 13 (9) 24 (16.8) 106 55 (51.9) 34 (32.1) 2 (1.9) 15 (14.1) 
Scheduling more frequent clinic visits in case of 
problems with NA 31 (21.7) 65 (45.5) 30 (21) 17 (11.9) 96 31 (32.5) 49 (51.1) 1 (1) 15 (15.6) 
Scheduling calls to patients’ homes in case of 
problems with NA 15 (10.5) 55 (38.5) 52 (36.4) 21 (14.7) 70 28 (40) 29 (41.4) 1 (1.4) 12 (17.2) 
Establishing case management services for high-
risk patients 22 (15.4) 43 (30.1) 59 (41.3) 19 (13.2) 65 24 (36.9) 23 (35.4) 3 (4.6) 15 (23.0) 
Using motivational interviewing 13 (9.1) 33 (23.1) 79 (55.2) 18 (12.6) 46 8 (26.1) 26 (56.5) 0 12 (26.1) 
Establishing peer-mentor programs 7 (4.9) 20 (14) 94 (65.7) 22 (15.4) 27 5 (18.5) 14 (48.2) 1 (3.7) 8 (29.6) 
Establishing support groups directed at adherence 3 (2.1) 17 (11.9) 102 (71.3) 21 (14.7) 20 3 (2.1) 9 (45.0) 0 8 (40.0) 
1 Cell colours indicate the proportion of nurses who applied the method/intervention in clinical practice 
 ≥75%   ≥ 50% ≥ 25%  < 25% 
2 Perceived effectiveness was only rated if the nurse used the intervention to enhance medication adherence 
NA = Nonadherence 
 
 
Table 2: Utilization of assessment/screening methods and interventions for nonadherence and their perceived effectiveness
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8.8 Discussion 
This is the first study to assess nurses’ patterns of practice in the field of SCT regarding medication 
adherence assessment/screening methods and interventions. The results show that in this sample 
educational interventions are used most frequently and considered most effective by SCT nurses. The 
two interventions given the highest rankings with regard to usage, were providing reading materials 
and training patients during their inpatient stay. Providing individual patient/family teaching and 
providing reading materials were however considered most effective. In clinical practice, nurses used 
an average of seven adherence-enhancing interventions and each used at least two different inter-
vention types.  
8.8.1  Frequency of adherence enhancing interventions used 
Overall, the educational interventions most commonly used in this study sample were providing reading 
materials (79%), providing printed medication instructions (58.7%), and initiating individual 
patient/family teaching (56.6%). Interestingly, these results echo those of a similar study on solid organ 
transplantation and cardiovascular care 9, 10. With an average of 36% of educational/cognitive 
interventions used by nurses in our sample, this intervention type was most frequently employed. Once 
again, this intervention type was also most often used by nurses in solid organ transplantation (47%) and 
cardiovascular care (36%) 9, 10. However, education alone does not guarantee that a patient will 
consistently engage in correct medication taking behaviour. Rather, it has been shown that complex 
programs which utilize multiple interventions delivered over a longer period of time are more likely to 
achieve better outcomes 14. It seems possible that these more complex interventions are effective because 
they address a greater number of the potential barriers impacting a patient’s ability to adhere to a therapy 
and provide reinforcement over time. Therefore, current expert opinions suggest employing individually 
tailored multi-faceted interventions focusing on a personal system change, i.e., ‘a process of 
systematically improving individual systems through collaboratively shaping routines, involving 
supportive others in the care, and using medication self-monitoring to change and maintain behaviour’ 19. 
To give an example, an elderly patient might be at risk of forgetting to take the medication because of 
memory problems. An effective multi-faceted intervention could be to instruct family caregivers in the 
administration of the drugs and to use pill-boxes with a reminding system. Further, an adolescent SCT 
survivor could be at risk for forgetting a dose because of a busy (social) life, here it might be helpful to 
tailor the medication regimen to the patient’s lifestyle (e.g. reschedule taking times) and use SMS 
reminders. Although most nurses in our sample reported using a variety of actions, we are unfortunately 
not aware if they also combined the different interventions in individual patient situations.  
Consistent with the findings of Berben et al. 9, 10, this study’s nurses frequently involved family 
or support persons in their interventions (51.1%). Our sample's second and third most commonly used 
psychological/affective interventions were ‘establishing partnerships with patients and significant others’ 
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(49%) and ‘providing telephone assistance if needed’ (44.1%). This is in accordance with Di Matteo’s 
meta analyis (2004) suggesting social support and family cohesiveness considerably improve adherence 
in several chronically ill patient populations20. The applicability of these interventions’ to the SCT setting 
however, warrants further testing since a recent systematic review of 62 trials testing 18 interventions 
only validated their efficacy in certain chronic conditions (e.g. depression, diabetes mellitus). Interven-
tions that improved adherence across multiple clinical conditions included policy interventions to reduce 
patients’ medication copayments or, systems interventions to offer case management, and patient-level 
educational interventions with behavioural support 21. The ecological model of medication adherence 
explains this perspective. It says that medication adherence can be influenced by three distinct levels of 
the healthcare system. The micro-level involves patient-healthcare provider interactions (i.e. interven-
tions directly focused at patients), the meso-level concerns the treatment centre or hospital, and the 
macrolevel encompasses the patient's healthcare system or the society 22.  
8.8.2  Perceived effectiveness of used adherence enhancing interventions 
Nurses in this survey reported using the strategies they personally considered most effective most 
regularly. These were ‘providing reading materials’, ‘patient and family care’ and ‘Involving family or 
support persons in education and behavioural interventions’. Evidence clearly indicates that 
interventions with behavioural components are very effective 12, 14, 16-18. However, many of them were 
perceived by nurses in this sample as less effective. For example, two thirds of our nurses seldom or 
never informed patients about reminder systems (e.g. SMS, mobile phone applications) yet results 
from a recent systematic review revealed evidence for the effectiveness of electronic reminders from 
eight randomized controlled trials 18. The intervention used least by our cohort was the application of 
reports from electronic monitoring as a feedback system. It is likely that electronic monitoring devices 
were not known and/or not available for many nurses. However, a recent systematic review involving 
79 randomized controlled trials showed an average increase of 20 % in medication adherence when 
electronic monitoring feedback was used as intervention 17. To conclude, in order to improve 
medication adherence in SCT, it may be necessary to challenge healthcare professionals’ current 
beliefs and practices and to develop multilevel intervention models which emphasize a patient centred 
approach and integrate greater behavioural support.  
8.8.3  Study limitations 
One major limitation of this study was the low response rate, which may have resulted from language 
barriers, as the questionnaire was only available in English and the conference was also attended by 
non-native English speaking colleagues potentially lacking the confidence to participate. Additionally, 
as this was a convenience sample of conference attendees, it might not accurately represent the 
majority of nurses working in SCT care. Further, only nurses were included in the survey, the 
perspectives of physicians and other healthcare workers would have added important information. 
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Regarding our data, certain gaps might have resulted from our respondents' work characteristics. For 
example, certain interventions would not be feasible for nurses working in paediatric or inpatient care, 
and as a consequence were marked ‘not applicable’ in our analyses. For future surveys the 
questionnaire should be refined to consider these aspects and also include questions about the 
implementation of multilevel interventions.  
8.8.4 Implications for practice and future research 
As nurses play a key role in assessing, monitoring and supporting patients in their pharmaceutical 
treatment including adherence to the prescribed medications, it is strongly recommended that the topic of 
adherence receives greater emphasis in their basic training and continuous education. With the increased 
use of new treatment protocols, maintenance therapy and oral anti cancer agents in the care of patients 
with haematological malignancies, nurses' training in medication management support is becoming 
increasingly important 23. Early steps in tackling this issue have been taken by the EBMT Nurses Group, 
who organized several interactive workshops and have recently developed a multilingual nurse tailored 
information booklet on medication adherence in oral chemotherapy 24 The evidence on adherence en-
hancing interventions in cancer care and stem cell transplantation is limited 25. Therefore, future studies 
should examine the prevalence of medication nonadherence during the stem cell transplant trajectory, 
identifying the points at which patients' needs are greatest concerning supportive interventions. Multisite 
interventional studies are needed to investigate the effectiveness of single and combined adherence 
enhancing interventions in SCT care. Such research is necessary to understand which interventions are 
consistently effective at facilitating patients' successful medication self-management. 
8.9 Conclusions 
Medication adherence is a critical factor in the efficacy of any treatment protocol. This study showed 
that nurses reported using various types of interventions, of which, despite previous studies' findings 
suggesting limited efficacy, educational approaches were most frequently used. It is therefore 
proposed that nurses be provided training to facilitate integration of more effective strategies into daily 
practice, e.g., multi-level behavioural interventions. Finally, as different techniques may be more 
effective within different patient groups (e.g. adults or children), it is strongly suggested that 
evaluation of initiated practice be treated as crucial to any initiated interventions.  
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9.1 Synthesis, discussion and perspectives 
Even years after allogeneic stem cell transplantation, recipients face a continuing risk of developing 
serious late effects 1-3. These effects, which often cause considerable discomfort, contribute to morta-
lity rates 4 to 9 fold higher than observed in the age adjusted general population, and life expectancies 
30% lower than average 4, 5.  
To improve these figures, previous studies have focused on the pathophysiological under-
standing of late effects, as well as on treatment and disease related prediction of long-term  
complications. Their findings have helped clinicians and researchers to improve stem cell transplantation 
techniques and develop enhanced supportive care strategies 6. Accompanying these developments, 
patients have been recognized as an invaluable source of information on the evolution of their 
conditions. Particularly over the past decade, patient-reported outcomes (PROs) have been increasingly 
incorporated into clinical care and research 7, 8. To date, however, few studies have used PRO data to 
focus on patients’ perspectives of late effects, symptom experiences or self-management strategies. 
Indeed, at the time of our preliminary research, no PRO instrument yet existed to measure late effect 
symptom experiences, and no investigations had yet focussed on components of patient self-
management, i.e., their day-to-day management of chronic conditions to maintain daily life activities and 
improve health behaviours 9, 10. However, to optimize patients’ self-management, PRO instruments offer 
unique insights into both their experiences of long-term post-transplant symptoms and their health 
behaviours 11. 
SCT survivorship begins with an intensive acute care episode, which then shifts to a life-long 
follow-up process. To prevent deterioration, to prevent, delay or minimize late effects, and ultimately to 
reduce morbidity and mortality, patients must engage actively and continuously in self-management 
tasks12, 13. To these ends, PRO instruments can be used to monitor adherence to preventive measures, en-
hance early detection techniques, and determine treatment options for symptomatic late effects and other 
chronic conditions. Because worsening of chronic health conditions (≈ late effects) could be related to 
patient’s lifestyle choices, self-management is a topic, which demands in-depth exploration 11, 14, 15.  
The research program of this doctoral thesis contributes in various ways to the evidence base 
regarding SCT patients’ self-management in view of symptom experience and lifestyle. More specifi-
cally, this thesis consists of six research papers, each addressing a specific aspect of these topics.  
The first paper (Chapter 3) illustrated the value of using PROs to gather patient perspectives 
on the experience of a haematological disease-exemplified in immune thrombocytopenia and summa-
rized the steps necessary to develop an effective PRO instrument. It also discussed challenges to the 
integration of PROs into research and clinical practice.  
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The second (Chapter 4) described the development of the PROVIVO instrument – a new 
PRO instrument developed to measure late-effect symptom experience. Based on the PRO-CTCAE 
item library, the PROVIVO instrument was designed, refined, and prepared for use in its target regions 
according to Food and Drug Agency (FDA) guidance for PRO instrument development16 and state-of-
the-art recommendations for translation17. Using the PRO-CTCAE item library allowed the efficient 
compilation of a SCTspecific item bundle broadly applicable for late effect symptom screening and 
resulting in immediately actionable data. Throughout the development process, we involved patients as 
well as expert clinicians. To test the clarity and acceptance of item terms in the user population, we applied 
cognitive debriefings, the results of which demonstrated that items were fully understandable and relevant 
to the SCT survivor experience 18, 19. 
In our third paper (Chapter 5) we reported on the refinement and preliminary validity testing 
of the newly developed PROVIVO instrument. Focussing on construct validity and relations to other 
variables, preliminary validity was explored in accordance with the “Standards for Educational and 
Psychological Testing” 20. An exploratory factor analysis revealed an eight-factor model explaining 
57.05% of variance. Cronbach's alphas indicated that internal consistency reliability was good for the 
entire scale (0.90), but only acceptable for the eight factor scores (0.53-0.82). Additional evidence 
supports relations between variables, e.g., between the number of symptoms and cGVHD occurrence, 
and between the number of late effects and performance status. 
The PROVIVO instrument is a PRO instrument efficient and versatile enough to assess late effect 
symptom experiences in diverse clinical and research contexts, and which can easily be integrated into 
clinical information systems. Further research is recommended to test its value for at least five additional 
uses: (1) assessing symptom experience throughout the survivorship trajectory and identifying treatable 
problems; (2) improving communication and shared decision making between patients and healthcare 
professionals; (3) distinguishing between symptom patterns based on late effect types; (4) informing 
decisions about proposed changes to treatment plans; and (5) monitoring intervention responses. 
Our fourth article (Chapter 6) identified and described considerable differences between SCT 
patients’ health behaviours and those of the general Swiss population, including several specific issues 
in medication taking behaviour. To our knowledge this was the first study to provide population-based 
data on the prevalence of health behaviours among SCT survivors in Switzerland. One particular 
strength was its case-match control design, i.e., via propensity scoring, each survivor was matched 
with a control from a representative sample of the Swiss population 21. The results were mixed: sur-
vivors were most likely to adopt beneficial health behaviours regarding not smoking and low alcohol 
consumption; however, relative to the general population, a considerable group engaged in unfavour-
able behaviours, particularly regarding physical activity and diet. These findings indicate a need for 
targeted interventions to promote a healthy lifestyle after SCT.  
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Among health behaviours, medication adherence to immunosuppressants (IS) is crucial: correct 
intake is essential to prevent and treat cGVHD. As no previous study had investigated the prevalence and 
consequences of post-SCT medication nonadherence (MNA), our fifth paper (Chapter 7) focussed on 
medication nonadherence and its associations to cGVHD. For the first time, we showed a relation 
between medication nonadherence and cGVHD grade, thereby highlighting a need for targeted 
interventions. In particular, patients prone to taking nonadherence and dose reduction were more likely 
to have moderate or severe cGVHD. We also found that those taking higher numbers of IS medications 
were more likely to be non-adherent. The converse was also true: IS nonadherence was less prevalent 
among those taking fewer co-medications.  
As reducing MNA prevalence demands a clear understanding of healthcare providers’ 
medication self-management support practice patterns, these were the focus of our sixth and final 
paper (Chapter 8). Concerning nurses’ assessment and support of medication adherence, our 
evaluation of their current practice patterns showed that they most often applied educational strategies. 
However, state-of-the-art evidence suggests that educational interventions alone have limited efficacy, 
favouring instead a combination of educational, behavioural and psychological interventions 22, 23. 
Therefore, resources devoted to optimizing healthcare providers’ adherence support competencies 
would be a worthwhile investment.  
Overall, rather than continuing to treat SCT survivorship according to the traditional acute-care 
paradigm, our findings support the integration of a chronic care model. Based on our findings, with a 
strong focus on practice implications, the remainder of this chapter proposes such a model. The final 
sections will deal with the model’s policy implications and present suggestions for further research. 
9.2 Proposing a new chronic care framework for survivorship 
Regarding symptom management and health promotion, survivorship care should build on 
the chronic care paradigm, particularly self-management support, enabling patients to 
increase their control over and improve their health. 
SCT’s impact and lingering late effects have life-long consequences concerning survivors’ daily lives 
24-27. With on-going survivorship, then, patients must assume increased responsibility for managing 
their follow-up care. Recognizing the magnitude of this job, the Institute of Medicine (IOM) report 
`From Cancer Patient to Cancer Survivor: Lost in Transition` outlines a survivorship care continuum 
based on four pillars 28: 
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1. Prevention of new (primary) and recurrent cancers and late effects  
2. Surveillance for recurrence or new cancers 
3. Interventions for consequences of the cancer and its treatment (including physical 
consequences of symptoms such as pain and fatigue, psychological distress experienced by 
cancer survivors and their caregivers, and concerns related to employment, insurance, and 
disability)  
4. Co-ordination between healthcare providers to ensure that survivors’ health needs are all met. 
The report recommends using systematically developed evidence-based clinical practice guidelines, 
assessment tools, and screening instruments to identify and manage late effects of cancer and its 
treatment. Further, it includes several specific recommendations on such topics as implementing 
quality measures for survivorship, supporting and developing new models of care coordination, 
educating healthcare providers, ensuring access to affordable care and integrating treatment summaries 
and survivorship care plans into survivorship care 28.  
Equally importantly, it clearly describes the problem of shifting cancer care from a 
predominantly acute treatment system to one that embraces both effective/curative treatment of the 
disease and the care/management of long-term secondary effects. Still, in many cases, SCT follow-up 
care remains largely organized around acute episodes of illness and might not meet survivors’ ongoing 
medical and psychosocial care needs 29. Challenges to optimal care for SCT survivors include inadequate 
communication and coordination between SCT centres and community healthcare providers, lack of 
awareness of screening and prevention guidelines, insufficient financial and personal resources for 
survivorship care and the absence of tools to facilitate survivor care 30, 31. It is assumed that delivery of 
optimal quality healthcare results in superior clinical outcomes 30-33, i.e., that patient outcomes will vary 
depending on how effectively centres manage their follow-up care. For example, in an observational 
multicentre study, Loberiza et al. have shown that the presence of physicians answering after-hours calls 
and a higher physician-per-patient ratio were associated with decreased 100-day post-SCT mortality 
among US transplant centres 34. It can be hypothesized that other elements such as the integration of a 
patient self-management support approach will also positively influence outcomes.  
In fact, most SCT centres still organize survivorship care reactively, i.e., becoming involved 
mainly when a patient becomes ill. Considering the high cost of acute treatment in comparison to 
those of on-going preventive measures, there is a clear need for a new model of SCT survivorship care 
– a proactive chronic care system based on lasting clinician-patient partnerships and focused on 
keeping patients as healthy as possible 35.  
As one excellent example of such a system, providing guidance for healthcare organizations to 
improve chronically ill patient care, is Wagner et al.’s Chronic Care Model. Based on the principle 
that patients and healthcare providers share responsibility for problemsolving and outcomes during the 
care process 36, 37, this model consists of six building blocks (1) healthcare system; 2) community;  
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3) delivery system design; 4) clinical information systems; 5) decision support; and 6) self-
management support), and can be applied to a wide range of chronically ill populations. Increasing 
evidence from different patient populations supports implementing the model’s components 38-45. 
Related interventions can focus on three dimensions: the general community and its healthcare system 
(macro level), the healthcare institution (meso level) and the patient-health care provider interaction 
(micro level). Upon closer examination of Wagner et al.’s six building blocks, assuming that the 
healthcare system supports the improvement of chronic illness care, it must also be prepared to accept 
a system-wide reorganization. One important element of the updated system, partnerships with 
community organizations to support and develop interventions, will fill gaps in needed services. 
Clinical information systems ensure timely access to key data both to individual patients and 
to patient populations. The datasets can be used for multiple purposes, including benchmarking, 
quality improvement and research. For example, by providing timely automated reminders for needed 
services, along with summaries of core data to plan and track care, a comprehensive clinical infor-
mation system can greatly enhance individual patient care 9, 46, 47.  
Decision support is provided through evidence-based guidelines that incorporate patients’ per-
spectives and are integrated via reminders into efficient clinical information systems. As those invol-
ved in treatment decisions need ongoing training, the guidelines also suggest methods of staying up-
to-date with the latest evidence 9, 46, 47. 
Self-management support has evolved beyond the practice of merely providing information 
and increasing patient knowledge to include support for patients’ health behaviour improvement, 
activities of daily life and day-to-day management of their conditions. Self-management support 
includes the use of proven programs that provide essential information, emotional support, and 
strategies for living with chronic illness conditions 9, 46, 47.  
The delivery system design assures the delivery of effective, efficient clinical care and self-
management support. This requires not only determining what care is needed, but clearly defining 
roles and tasks to ensure patient care via structured, planned interactions at regular intervals. To 
optimize both clinical care and self-management, patients whose needs are more complex may require 
periods of more intensive attention 9, 46, 47. 
Based on the above reflections on the IOM 28 report, the Chronic Care Model 46,47 and its 
multi-level applications 48, we created the SCT Survivorship Care model. This care model is designed 
to facilitate productive interactions between informed patients and supportive healthcare providers, 
particularly concerning the key elements of cancer survivorship follow-up, i.e., prevention, 
surveillance, interventions, and coordination 28. As a practical basis for these actions, it also incor-
porates four of the Chronic Care Model’s six building blocks: 1) clinical information systems; 2) 
decision support 3) self-management support; and 4) delivery system design.  
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The third inner layer includes important tools for enhancing the quality of survivorship care as 
recommended by the IOM and leading associations 28, 30-33, 49, 50. The model’s implications regarding 
the micro, meso and macro levels of the healthcare system are also depicted.48 At the micro-level, 
interventions can focus either on individual patients or on the relationships between patients, care-
givers and healthcare professionals. Meso-level interventions deal with healthcare settings; and those 
at the macro level are aimed at public policy makers and society in general. Each level influences each 
of the others.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The SCT Survivorship Care Model 
The findings of the PROVIVO research program support a systemic change to a chronic care SCT 
survivorship approach. Therefore, the following four sections provide a detailed discussion of the 
program’s findings in light of the SCT Survivorship Care Model.    
DISCUSSION 
- 146 - 
 
9.3 Clinical information systems 
 
 
Clinical information systems assure ready access to key data on individual patients as well 
as populations of patients 9,10. 
Integrating patient perspectives of late effect symptom experience and self-management into 
the clinical information system can be highly informative for understanding the 
consequences, safety and effectiveness of treatment. 
Based on our adapted SCT survivorship care model, effective clinical information systems offer quick 
access to key data on individual patients and populations, include reminder systems, and facilitate perfor-
mance and quality improvement monitoring 9, 46, 47. Therefore, the integration of PRO data – both on 
symptom experience and selected health behaviours – to these systems will reveal valuable information.  
Traditionally, for most clinical trials, data collection begins with investigators recording 
adverse events in medical charts, after which data managers transfer it into databases. Similarly, 
during clinical care, healthcare providers elicit and document information about side effects in patient 
charts. These include symptoms such as nausea, pain, fatigue, or sleep disturbances, most of which the 
patient could provide directly via a PRO questionnaire 51. In addition to information on symptoms and 
reactions, questionnaires can include direct questions on health behaviours, thereby allowing 
important inferences concerning treatment effectiveness. For instance, in a case of non-response to 
immunosuppressants, a single item or scale might reveal that the underlying issue is nonadherence. 
As clinicians and researchers, our work with SCT patients has to be set in relation to current 
developments in PRO instruments used in research and in cancer care. Recently, interest has emerged in 
the use of PRO measures directly integrated in clinical information systems – a concept which could pro-
vide novel opportunities for clinical practice and research 52. In particular, innovative PRO applications 
within the broader context of patient-centeredness have recently emerged, reflecting a growing focus on the 
patient experience in clinical research and care delivery 53, 54. According to the FDA 16 and the Patient-
Centered Outcomes Research Institute 55, PROs should be increasingly used for (1) assessment of adverse 
events and side effects, (2) comparative effectiveness research, and (3) care quality assessment 56.  
Each of these areas has become a focus of innovations in the logistics and science of PRO data 
collection, e.g., electronic interfaces (websites, tablet computers, or automated telephone systems). New 
information technology can also facilitate care sharing among healthcare providers, are available at low 
cost and can hugely accelerate information processing. PRO assessments can be tailored to specific 
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groups, and information and/or problem-solving strategies that focus on priorities can be delivered 
directly by healthcare providers, via websites or text messaging 52. Also, via repeated PRO assessments, 
interventions can be evaluated and modified 50. Additionally, a single PRO data source can be used for 
multiple purposes. For example, information based on PRO data collected through electronic patient 
records can be used to manage individual patient needs, or aggregated for safety surveillance systems, 
effectiveness research, and care quality assessments. More broadly, the emerging interest in PROs across 
healthcare contexts reflects a growing awareness that the patient perspective can be highly informative 
concerning the effectiveness, safety, and value of treatments 57. 
In the PROVIVO instrument we have developed an important PRO instrument for measuring 
late effect symptom experiences. While it can easily be integrated into an SCT centre’s clinical 
information system, the version currently exists only as a paper-pencil questionnaire. Converting it to 
an electronic format will require additional development and testing for validity and equivalence to the 
original paper-and-pencil version 58, 59. When available, in addition to enhancing care delivery, an 
electronic PROVIVO version should be usable for multiple analytic purposes.  
In this respect, Wood et al. (2013) provided important evidence regarding the feasibility of 
weekly-collected electronic PRO-CTCAE patient reports. The authors tested the feasibility of the 
clinical information system by using 34 symptom severity PRO-CTCAE items in 32 SCT patients 
during the first 100 days following transplantation. Offered a choice between paper-and-pencil and 
electronic reporting, the vast majority (94%) of patients chose the electronic system. Although patients 
were in the intensive acute SCT treatment phase, the median weekly response rate remained at 100% 
until discharge. Patients were satisfied with the questionnaire’s readability, comfort, and content 60.  
Further research supported the feasibility and credibility of integrated PRO symptom or 
quality of life assessments in clinical information systems in cancer care. In particular, positive effects 
were shown regarding patient-provider communication, patient satisfaction with care, and detection of 
unrecognised problems. Additionally, real-time PRO symptom assessment systems with integrated 
alarms and reminder systems improved treatment response monitoring.61, 62 In terms of health 
behaviours, PRO information allows the care team to deliver proactive follow-up care and self-
management support via effective reminder systems, performance measures providing feedback, and 
initiation of targeted interventions. However, if health behaviour assessment – an integral part of 
clinical information systems – is intended to improve patient outcomes, it must be connected with 
effective behavioural change/enhancing interventions 63.  
To conclude, innovative clinical information systems should integrate PRO measurement in 
routine survivorship care. PRO datasets are increasingly used for multiple purposes: with growing 
benefits for quality of care and research on comparative effectiveness, they already contribute strongly 
to symptom experience and health behaviour assessments. However, while the current evidence is 
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promising, future research will be necessary to verify the effectiveness of interventions using PRO 
data collection in SCT or other survivorship programs.  
 
9.4 Decision support 
 
Following evidence-based guidelines, decision support hinges on patient perspectives and is 
integrated into daily clinical practice through reminders. 9,10 
Obtaining information on symptom experience and self-management problems via self-
reporting is fundamental to decision making in SCT care. 
Evidence-based practice guidelines provide standards for optimal chronic care and should be 
integrated into daily clinical practice through automated reminders 9. However, while SCT-specific 
guidelines exist 64, no tools are yet available to improve their usage, such as reminder systems, 
feedback loops, and printed information materials for healthcare providers and patients 46, 47. Also the 
current research program’s PRO information on symptom experience and relevant health behaviours 
can offer important information which could be included in the development of such tools.  
Clinical decisions regarding triaging for self-management interventions (e.g., smoking cessa-
tion), monitoring for problems in treatment efficacy (e.g., medication adherence), therapy changes 
(e.g., reduction of IS doses to reduce tremors), or supportive therapy (e.g., analgesic medication), all 
depend on information available via PROs. Also, patient-reported changes in symptom occurrence and 
distress can indicate whether an intervention is working.  
With the development of the PROVIVO instrument we offer a promising tool with the 
potential to guide clinical decision-making. Its two-dimensional reporting of symptom occurrence 
(frequency, severity) and distress are a particular strength 65. For example, after completion of 
treatment, patients might feel unprepared for the occurrence of new symptoms and limitations, and 
might have difficulty interpreting their significance. For these patients, it is often unclear whether 
symptoms are due to a new illness, disease recurrence, or simply lingering effects, the uncertainty of 
which might cause symptom distress 66, 67. Even survivors in complete remission or maintenance are 
frequently concerned about possible signs of relapse 68.  
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For example, responding to the PROVIVO questionnaire, a patient treated for a mantle cell 
lymphoma reported itching which, though mild, was severely distressing for him. Based on his self-
report, topical treatment and further blood tests were initiated. Asking about his symptom distress, the 
nurse administering the instrument learned that he had experienced itching in the past, with the first 
diagnosis of his lymphoma. Therefore, additional emotional support by a psychologist could be 
arranged. This case illustrates how the PROVIVO can help a healthcare team make meaningful 
clinical decisions.  
To effectively guide the decision-making process in survivorship care, PRO data should be 
embedded in a clinical information system, which triggers automatic reminders for healthcare 
providers to initiate appropriate interventions. Used alongside electronic symptom monitoring, such 
alerts have proven effective in several cancer follow-up studies 69, 70, and can also be used in 
behavioural interventions.  
For the future, there is abundant room for further progress regarding electronic PRO reporting 
for decision support. Ideally, features should include simple interfaces, reminders to patients to self-
report, and alerts to clinicians concerning interventions. Clear illustrations of longitudinal symptom 
and health behaviour trajectories, notifications to staff when patients miss scheduled self-reporting 
appointments, and triggers for patient self-management interventions would also be important 
elements of such a system. The easier it is for healthcare providers to work with PRO information, the 
more likely it is that they will adopt it as a tool for clinical decision making in SCT survivorship care. 
 
9.5 Self-management support and health promotion 
 
 
Self-management aims at supporting patients in their day-to-day management of chronic 
conditions, to maintain daily life activities and to improve health behaviours. It acknowledges 
the patients’ central role in their care and includes the use of proven intervention. 9,10 
Our study’s findings indicate the need for self-management interventions as an integral part of 
SCT survivorship care. 
Considering the increasing longevity of the SCT survivor population–and the consequent growth of 
that population – 71, the work described here emphasizes self-management’s central role concerning 
our SCT Survivorship Care Model. In particular, by supporting symptom management and healthy 
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lifestyle patterns, self-management has a high potential to delay or prevent new, secondary and tertiary 
morbidities 11. Our findings revealed high numbers of symptoms in a significant number of patients, 
indicating the need to integrate symptom management into self-management support. Furthermore, 
regarding lifestyle choices, several contraindicated behaviours were detected, including low physical 
activity, a diet low in fruits and vegetables, and medication nonadherence. However, only smaller 
subgroups of patients persisted in unfavourable behaviours regarding smoking, elevated alcohol 
consumption and unprotected sun exposure.  
In addition to reducing proven risk factors, primary disease prevention includes developing 
healthy behaviours, such as improving nutrition and increasing physical activity. Secondary pre-
vention strategies include reporting for scheduled follow-up tests, participating in suggested interven-
tions, receiving recommended vaccinations, responding to reminders to address follow-up care plans 
and actively supporting medication management. Finally, in addition to medical management of late 
effects, tertiary prevention relies heavily on patient involvement, especially via self-management acti-
vities, e.g., symptom reporting and management or adherence to medical and dietary recommen-
dations. Strategies for these three levels of prevention certainly overlap. For example, supporting 
medication adherence has implications in both secondary (e.g., preventing cGVHD) and tertiary 
prevention (e.g., reducing the risk of disease elevation) 11, 72.  
Of the full range of recommended preventive self-management activities, four have been 
proven to contribute outstandingly to a longer and healthier life: adequate physical activity, healthy 
diet, non-smoking, and moderate alcohol consumption. Evidence from the general population clearly 
indicates that their benefits include slowed progression of existing chronic conditions and decreasing 
mortality.73 Compared to people who engage in none of these behaviours, a large-scale prospective 
study (N= 23.125) demonstrated that participants who engaged in all four were 66% less likely to die 
early from cancer, 65% less likely to die early from cardiovascular disease, and 57% less likely to die 
early from other causes 74.  
Apart from observational descriptions of long-term post-SCT health status 2, 6, 75-77, little 
research has examined health behaviours’ impacts on morbidity and mortality in this patient group. It 
has been acknowledged, however, that regular physical activity results in reduced fatigue and an 
attenuated risk of developing diabetes or cardiovascular conditions, while lower fruit/vegetable intake 
is associated with greater risk of dyslipidaemia and diabetes 78, and non-smoking correlates with fewer 
days of hospitalization and better overall survival 79. Among CML patients who received SCT, the 5-
year survival rate was highest among non-smokers (68%), compared to low-dose smokers (1-9 pack-
years: 62%) and high-dose smokers (>10 pack years, 50% survival) 80.  
To date, no intervention study has examined self-management and health promotion in long-
term post-SCT patients. However, systematic reviews and meta-analyses of self-management and 
health promotion interventions in solid tumour cancer survivor populations indicate promising results 
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14. Physical activity interventions have shown beneficial effects on diverse aspects of health-related 
quality of life including emotional well-being and social functioning, and also against diverse 
symptoms such as sleep problems, fatigue, and pain 81. Further results suggest that physical activity 
interventions are safe for cancer survivors, producing improvements in fitness, strength, physical 
functions, and, alongside dietary interventions, nutrition-related biomarkers and body weight. Pre-
liminary evidence also suggests that combining interventions to target diet and exercise concurrently 
may positively influence biomarkers associated with progressive disease and overall survival (e.g., 
insulin levels, oxidative DNA damage, tumor proliferation rates) 82-84. However, in both short-term 
and long-term follow-up groups, findings on smoking cessation interventions remain inconclusive, as 
a meta-analysis could not show a consistent decrease in the prevalence of smokers 85.  
Regarding adherence enhancing interventions aimed at cancer survivor populations, the few 
available results are conflicting. Of the six published studies on the topic, only one employing education, 
pill shaping and restructuring of the physical environment showed a significant benefit 86. And while 
results on symptom management and survivorship concerns are similarly rare, positive results have been 
shown for provider-patient-communication enhancement, lowering symptom distress and improving 
emotional well-being 61, 87, 88.  
Overall, research has demonstrated that, after cancer diagnosis, individuals who improve their 
self-management and health behaviours feel better, experience less fatigue, and may even decrease their 
risk of cancer recurrence 84, 89, 90. Still, the effectiveness of interventions may be affected by multiple 
mediating or moderating factors, e.g., patient age (current and at diagnosis/treatment), genetic risk pro-
file, and concurrent symptom experience. Clearly, more intervention research is needed to identify effec-
tive means of supporting SCT survivors to enact and maintain meaningful improvements in their self-
management behaviours.  
However, what is the optimal time to initiate self-management support? And which components 
should be included in an inventory of self-management interventions? Certainly, self-management 
support is a continuous process. Although the period immediately following cancer diagnosis has been 
called a “teachable moment,” as it is a period when patients are thought to be particularly receptive to 
enhancing health behaviours 91, 92, the literature indicates that, after initial signs of progress, many sur-
vivors relapse into unhealthy behaviour patterns, with only a subgroup proving capable of significant 
long-term behavioural changes 93. Intervention timing (i.e., which intervention in which follow-up 
phase?) and intensity (i.e., how much intervention is needed to improve a specific behaviour?), as well as 
channels of delivery (e.g., what member of the care team is responsible for what? which media will be 
most effective?) must be carefully considered in developing programs to meet the needs of this 
vulnerable population 94.  
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Finally, all self-management support in survivorship care programs should emphasize the patient's 
central role, i.e., the net value of any such program depends directly on the extent to which patients’ needs 
are met. Therefore, on one hand, SCT patient support should reflect topics that impact survivors’ health; on 
the other, it should consider the patient’s concerns and restraints, e.g., a high symptom burden. The long-
term effects of SCT involve stress not only for patients but also for their families. Therefore, self-manage-
ment interventions should also recognize the concerns of family or partner caregivers, who have to deal 
with uncertainty, adapt to changing roles, and balance patient needs against their own 95.  
 
9.6 Delivery system design 
 
 
The delivery system design assures the delivery of effective, efficient clinical care and self-
management support. That requires determining tasks and roles for ensuring the patient gets 
optimal care using structured, planned interactions between providers. 9,10 
The findings of this study indicate a need to change from the current care delivery system to 
one that considers the shifting balance between acute and chronic healthcare needs in SCT 
patients. 
The integration of a chronic care approach to SCT survivorship requires a new care delivery model –
one which redefines both service arrangements and coordination of the involved multidisciplinary 
healthcare providers. To assure that each SCT survivor receives appropriate and comprehensive care, 
the necessary actions (including assessments, treatments, and supportive interventions) should be 
planned, coordinated, and delivered by a multidisciplinary team 35. The new care delivery system must 
provide survivors with access to appropriate evidence-based treatment, while organizing all necessary 
services in a timely and technically competent manner, with clear communication and shared decision-
making between patients and healthcare providers across the entire survivorship continuum 30, 32, 96. 
Care should follow survivorship care plans, which also guide disease and late-effect surveillance and 
specify appropriate self-management actions 33. 
Increasing evidence in chronically ill patient populations supports the effectiveness and 
implementability of a delivery system change towards a collaborative chronic care approach 38-45. As 
an example, Bissonnette’s (2013) prospective quasi-experimental study illustrated how a successful 
system change can improve kidney transplant recipients’ self-management support. The study’s results 
were promising: participating patients were more likely to attain targeted clinical outcomes (e.g., 
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improved blood pressure, favourable renal function) and participate in discussions about treatment 
options, and required fewer emergency room visits and rehospitalisations 40.  
Replacing the current SCT care system with a collaborative chronic care approach will require 
interventions at all levels of the healthcare system: public officials will need to redraft policies (macro 
level), healthcare institutions (meso level) will need to reallocate resources, and the direct clinical 
practitioners (micro level) will need to refocus on long-range care objectives. This section will focus 
on the micro and meso levels, providing an example of a possible self-management intervention for 
SCT patients; the next section will illustrate the implications at the policy level.   
At the patient care level, an advanced practice nurse would coordinate the care program and 
the collaboration of the multidisciplinary team. Tools and interventions would be implemented based 
on the SCT Survivorship Chronic Care Model. In addition to the currently-used physical examinations 
and laboratory tests, patients would be asked to complete PRO self-management assessments at 
defined intervals. These would cover symptom experience (via the PROVIVO instrument), a 
comprehensive set of health behaviour tasks (e.g., regarding medication taking, smoking, weight 
control, physical activity and diet) and additional supportive care needs. Each patient would also 
receive a survivorship care plan 33, which would be discussed with an advanced practice nurse in a 
regularly scheduled counselling session.  
Based on the survivorship care plan, the self-management assessments, and any issues that might 
arise, subsequent individually-tailored interventions would be initiated 94. Symptom management 
strategies would follow state-of-the-art practice guidelines.64 Behavioural interventions should be chosen 
in accordance with Michie et al.’s taxonomy, combining cognitive/behavioural and psychological 
interventions to draw upon skill development and consolidation of favourable behaviours 23, 97-99. 
Motivational interviews, combining brief written (one page) instructions with oral instructions to shape 
the patient’s knowledge, support goal-setting, and provide advice on behavior self-monitoring 100 would 
be the most often applied interventions.  
As medication management support should be a major component of the intervention 
program, multiple support strategies, e.g., reminders to take medications regularly, dose modifications 
and special packaging, should focus on this topic 23, 97-99. Additional use of an electronic Medication 
Event Monitoring System (an electronic pill box that records the date and time of each removal of the 
cap) could provide feedback data for patients to track their medication taking progress 101-103.  
The intervention would reflect an institutional (meso-level) policy outlining the specific roles 
and tasks of the team members. The healthcare providers would meet weekly for interprofessional 
patient rounds. During these conferences, additional measures would be implemented and ongoing 
educational training offered.  
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In summary, we see a definite need for a change in the current system of survivorship care 
delivery to reflect the chronic nature of SCT survivorship. In our opinion, a nurse-led collaborative 
care approach would have the most potential to improve SCT patients’ clinical outcomes. However, 
this conclusion should be further tested in a randomized controlled trial.  
9.7 Policy implications 
Our findings imply that self-management support, focussing on both symptom management and 
health behaviour promotion, should be implemented as an integral part of SCT survivorship care. 
This doctoral thesis has far-reaching implications for clinical practice and for health policy. This 
section follows on previous illustrations of a possible advanced practice nurse-led multicomponent 
self-management program for SCT survivors. To implement such a system change will require action 
across all healthcare levels. As implications on the micro and meso level have been described above, 
this section will focus on the actions necessary on the macro level of the Swiss healthcare system. 
Three main issues should be addressed by policy initiatives: (1) promotion of policy changes to 
support the implementation of a comprehensive survivorship care program: (2) legislation and 
promotion of education and training programs for healthcare professionals working in survivorship 
care; (3) educational public health initiatives promoting health behaviours proven to lower the risks or 
ameliorate the effects of various chronic diseases.  
9.7.1 Promotion of policy changes that support the implementation of comprehensive 
survivorship care programs  
One major barrier to the widespread implementation of comprehensive SCT survivor care programs is 
the lack of cost-coding and reimbursement for self-management interventions. Switzerland has a 
mandatory health insurance system which covers costs for follow-up consultations and medication 104. 
However, as the current policy favours paying for acute physician-led care, nurses are not reimbursed 
for executing self-management interventions in the outpatient setting. This increases the risk of costly 
and avoidable patient transitions to and from acute care facilities. To adequately recognize and 
compensate nurse-led services – including self-management interventions – in outpatient settings, and 
to support the development and evaluation of an efficient and effective chronic care paradigm, 
changes to the current reimbursement legislations are essential. This would support the development 
of continuous survivorship care programs focussed on care planning, self-management enhancement, 
prevention, and late-effect management.   
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9.7.2 Education programs for healthcare professionals working in survivorship care 
Our fifth study revealed that the most commonly used strategies to support patient medication-taking 
self-management were educational/cognitive. However, knowledge alone may not be sufficient to 
change deeply impressed habits. Instead, drawing upon skill development and consolidation of favour-
able behaviours, combinations of cognitive, psychological and behavioural interventions more effec-
tively engage patients in their own medication management 22, 23, 97, 105, 106.  
Cancer follow-up provides an opportune time for clinicians to counsel patients on health 
promotion; however, self-management support is not yet regularly implemented in most survivorship 
clinics 15. One possible explanation is that, since few graduate health science curricula include 
modules on innovative behavioural interventions, proportionally few clinicians have the knowledge 
and training to provide them 107. If this is true, it highlights a serious gap in the competencies of the 
healthcare professionals who deal with cancer survivors’ emerging and evolving needs for on-going 
chronic care 108, 109.  
Developing and running state-of-the-art survivorship care programs will demand a clinical 
work force appropriately skilled to provide services based on a chronic care approach 32. To date, most 
healthcare professionals working in survivorship care have developed their skills and competences on 
an ad-hoc basis, and few institutions offer associated online courses 110 or post-graduate training 
programs 111. Still, pioneer examples of curriculum based survivorship training programs for 
healthcare professionals are currently running 112-115.  
Clearly, political, educational and institutional efforts are urgently needed to develop post-
graduate and continuous education programs for survivorship care. The first step is to define the 
required skills. As introduced in the current study, the SCT Survivorship Care Model provides 
guidance on the key components of cancer survivorship chronic care. These include the use of 
appropriate assessment instruments, development of individualized treatment summaries and care 
plans, promotion of health behaviour self-management skills, provision of information and 
behavioural change techniques, cooperation within the multidisciplinary team to optimize comprehen-
sive care, and provision of care guided by evidence-based practice guidelines 112-115. Since nurses will 
play a major role in future survivorship care, it is especially important that educational and organiza-
tional leaders support their preparation by providing on-going education and training 35, 116. 
9.7.3 Public health initiatives dealing with health behaviours and chronic diseases 
While the two issues addressed above dealt with the implications of a chronic care approach to SCT 
care delivery, the third addresses primary and secondary prevention of chronic diseases in the general 
society, and would therefore contribute indirectly to SCT survivors’ health function. Observing health 
behaviour trends in the general population, western healthcare systems face several problems in terms 
of smoking, alcohol consumption, and diet-related imbalances 117.  
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In particular, sedentary behaviours and high density diets are major factors of population-wide 
weight gain 118, 119. Obesity has nearly doubled in Europe over the past 20 years, regardless of previous 
levels in most countries 117. The consequences include growing prevalences of diabetes, hypertension, 
and elevated cancer risk 120.  
These trends are even more alarming for SCT survivors, who already have an elevated risk for 
developing various chronic diseases at an early age.78, 121 For a survivor who has received a high-toxicity 
treatment such as total-body irradiation, many such diseases can be fatal. However to effectively address 
healthy lifestyle as a primary – and potentially, for cancer survivors, a secondary-preventive measure, 
this topic requires top-level priority as a public health issue. In recent years, several national health-
related initiatives (e.g., on passive smoking and on fruit and vegetable consumption in schools and 
workplaces) have achieved surprising success 122; however, continuous, concerted action is urgently 
needed to promote the elements of a healthy lifestyle as preventive measures against chronic disease.  
9.8 Perspectives for future research 
Future research should aim at (1) further psychometric testing of the PROVIVO instrument;  
(2) prospective studies examining the relations between the trajectory of symptom experience, 
and self-management behaviours after SCT; and (3) testing of the efficacy of a multi-component 
intervention program to manage symptoms and support self-management. 
Based on this thesis’ findings, we recognize manifold directions for future research: (1) further 
psychometric testing of the PROVIVO instrument; (2) prospective studies examining the relations 
between symptom experience trajectories and self-management behaviours after SCT; and (3) tests of 
the effectiveness and outcomes of multi-component self-management interventions integrated in a 
collaborative chronic care approach to SCT survivorship.   
For validity testing, we used the AERA Standards for Educational and Psychological Testing, 
which acknowledge that confidence in a questionnaire develops based on the long-term accumulation 
of psychometric data provided by a variety of testing procedures. To date, we have only been able to 
test the preliminary validity of the PROVIVO instrument using a cross-sectional design. As a result, 
we could neither capture changes in symptoms over time nor assess re-test reliability or predictive 
validity. It should also be stressed that the AERA guidelines will soon be updated to include enhanced 
coverage of test fairness, educational accountability, workplace testing, and technology 123. Therefore, 
we recognize that our preliminary validity results represent only an initial step in validation. 
Subsequent steps should include examining the instrument's responsiveness to change over time and 
developing interpretation guidelines, e.g., concerning minimally clinically important differences 124.  
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Further, there is a clear need for prospective research investigating the relations between the 
trajectory of symptom experience and behavioral patterns after SCT. The survivorship literature includes 
little information on long-term symptom trajectories after SCT, i.e., it is unclear how long symptoms 
persist, or of which patient, disease, or treatment characteristics correlate with which levels of severity or 
distress. Optimally, future studies exploring symptom trajectories should use graphic techniques such as 
heat intensity mapping 125 or innovative statistical approaches such as latent profiling 126, which identifies 
underlying characteristics that contribute to the likelihood/risk of membership in a particular latent 
profile 126. Such knowledge can allow clinicians to proactively modify strategies to mitigate or prevent 
future symptoms and late effects. For instance, patients identified as specifically at risk for developing 
higher levels of pain, anxiety, and depression might benefit from consultations with a mental health 
nurse or psychologist before these symptoms occur. Such research would acknowledge different 
symptom patterns which call for tailored assessment and management approaches. 
To advance current knowledge on the interplay of biophysiological, behavioural and 
psychosocial factors for outcomes after SCT, larger cohort studies are needed. The nationwide Swiss 
Transplant Cohort Study (STCS), an open prospective cohort study, offers an excellent research 
framework to describe characteristics of transplant populations, to report clinical and psychosocial 
outcomes and to explore specific risk factors that influence these outcomes. The STCS includes all 
solid organ and stem cell recipients in Switzerland 127. Based on Dew et al.’s adapted biopsychosocial 
framework 128, the STCS measures five psychosocial domains: (1) physical/functional (e.g., perceived 
health status, sleep quality, daytime sleepiness); (2) psychological (e.g., depression, stress); (3) 
behavioural (e.g., medication adherence, smoking, drug use, physical activity, sun protection); (4) 
social (e.g., work capacity/return to work); and (5) global quality of life. Factors relating to the 
healthcare system (e.g., trust in the transplant team) are also considered 129. The resulting data are best 
suited to analysis in view of post-SCT clinical outcomes, e.g., to identify socioeconomic, psychosocial 
and behavioural factors that distinguish between survivors with better or poorer clinical outcomes. 
To improve long-term outcomes after SCT, alongside the integration of a collaborative 
chronic care approach for SCT survivorship, a multi-component self-management intervention is 
strongly recommended. As such an intervention program is complex, its development and testing are 
challenging and require extensive preparative work. The overall process will include considerations of 
ways to maximize trial efficacy and implementation via fidelity monitoring and measurement, as well 
as the selection of an appropriate design, target population and control group. Attention should also be 
paid to identifying barriers to behaviour change among SCT survivors, and to delivery channels and 
methods of overcoming those barriers. Ideally, a clustered randomized trial would test the efficiency 
of such a program. Also, the role of technology in intervention delivery and measurement will require 
careful consideration. Integral to this study, analyses will weigh the costs of delivery against potential 
savings from decreased morbidity and mortality and increased function and quality of life 130.  
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9.9 Conclusion 
The research program presented here was innovative, presenting, for the first time, a PRO instrument 
measuring late-effect symptom experience after SCT. Its findings add significantly to the scarce 
available knowledge both of symptom experiences in SCT survivorship and of long-term survivors’ 
health behaviours. They also support the association between medication nonadherence and the 
occurrence of cGVHD. Moreover, this research program provides insight into current practice patterns 
of healthcare professionals relative to the assessment and support of medication adherence. Finally, it 
has enabled us to outline specific issues and additional topics of interest for further research on SCT 
patient self-management, particularly regarding symptom experience and health behaviours.  
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